Synthetic routes to 18F-labelled gemcitabine and related

2’-fluoronucleosides by Meyer, Jan-Philip
Synthetic Routes to 18F-Labelled
Gemcitabine and related
2’-Fluoronucleosides
A thesis submitted in accordance with the
conditions governing candidates for the degree of
Philosophiae Doctor
by
Jan-Philip Meyer
December 2014
Cardiff School of Pharmacy and Pharmaceutical
Science
Cardiff University

Acknowledgements
I want to take the opportunity to thank all my supervisors for their great sup-
port. In particular, I want to thank Dr. Andrew Westwell for his guidance in not
only research related matters but all sort of challenges that arose along the jour-
ney towards the submission of my PhD thesis. Furthermore, I want to express
my gratitude to Prof. Chris McGuigan for his fruitful ideas during my group
meeting presentations that significantly improved my understanding of how re-
lated fields are connected and how important it is to put all assumptions and
results to the test. Finally, I thank Dr. Katrin Probst mainly for her assistance
in radiochemistry but also for giving me the opportunity to experience various
aspects of clinical tracer production. I also would like to thank all members from
Andrew’s and Chris’ lab and the PETIC staff for really nice talks, suggestions
and coffee breaks. Additionally, I thank Cancer Research Wales and the British
Association for Cancer Research for their financial support and the opportunity
to attend interesting scientific conferences. Finally, I would like to express my
sincerest appreciation to my family, my fiance (Liz) and my friends in and around
Cardiff for their support, motivation and patience.
i
Abstract
Gemcitabine (2’,2’-difluoro-2’-deoxycytidine, dFdC) is an established chemothera-
peutic agent used in the treatment of various carcinomas such as lung, breast,
bladder and especially pancreatic cancer. However, its general application and
bioavailability is compromised due to both poor cell uptake and rapid metabolism
by gut and liver cytidine deaminase (CDA). A 18F-gemcitabine positron emission
tomography (PET) probe could enable biodistribution studies and the imaging
of gemcitabine pharmacodynamics in vivo. However, the potential and clinical
relevance of a 18F-gemcitabine PET probe would have to be evaluated using
appropriate PET tumour models.
In order to approach the synthetic target molecule 18F-dFdC, proof-of-principle
studies on more straightforward synthetic targets including 18F-FAU and 18F-
FAC (see figure below) were carried out first. An appropriate precursor was
synthesised for 2’-stereoselective late-stage radiofluorination based on previously
developed conditions. First, the 2’-[18F]fluorinated arabino nucleoside 18F-FAU,
which was considered as a rapidly accessible 2’-fluorinated uracil-based dFdC ana-
logue was successfully synthesised in our radiochemical laboratory. Subsequently,
this procedure was used as a template method to obtain the cytidine analogue
18F-FAC via a novel synthetic route in moderate radiochemical yield (4.3-5.5%,
decay-corrected), high specific activity (≥1700 mCi/µmol) and purity (≥98%)
after a synthesis time of 168 min.
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Prior to radiofluorination, experimental and computational methods were
used to design a novel precursor that combines stability and reactivity. The
selected precursor gave promising RCYs (5-10%) of the 18F-labelled protected
intermediate. The impact of temperature and reaction time on radiochemical
yield and the stereospecificity of the radiofluorination was investigated in order
to determine optimal conditions. The developed radiofluorination method could
simplify the production of 18F-FAC for clinical purposes via a fast transfer to
automated radiosynthesisers in good manufacturing practice (GMP) labs.
Considering the final target 18F-dFdC, the 2’-carbonyl fluorination precursor
used for first radiofluorination studies towards the protected 18F-gemcitabine
intermediate was based on previously published results. Radioanalytical data
provided evidence that deoxo[18F]difluorination occurred when DAST in combin-
ation with [18F]fluoride was used. Low radiochemical yields (0.2-0.3%, decay-
corrected) of the 2’-[18F]difluorinated gemcitabine intermediate were achieved.
However, extensive studies including the use of simplified radiosynthesisers and
modern synthesis techniques such as microwave-assisted synthesis as well as de-
protection conditions to give the final target 18F-dFdC have to be carried out in
order to assess the potential of this radiochemical approach.
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1 Introduction
1.1 Fluorinated nucleoside analogues
1.1.1 Overview
Although fluorine is relatively abundant on earth it is very rare in naturally oc-
curring biologically active compounds. However, regarding medicinal applications
the introduction of fluorine into potential drug molecules is common and useful
due to both its bioisosterism to a proton substituent and its bioisopolarity to the
hydroxy group and the resulting pharmacological properties of the corresponding
fluorine containing compounds, such as lipophilicity and metabolic stability [1–3].
The fact that 15-20% [4] of all drugs released worldwide during the last five dec-
ades contained one or more fluorine atoms indicates the important role of fluorine
in modern medicinal chemistry and general medical applications [5].
Naturally occurring purine nucleosides, such as guanosine, adenosine and in-
osine, and pyrimidine nucleosides, such as uridine, cytidine and thymidine are not
only subunits of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) of liv-
ing organisms, but are also important signalling molecules. Extracellular purines,
for instance, mediate biological responses, such as neuromodulation and coronary
vasodilatation through surface receptors [6–8]. Synthetically modified nucleoside
analogues can act as antimetabolites in important biochemical processes and
hence represent an important class of antiviral [9] and anticancer [10] therapeutics.
These artificial modifications are either performed on the base and/or the sugar
1
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moiety using a wide range of synthetic techniques. 2’- and 3’-fluorinated nucleos-
ide analogues play an important role as both anticancer and antiviral agents [9,10].
The chemical structures of some important fluorinated purine and pyrimidine
nucleoside analogues are shown below (Figure 1). Gemcitabine (1), for instance,
is used as a first-line treatment of pancreatic adenocarcinoma and non-small cell
lung cancer [11] and marketed as GemzarT M by Eli Lilly. Clevudine (4) represents
another pyrimidine nucleoside analogue which is used as an antiviral agent for the
treatment of hepatitis B in south-east asia [12]. Clofarabine (2) is a representative
of the purine nucleoside analogue family and FDA approved as EvoltraT M for the
treatment of acute lymphoblastic leukaemia in children [13]. The 18F-labelled ana-
logues of fluoro-deoxy-L-thymidine (FLT) [14,15] (3), fluoro-deoxy-arabinocytidine
(FAC) [16] (5) and fluoro-deoxy-arabino-5-methyluridine (FMAU) [17] (6), for in-
stance, represent a class of interesting biomarkers for positron emission tomo-
graphy (PET) imaging with pre-clinical and clinical applications. The use of
18F-labelled nucleoside-based PET probes is further discussed in section 1.2.5.
N
NH2
ON
O
OH
HO F
N
NN
N
NH2
O
OH
HO Cl
O
HO
N
NH
O
O
O
N
NH
O
O
Gemcitabine Clofarabine FLT
HO F
Clevudine
N
NH2
ON
O
OH
HO F
FAC
NH
ON
O
OH
HO F
O
D-FMAU
F
OH
1 2 3
4 5 6
F F
Figure 1: Examples of important fluorinated nucleoside analogues (1-6).
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Bioisosteric replacement of either a hydrogen atom or a hydroxy group at the
2’- or 3’-position of the ribose moiety through a fluorine atom leads to several
interesting properties which are responsible for the pharmacological importance
of these fluoro-deoxy-nucleosides [2,3]. Although hydrogen and fluoro substituents
are comparable in terms of size and steric effects which is, for instance, import-
ant in terms of receptor binding, the overall molecular topology remains almost
unaffected [18]. Since the bond lengths of carbon-hydrogen (1.08-1.10 Å) and
carbon-fluorine (1.26-1.41 Å) bonds are comparable [19] the steric bulk of the mo-
lecule does not change significantly. However, both the pKa-value and the dipole
moment of the molecule may change and affect pharmacokinetic (PK) properties
such as logP-values as the fluorine substituent mimics closely a hydroxy group
in terms of isopolar behaviour [11]. Furthermore, the incorporation of a fluorine
substituent often leads to an increased biological stability of the new compound
against oxidative enzymatic modifications due to the high dissociation energy [20]
of the carbon-fluorine bond which is in many cases a deliberate feature in drug
design.
1.1.2 Mechanism of action
The anticancer and antiviral activity of 2’-fluorinated nucleoside analogues ob-
served in different cell lines initially requires cell uptake by certain nucleoside
transporters which are embedded in the cell membrane [21].
3
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Figure 2: Metabolism and intracellular mode of action of FAC, D-FMAU and FLT.
Most of the nucleoside transporters known so far belong to the solute car-
rier (SLC) family and are divided into Na+-dependent human concentrative
nucleoside transporters [22] (hCNT/SCL group 28) and Na+-independent human
equilibrative nucleoside transporters [23] (hENT/SCL group 29). Certain trans-
porters within these two groups are specific for particular nucleosides, such as
SLC28A2, which is a purine-specific Na+-cotransporter or SLC28A1, which is a
Na+-dependent pyrimidine-specific transporter, for instance. The 2’-fluorinated
nucleoside analogues shown above (Figure 2) are prodrugs and thus have to un-
dergo certain metabolic transformations, mostly phosphorylations, in order to
generate their cytotoxicity [24]. Depending on the phosphorylation stage cyto-
toxicity occurs due to inhibition of different target enzymes. Intracellular, 1-
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(2’deoxy-2’-fluoroarabinofuranosyl)cytosine (5, FAC), for instance, is first mono-
phosphorylated to FAC-MP which can either be deactivated by deoxycytidylate
deaminase (dCTD) or transformed into the diphosphate FAC-DP which is a po-
tential inhibitor of ribonucleotide reductase (RR) [25]. The triphosphate form
FAC-TP represents the actual cytotoxic metabolite that is incorporated into DNA
causing chain termination and subsequent apoptosis (Figure 2) [25].
The described intracellular mechanism of action of FAC is not coercively
transferable to any other 2’- or 3’-fluorinated nucleoside analogue nucleoside but
should rather be regarded as a model system for a general description of possible
intracellular transformations. Depending on the nucleoside analogue and the
cell type examined, the mode of action may be different. However, it gives an
overview about some important aspects that have to be considered concerning
nucleoside analogues as potential drug candidates. Targeting an intracellular
pathway to treat a particular disease often raises pharmacological questions such
as cell uptake and metabolic deactivation of drug molecules, especially in the case
of nucleoside analogues. Gemcitabine will be used as an important example to
highlight these pharmacological issues.
1.1.3 Gemcitabine
Initially developed as an antiviral agent [26] 2’,2’-difluoro-2’-deoxycytidine (1, gem-
citabine, dFdC) showed significant activity against leukaemia cell lines in vitro
in pre-clinical testing [27]. Today, it is used in chemotherapy for the treatment
of various carcinomas such as lung, breast, bladder and especially pancreatic
cancer [28], both alone or in combination with other chemotherapeutics such as
carboplatin [29] or paclitaxel [30].
Gemcitabine shows high cytotoxicity against various cancer cell lines it is
thus approved for the first line treatment of advanced and metastatic pancreatic
cancer [31]. However, general application and bioavailability are compromised due
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to both poor cell uptake and rapid metabolism by gut and liver cytidine deaminase
(CDA) resulting in the toxic side product 2’,2’-difluoro-2’-deoxyuridine (dFdU) [32].
Hence, gemcitabine is applied intravenously on a frequent schedule in order to
extend the systemic exposure time as much as possible. The human terminal
plasma half-life of dFdC is about 17 min [33].
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Figure 3: Metabolism and intracellular mode of action of Gemcitabine 1.
Cellular uptake of dFdC occurs via subtypes of both transporter families
hCNT and hENT. Even though dFdC is a substrate of hCNT1-3 and hENT1-2
with varying affinities, hENT1 seems to play a major role for dFdC cell uptake
as hENT1-deficient cells show resistance to dFdC treatment [34]. Consequently,
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cell uptake is one of the main factors that limit bioavailability of dFdC and
nucleoside transporter gene expression constitutes one of the key mechanisms of
dFdC sensitivity [35].
Once affiliated by the target cell through active transport either monophos-
phorylation catalysed by deoxy-cytidine kinase (dCK) or deamination catalysed
by deoxy-cytidine deaminase (dCDA) [36] occurs to give pre-activated dFdCMP or
deactived dFdU, respectively [37]. In fact, dCK-mediated phosphorylation is the
rate-limiting step in the bioactivation sequence of dFdC. Potential prodrugs able
to circumvent this step would enhance bioactivation of dFdC while using reduced
administration doses which could significantly reduced side-effects such as nausea,
vomiting and gastric ulceration [38]. Mutational dCK-deficiency is another mech-
anism of intrinsic dFdC resistance [39] besides hNT deficiency described above.
The mono-phosphate form dFdCMP can either be deactivated to dFdUMP or
metabolized to the first active metabolite dFdCDP which is an inhibitor of ribo-
nucleotide reductase (RR) and thus depletes the ribonucleotide pool required
for DNA synthesis [40]. Further phosphorylation results in the triphosphate form
dFdCTP, the second active and most important metabolite of dFdC which is
incorporated into DNA/RNA and hence leads to apoptosis [41].
Since the active nucleotide analogue dFdCTP is a substrate of DNA-poly-
merase I as its natural counterpart deoxycytidine triphosphate (dCTP), dFdCTP
inhibits DNA-polymerase I competitively. Once incorporated into DNA dFdCTP
leads to DNA chain termination [42]. Furthermore, incorporation of dFdC into
DNA appears to be resistant to the usual mechanisms of DNA repair. However,
details concerning this fact still remain unclear [43].
Recently published data indicate that gemcitabine-ProTides are able to by-
pass these resistance mechanisms [39]. In fact, dFdC-ProTide NUC-1031 (Scheme
1.1) is currently in Phase I clinical trial for various cancers [39] and consists of a
chiral phosphoramidate moiety which represents a pre-activated form of the mono-
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phosphate form dFdCMP. The biolabile residues are cleaved in an intracellular
step-by-step bioactivation pathway to finally give dFdCMP. This 5’-modification
strategy not only bypasses the key rate-limiting monophosphorylation step but
also allows transporter-independent uptake of NUC-1031 and improved resistance
to CDA-mediated deamination in-vivo.
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in-vivo enzymatic
activationF
F
N
O
NH2
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Scheme 1.1: Intracellular in-vivo activation of the novel gemcitabine-ProTide
NUC-1031 towards dFdCMP involves different enzymes such as esterases and
phosphoramidase-type enzymes.
1.2 Positron emission tomography imaging
Positron emission tomography (PET) imaging is a cross-sectional (tomographic)
functional imaging modality that is used to diagnose many types of cancer [44] as
well as a variety of other diseases such as gastrointestinal, endocrine and neurolo-
gical disorders [45]. Even though magnetic resonance imaging (MRI) serves clinic-
ally a high spatial resolution in the submillimetre range [46,47], PET is the method
of choice for in vivo imaging applications, especially in oncology [5]. For instance,
according to the molecular imaging and contrast agent database (MICAD), 41%
of all molecular imaging probes listed were PET-based [48,49]. Picomolar tracer
concentrations [50] and high sensitivity makes PET the imaging modality of choice
within pre-clinical, clinical and drug development studies [51].
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One of the prime reasons for the importance of PET is the availability of
organic positron-emitting radionuclides [52] such as 11C, 13N,15O and 18F that are
radionuclides of elements that are occurring in natural and synthetic biologically
active compounds. Hence, PET radiotracers can be developed that are chemically
and biologically identical or similar to existing natural or synthetic biomolecules
and may be able to provide quantifiable information about their pharmacokinetic
(PK) and pharmacodynamic (PD) properties in vivo [53].
1.2.1 Physical principles of PET imaging
Radioactive decay
The radioactive labelled molecules used in PET imaging contain ‘proton-rich’
radionuclides that decay under spontaneous emission of a positron (β+-particle)
and a neutrino [54]. The resulting nuclear transmutation of a proton to a neutron
within the nucleus does not change the mass number A (sum of all nucleons) of
the radioactive atom but reduces the atomic number Z (sum of all protons) by
one unit. Consequently, an atom of a chemical element X is transformed into an
atom of a chemical element Y that is less by one unit (Z-1) [55] (Equation 1.1).
The nuclear transmutation is exemplified by the β+-decay of the 18F radionuclide
(Equation 1.2):
A
ZX →
A
Z−1Y + e
+ + ve (1.1)
18
9 F→
18
8 O+ e
+ + ve (1.2)
Radioactive decay is a statistical process and thus individual nuclear decays are
purely random. The radioactive decay can be quantified by the radioactive decay
law where the number of disintegrations per unit time (dN/dt) is proportional to
the total number N of radioactive nuclei in the probe [56]:
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dN
dt
= −λN (1.3)
The decay constant λ is radionuclide-specific [57]. The solution of this first-order
differential equation can be written as:
N(t) = N0 exp (−λt) (1.4)
The half-life of a radionuclide is defined as the time t1/2 taken for half the radio-
active atoms to decay:
N(t = t1/2)
N0
= 0.5 = exp (−λt1/2) (1.5)
which leads to the following expression:
t1/2 =
ln(2)
λ
(1.6)
γ-Ray detection and image reconstruction
After emission, the positron travels a certain distance in the tissue while losing
energy until it annihilates with an electron into two nearly antiparallel γ-photons
that can be detected by external γ-detectors. The loss of energy from the positron
is due to Coulomb interactions with electrons of atoms of the surrounding tis-
sue [56]. The distance travelled by a positron until annihilation depends on its
initial energy which in turn depends on the radionuclide and imposes a limit
of the physical resolution of this modality. The use of different radionuclides [5]
(Table 1) in PET consequently leads to different spatial resolutions [53].
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Table 1: Selected radionuclides used in PET imaging
radionuclide Half-life β (positron) emission
124I 4.17 days β+, 1535 keV (11.8%),
2138 keV (11%)
64Cu 12.7 h β+, 653 keV (17.9%),
β−, 578.7 keV (39%)
18F 109.8 min β+, 633 keV (96.7%)
11C 20.39 min β+, 960 keV (99.8%)
13N 10 min β+, 1199 keV (99.8%)
18O 2 min β+, 1732 keV (99.9%)
According to the laws of conservation of energy, the electric charge, the lin-
ear and angular momentum a positron-electron annihilation event results in two
nearly antiparallel (180±0.25◦) [56] γ-photons with an energy of 511 keV [58] (Fig-
ure 4). Positron emission tomography imaging uses exactly these two diamet-
rically emitted photons for the reconstruction of the spatial radioactivity distri-
bution within the object. The deviation of the angle between the annihilation
photons from the exact 180◦ angle contributes to the inherent degradation of
spatial resolution in all PET detector systems [56].
Figure 4: Physical principle of PET showing the annihilation process of an emitted
positron with an electron using the PET probe 18F-FDG as an example. The generated
nearly antiparallel 511 keV γ-rays are subsequently used to reconstruct the spatial
radioactivity distribution within the object.
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The 511 keV annihilation γ-photons that reach the external detector system
are registered using scintillation crystals. Incoming high energy photons are ab-
sorbed and their energy subsequently re-emitted as low energy photons in the
range of visible light or near UV [56]. PET scanners may use different material
for scintillation crystals such as the inorganic crystals BGO [59] (Bismuth german-
ate, (Bi4Ge3O12)), LSO [59,60] (Lutetium orthosilicate, (Lu4Si3O12)), lanthanum
chloride (LaCl3) [61] or lanthanum bromide (LaBr3) [61], among others. Different
material results in varying physical characteristics of the scintillation crystals such
as energy resolution and light output [62] and hence may influence the sensitivity
of the PET scanner [63].
Considering a single PET detector, the scintillation crystals are located at
the front of the detector and are coupled with a visible light sensor such as
a photomultiplier tube (PMT) or an avalanche photodiode (APD, suitable for
PET/MRI systems due to the sensitivity of PMTs to strong magnetic fields) [64]
which is located behind the crystal matrix. For instance, a crystal matrix of 64
(8 × 8) single scintillation crystals may be coupled with 4 PMTs (each PMT
is located directly behind 16 single crystals) [55] (Figure 5, left). Low energy
photons that are re-emitted by the scintillation crystal are detected by the PMTs
and transformed into an electrical signal. In order to prevent crosstalk between
single crystals they are separated by mirror-coated cuts so that the re-emitted
low energy photons can only reach the PMTs behind the crystal matrix.
A light-distributor is located between the scintillation crystals and the PMTs
to ensure that the low energy photons emitted by one of the 64 single crystals
can reach all 4 PMTs (Figure 5). The single crystal that initially detected the in-
coming γ-photon can consequently be identified by comparing the different light
intensities measured within the PMTs [65,66]. The identification of the single crys-
tal is important in order to locate the annihilation event as precisely as possible
to ensure high spatial resolution of the PET scanner [66]. Figure 5 shows a schem-
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atic figure (left) and a single PET detector (right)∗ currently utilised in PET
scanners.
One single crystal 
(e.g. BGO, LSO)
Cuts
Front view Side view
One single crystal
Lightdistributor
Photomulitplier tube (PMT)
Single PET detector block
Figure 5: Left: Schematic figure of a scintillation detector. Each detector may contain
64 (8×8) single crystals coupled with 4 PMTs. An incoming γ-photon is registered by
one of the 64 crystals which can afterwards be identified by comparing the different
light intensities that were measured within the PMTs. However, the detector size
limits the spatial resolution. The smaller the detector the better the resolution. Right:
A scintillation detector used in modern PET scanners. Usually, several thousand single
crystals are utilised in a PET scanner detector system.
The detector system of a PET scanner consists of many single detectors (the
number of rings and single detectors may depend on the scanner type) that are
arranged perpendicular to the scanner axis in parallel detector rings (Figure 6,
right)†. Each detector generates an electric signal when it registers an incident
photon [56]. If the electric signals of two opposite detectors are detected within a
coincidence time window (≈6-12 ns) [67] they are considered to be coincident [68].
The coincidence event is assigned to a line of response (LOR) that connects both
detectors involved in the detection (Figure 6, left). Thus, in combination with
the measured time difference of the detected photons, positional information of
the annihilation event is gained (electronic collimation) without using a physical
collimator [55].
∗http://cfi.lbl.gov/instrumentation/instrumentation.html
†http://cerncourier.com/cws/article/cern/29248
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Figure 6: Left: The emitted positron travels a distance within the tissue until it
annihilates with an electron and forms two antiparallel 511 keV γ-rays which can be
detected by two opposite detectors of the detector ring. A coincidence event is assigned
to a line of response (LOR, dashed red line) that enables the localisation of the anni-
hilation event. Right: Schematic figure of parallel detector rings that are arranged
perpendicular to the scanner/object axis.
In addition to ‘true’ coincidences where both annihilation photons reach the
detector without being scattered or absorbed random and scattered coincidences
are measured during a PET scan [69] (Figure 7). Furthermore, attenuation, which
is the loss of true coincidences due to scatter and absorption of annihilation
photons within tissue, must be taken into account for the correction of the ac-
quired raw data in order to obtain a correct quantitation of the radioactivity
distribution. Hence, correction algorithms are applied to the acquired raw data
in order to keep the degradation of the PET images at a minimum [55,69].
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Figure 7: True (left), scattered (middle) and random (right) coincidences are registered
in the PET detector ring. Scattered and random coincidences, however, may be as-
signed to the wrong LOR (dashed red lines). The amount of scattered and random
coincidences depends on the volume and attenuation characteristics of the object that
is being imaged and has to be corrected from raw data.
For 3D image reconstruction, data acquisition can either be performed in 2D-
or 3D-mode depending on the type of acquired data. In 2D-mode, coincidence
detection is allowed only within one detector ring (direct) or between detectors
of closely neighbouring detector rings (indirect) [70]. However, if coincidences are
detected by any detector of any detector ring (cross coincidences), an increased
number of coincidence events is detected which in turn leads to an increased
sensitivity and a higher signal-to-noise ratio [71,72]. At the same time the amount
of detected scatter and random coincidences also increases so that more soph-
isticated 3D reconstruction algorithms have to be applied. Most scanners have
the capability of data acquisition in both 2D- and 3D-mode by retracting septa.
Septa are thin rings made of lead or tungsten that can be placed between detector
rings to reduce cross coincidences [69]. Furthermore, the combination of PET as
a functional imaging technique with computed tomography (CT) as a structural
imaging modality not only allows acquisition of both functional and structural
data in one study but also improves the quantification of PET data by more ac-
curate correction of attenuation [73]. For that purpose, a CT transmission scan is
carried out using an external X-ray source (≈30-120 keV photons) and an atten-
uation map is generated based on the measured attenuation of the transmission
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X-rays [74,75]. The attenuation coefficients obtained from the CT scan are then
scaled to reflect the attenuation of the high-energy γ-photons (511 keV) and are
applied to the emission data from the PET scans for more accurate attenuation
correction [74].
After the raw data have been corrected from scattered and random coincid-
ences, attenuation, as well as detector dead-time, the number of counts assigned to
a LOR that connects a pair of opposite detectors is proportional to a line integral
of radioactivity along that LOR. Parallel sets of line integrals create projections
that are used for image reconstruction [69]. The reconstruction of an image from
projections can either be analytical or iterative. Filtered-back projection, for in-
stance, represents an analytical procedure to reconstruct images in 2D-mode and
has been widely applied [63,76]. Even though iterative algorithms such as OSEM
(Ordered subsets - Expectation maximization) [63,77] require longer computation
times, the generated images reflect the radioactivity distribution more accurately.
Thus, 3D-mode acquisition and iterative algorithms for image reconstruction are
the method of choice in PET imaging supported by advances in information and
detector technology [63,69].
The principle of radiotracers
The principle of radiotracers defines a radiotracer as a radiolabelled biologically
active molecule that can be used to trace its natural analogue in vivo and hence
provide information about biological processes in living organisms [78–81]. Regard-
ing PET, a radiolabelled tracer usually consists of a pharmacophore or targeting
moiety and a positron-emitting radionuclide [52]. The tracer principle is further-
more based on the fact that the chemical and biological properties of a certain
molecule remain unchanged when a stable atom is replaced by a radionuclide of
the same element [51,52]. For instance, replacing a 19F-substituent of a certain drug
molecule by the positron-emitting radioisotope 18F will not change the behaviour
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of this molecule in biological systems [82]. In addition to the isotopic exchange
that transforms a natural biologically active molecule into a radiotracer with
identical biological properties (isotope tracer), a radiotracer may be chemically
different from its natural analogue (analogue tracer) [52]. For instance, 11C-glucose
is chemically identical to natural glucose whereas the 18F-labelled glucose ana-
logue 2-[18F]fluoro-2-deoxy-glucose (18F-FDG) is chemically different to natural
glucose and hence behaves differently in biological environments. More precisely,
18F-FDG is transported into cells facilitated by glucose transporters (GLUT) and
subsequently phosphorylated in the 6-position by hexokinase to form 18F-FDG-
6-phosphate. 18F-FDG-6-phosphate, however, is not further metabolised along
the glycolytic pathway and thus accumulates inside cells in proportion to their
glucose uptake [83]. That is the principle of 18F-FDG PET [84].
Regarding non-invasive functional imaging techniques such as PET, the ad-
vantage of replacing a stable and non-radioactive isotope of a certain element
by a positron-emitting radionuclide is that the detection of the latter is possible
with high sensitivity compared to the stable isotope as the resulting highly ener-
getic annihilation γ-photons may be detected outside the object using sensitive
γ-detectors as described above. As a result, the physiological concentrations of
radiotracers can be low enough to be considered as ‘non-pharmacological’, indicat-
ing that the tracer has no pharmacodynamic effects [85,86]. Hence, it is possible to
gain information about PK parameters such as biodistribution, metabolic rates,
retention in target tissue and clearance without disturbing the system or having
a toxic effect in organisms [79,86,87]. In fact, PET is an emerging modality in the
drug development process and can be used to obtain information about human
PK in the early stage of human clinical trials in order to reduce costs and identify
poor performing compounds early in the development process [82]. A PET tracer
may be used to image a certain biological target or pathway. For that purpose,
the tracer must meet specific requirements such as high target specificity, low
non-specific binding and a distribution profile that depends on the concentration
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of the target [52,88]. Furthermore, the PK of the tracer should match the physical
half-life of the utilised radionuclide in order to image the biological process in
the appropriate time frame and with an adequate signal-to-noise ratio [52,89]. For
instance, the physical half-life of 89Zr (78.41 h) matches the biological half-life
of monoclonal anti-bodies (T1/2 of days) [90] and hence is used to label mono-
clonal antibodies for PET studies [91]. Additionally, PET may depend on certain
tracer-target interactions such as enzymatic conversion, e.g. phosphorylation in
the case of 18F-FDG or 18F-FLT, binding to a specific transporter or receptor, or
adsorption in case of [18F]-NaF as a bone-seeking radiotracer [92].
Altogether, more than 500 PET probes are currently available [54] that address
various biological targets. However, not every PET probe produces the desired
results in terms of target specificity, for instance, and the radiochemical syntheses
are often complex and not suitable for automated GMP production and hence hu-
man clinical applications [48]. In fact, tracer availability from a synthetic point of
view is currently one of the main limitations in PET [48], despite inherent physical
limitations such as spatial resolution [93]. The development of novel PET tracers
using radionuclides such as 18F, 11C, 64Cu and 89Zr, as well as the improvement
of the radiochemical accessibility of existing tracers is of great interest in current
PET research [48,53,94].
This research project lies within the field of PET-radiochemistry with focus
on the development of novel synthetic routes towards 2’-18F-labelled nucleosides.
1.2.2 Common PET radionuclides
PET imaging can be performed using different positron-emitting radionuclides
such as 11C, 18F and 15O. Despite their physical characteristics such as half-life
and positron energy, different radionuclides have mostly varying biological applic-
ations as they are linked to a certain class of biomolecules. For instance, 89Zr
and 64Cu are commonly used for antibody labelling whereas 15O-water or 13N-
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ammonia are suitable imaging probes for perfusion studies [95]. Antibody-labelling
using either 89Zr or 64Cu-complexes is mostly performed using cycloaddition or
’click’-chemistry [96] to attach the ligand system to the antibody (Scheme 1.2). [97]
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Scheme 1.2: Antibody-labelling with 64Cu using a trans-cyclooctene moiety which
is attached to the antibody and a tetrazine linked to the 64Cu-complex. The inverse
electron-demand Diels-Alder reaction generates nitrogen as a byproduct.
A recent report by Kung et al. [98] indicated that 64Cu-labelled anti-CD99 anti-
body was capable of imaging glycoprotein CD99 expression in mouse xenographs
(675 CD99+ xenographs). CD99 is a diagnostic marker in routine histologic
staining for Ewing sarcoma cells. This study did not only demonstrate that 64Cu-
labelled antibody imaging is able to replace invasive histological methods but also
that small lesions, otherwise only detectable by MRI but not with 18F-FDG-PET,
can be imaged. Similar experiments using 89Zr instead will be repeated [98] as its
longer half-life (78.4 h compared to 12.7 h for 64Cu) allows imaging studies at a
later time point after injection resulting in a higher signal-to-background ratio
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due to clearance of non-bonded antibodies.
As immunotherapy is becoming an alternative and effective way in the treat-
ment of various cancers and other diseases, [99]genetically engineered and 64Cu-
labelled minibodies (Mbs, reformatted antibody fragments) were used to image
CD8+ T cells in mouse models [100]. The detection and quantification of CD8+
expression in CD8+ lymphomas is critical in the evaluation of treatment response
in cancer immunotherapy.
Until a decade ago, 124I has found almost no recognition in PET mostly due
to its complex decay pattern where only ≈23% of disintegrations lead to positron
emissions [101,102]. However, its well-understood behavior in vivo as well as its
long half-life of about 4.2 days allows imaging studies of slow and complex PK at
low background noise [103]. Indeed, a study by Robinson et al. showed that 124I-
PET dosimetry using a genetically engineered 124I-labelled antibody fragment
was capable of imaging HER2 receptor tyrosine kinase expression in xenograft
models, which is potentially useful for planning the treatment of HER2-positive
cancer [104]. Another study performed by Jentzen et al. used 124I-PET dosimetry
in order to estimate therapeutic doses of 131I-radiotherapeutics for patients with
differentiated thyroid cancer [105].
Besides 18F, 11C is the most commonly used radionuclide in the early dia-
gnosis of cancer and for monitoring treatment response [106] as its labelling chem-
istry became more advanced and clinically applicable [53] to a large variety of
tracers with broad application [107]. 11C-acetate (Figure 8), for instance, was
found to be superior to 18F-FDG in imaging prostate cancer, especially at an
early stage of the disease where 18F-FDG-PET is quite unreliable mainly due to
low glucose uptake of most prostate cancers [108]. Reets et al. used 11C-methionine
([C-11]-MET, Figure 8) PET, a marker for tumour uptake of amino acids and
protein synthesis, in order to study its potential superior sensitivity to 18F-FDG
PET for determination of 3D-target volumes in head and neck cancers prior to
20
1 Introduction
radiotherapy [109]. However, their study demonstrated that 18F-FDG PET is ac-
tually superior over [C-11]-MET PET in terms of showing correct target volumes
mainly due to low tissue discrimination of [C-11]-MET PET. This result is an
example of the actual strength of 18F-FDG PET and its clinical significance and
is amongst other reasons explaining why 18F-FDG PET is still the work horse in
clinical cancer imaging [110].
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Figure 8: Structures of the 11C-labelled PET probes 11C-acetate and [C-11]-MET.
Despite the range of different radionuclides potentially available for applications
in PET imaging 18F has an outstanding role due to certain properties.
1.2.3 Advantages of the 18F radionuclide
According to the physical data shown above (Table 1) the 18F radionuclide com-
bines a sufficient half-life for radiosynthesis with an optimal positron energy [111].
A half-life of around 110 minutes enables both an adequate time frame for tracer
synthesis (radiofluorination as key synthetic step followed by deprotection and/or
other chemical modifications) as well as a minimisation of the radiation dose to
the patient [48,112]. Additionally, 18F decays almost exclusively through positron
emission (18F decay mode to 18O: β+-emission (97%) and electron capture (EC,
3%)) [113] that have a relatively low energy compared to positrons of other util-
ised PET radionuclides (see table 1). Subsequently, the annihilation event into
two antiparallel 511 keV γ-rays occurs on average closer to the point of emission
which leads to a higher spatial resolution (≈1-2 mm for pre-clinical and 4-5 mm
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for clinical PET) [48,52]. Another advantage of using 18F in PET imaging is linked
to the common use of fluorine as a bioisosteric substituent in drug molecules as
an isotopic exchange does not effect either PK or PD of the bioactive fluorinated
molecules [114].
1.2.4 18F-FDG PET
18F-FDG (7) was first synthesised in 1978 [115] and the first scans were performed
by Shields et al. [116] in 1979 at the University of Pennsylvania. Currently, the
glucose analogue 18F-FDG (Figure 9) is the most widely used PET tracer in
oncology [117] (≥90% of all scans), mainly for diagnosing and staging various types
of cancers [118]. Cells of malignant tumours mainly use glycolysis and subsequent
lactic acid fermentation (’Warburg Effect’) [119] for the rapid production of energy
equivalents needed due to upregulated cell proliferation and cell division.
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Figure 9: Structure of the widely used glucose analogue 18F-FDG (7).
The chemically modified 2-position of the pyranose ring does not significantly
impact the affinity of 18F-FDG for both the glucose transporter and cytosolic
hexokinase [114]. The latter is responsible for intracellular 6-O-phosphorylation
which traps the tracer inside the cell since charged molecules are not capable
of passing the cell membrane. Phosphofructose isomerase, however, does not
tolerate the substitution at the 2-position which is why 18F-FDG-6-phosphate
remains unmetabolised in the cytosol [114]. Both, increased glucose uptake and
phosphorylation are important parameters that distinguish malignant tumour
cells from most normal body tissue apart from inflammatory lesions of necrotic
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cells, T-cells, bone marrow and the brain, for instance [120]. Hence, 18F-FDG
PET lacks specificity due to cells that carry out body functions that require
high glucose metabolism. For instance, small lesions located in the bone marrow
are not detectable with 18F-FDG-PET due to high background signal and hence
require more specific approaches [100]. The development of novel tumour and
tissue specific radiotracers is indeed of great interest to current research [48,88] as
current clinical practice still depends on a combination of different invasive and
non-invasive imaging techniques to fully understand tumour characteristics.
1.2.5 18F-labelled nucleoside analogues used in PET imaging
As this research project focuses on novel radiosynthetic routes towards 18F-labelled
nucleosides, the following section will briefly introduce selected nucleoside-based
PET probes by highlighting their application and main limitations.
Overview
As nucleoside analogues such as gemcitabine, clofarabine, and cytarabine are
widely used in the treatment of cancer [21,121] (about one in six small molecule an-
ticancer agents are nucleoside-based antimetabolites) [122], 18F-labelled nucleoside
PET probes are considered capable of providing a deeper understanding of drug
behaviour in vivo and important imaging tools towards personalised treatment
approaches with nucleoside-based chemotherapy [123]. The multiplicity of interac-
tions that nucleosides undergo in biological environments and the resulting lack
of selectivity of nucleoside analogues in cancer treatment [122] makes nucleoside
based PET imaging highly desirable for both clinicians and patients with the
prospect of individualised nucleoside based chemotherapy [124]. Figure 10 shows
structures of some of the most commonly used 18F-labelled nucleosides.
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Figure 10: Selected 18F-labelled nucleosides (8-16) currently used in clinical dia-
gnostics and 18F-PET research.
Although several 2’- and 3’-18F-labelled nucleosides are of great importance as
PET probes in clinical diagnostics and PET research [10,125] 18F-FLT is currently
the only 2’- or 3’-18F-labelled nucleoside based PET tracer that is routinely used
in clinical practice.
The first nucleoside-based PET tracer 11C-thymidine [126] was developed in
the early 70s. However, 11C-thymidine was substituted by the much more con-
venient PET tracer 18F-FLT (8) due to both the longer half-life of the 18F radi-
onuclide and an improved biostability in vivo [127]. 18F-FLT is synthesised using
automated module systems and produced under good manufacturing practice
(GMP) guidelines [128,129] for clinical use.
18F-FLT
As a successor of 2-11C-thymidine [126] 18F-FLT shows a higher biostability [127] in
vivo as it is not a substrate for thymidine phosphorylase. 18F-FLT is accessible via
an effective radiochemical synthesis in good RCY (19.8%, decay-corrected) and
purity suitable for human production under GMP guidelines [128,129]. Further-
more, the longer half-life of the 18F radionuclide (110 min) simplifies synthesis,
quality control and the imaging process significantly (see section 1.4.1). Hence,
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18F-FLT is currently commonly used for the early detection of various cancers [130]
and the evaluation of treatment response [131]. After cell uptake by passive dif-
fusion or facilitated transport 18F-FLT is 5’-phosphorylated by TK-1, the key
enzyme in the salvage pathway of DNA synthesis, which traps the nucleoside
monophosphate inside the cell [132]. This enzyme is significantly upregulated in
malignant tissue compared to quiescent cells [133] as the majority of the malignant
cell population is in the S-phase of the cell cycle. Thus, 18F-FLT is used as a pro-
liferation marker in clinical oncology. The nucleoside triphosphate 18F-FLT-TP,
however, is not incorporated into DNA due to the absence of the 3’-OH group but
rather acts as a chain terminator [130], which is why 18F-FLT is not a marker for
DNA synthesis [134]. This is a limitation as tumour cells which utilise the de novo
thymidine salvage pathway via TS catalysed dUMP methylation [135] give a false
negative response. However, 18F-FLT PET provides in many cases more distinct
information compared to 18F-FDG PET, especially in high-grade tumours where
it appears to be more predictive of treatment response and survival [127,136].
18F-FAU
The treatment of colorectal, breast as well as head and neck cancer with thymidylate
synthase (TS) inhibitors such as 5-fluorouracil (5-FU) [137] or floxuridine [138] is
mainly compromised due to over-expressed TS [139]. As a substrate of TS 18F-
FAU seems suitable for imaging TS expression and hence treatment prediction
for TS inhibitors such as 5-FU or FAU, respectively. Furthermore, a study [140]
using 18F-FAU as a biomarker for the incorporation of the metabolite 18F-FMAU
into DNA indicated that FAU could indeed serve as a prodrug in patients with
high TS expression. In contrast, however, Sun et al. [141] found that 18F-FAU has
limited use as a proliferation marker due to its low affinity to thymidine kinase 1
(TK-1) which is even more significant at low tracer concentrations.
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18F-FMAU
Unlike 18F-FLT, 18F-FMAU is significantly incorporated into DNA [130] and thus
a superior PET probe for proliferation as DNA synthesis is a much more accur-
ate parameter for cellular proliferation than simply TK-1-mediated phosphoryla-
tion [142]. In-vitro studies [143,144] demonstrated that FMAU retention is propor-
tional to its DNA-incorporation and cytotoxicity. PET studies in dogs [144] showed
that 18F-FMAU uptake in highly proliferating tissue such as bone marrow and
testicles is significantly higher than in normal tissue indicating that 18F-FMAU
might be a strong candidate for imaging DNA synthesis in vivo. Indeed, human
studies with brain and prostate cancer patients using 18F-FMAU [145] were carried
out showing that 18F-FMAU is a reliable marker of DNA-synthesis/cell prolifer-
ation with a significantly shorter imaging period (5-11 min, instead of 50-60 min
in the case of 18F-FDG).
18F-FAC
Studies reported by Lee et al. [124] and Nathanson et al. [146] suggest that the de-
veloped PET probe 18F-FAC is a promising candidate to determine treatment
response to nucleoside analogues based chemotherapy. In fact, 18F-FAC has been
used in a non-invasive tumour response study [25] with gemcitabine as the chemo-
therapeutic agent [147]. Since 18F-labelled gemcitabine is not available as a PET
probe, 18F-FAC was expected to reveal some of the unknown metabolic para-
meters such as cell uptake and deamination and whether or not the outcome of
a gemcitabine-based chemotherapy could be predicted. FAC as well as gemcit-
abine are specific substrates for both deoxycytidine kinase (dCK) and deoxycytid-
ine deaminase (dCDA) which are rate-limiting enzymes in the nucleoside salvage
pathway. Hence, 18F-FAC PET may provide a powerful and non-invasive clinical
tool to examine potential resistance mechanisms of tumours against these drugs
caused by overexpression of deactivating enzymes such as dCDA [147]. Further-
26
1 Introduction
more, lymphoid organs and related immune activation mechanisms have been
studied using 18F-FAC PET [16].
1.3 Synthesis of non-radioactive fluorinated
nucleosides
With regard to this research project, the following section will focus on the non-
radioactive synthesis of 2’- and 3’-fluorinated nucleosides.
1.3.1 Early-step fluorination
The fluorine substituent can be incorporated either early or late during a multi-
step synthesis. One approach is to introduce the fluorine substituent before the
appropriate base moiety is attached. This is realised by either using fluorine
containing starting materials or an early-step fluorination. The Eli Lilly syn-
thesis [28,148] of gemcitabine is based on Hertel’s general method [149] to synthesise
2’-deoxy-2’,2’-difluoro-D-ribofuranosyl nucleosides (Scheme 1.3). This multi-step
synthesis [28] is one among several other approaches to give gemcitabine [28] and
starts with the difluorinated precursor ethyl-bromodifluoroacetate 18 and thus
exemplifies the use of fluorine containing starting materials.
27
1 Introduction
O
O
O
F F
Br
O
OEt i
O
O OEt
O
F F
OH
O
O OEt
O
F F
OH
ii O
OH
HO
O
F
F
iii
O
TBDMSO
TBDMSO
O
F
F
iv O
TBDMSO
TBDMSO
F
F
OH v
O
TBDMSO
TBDMSO
F
F
OMs
vi,vii
N
NH2
ON
O
OH
HO
F
F
Reagents and conditions: i) Zn, THF/Et2O, reflux, 1 h, 65% (a); ii) Dowex 50W-X12, r.t., 4 d, 95% 
iii) TBDMSOTf, 2,6-lutidine, DCM, 12 h, 92%; iv) DIBAL-H, toluene, -78°C, 2 h, 79%; v) MsCl, Et3N, 
DCM, RT, 3 h, 90%; vi) bis(trimethylsilyl)-N-acetylcytosine, TMSOTf, DCE, reflux, 15 h; vii) AG 50W
-X8, MeOH, r.t., 12 h, 10% (β−anomer, after both steps).
O
O OEt
O
F F
OH
17 18 19a 19b
19a 20
21 22
23 1
Scheme 1.3: Hertel’s method for the synthesis of gemcitabine 1.
The main disadvantage of this approach is the lack of diastereoselectivity
when the base moiety is attached and thus includes many separation steps using
HPLC. The improved modern synthesis of 1 at least avoids one isomeric separa-
tion step due to the preparation of the gem-difluorolactone using the electrophilic
fluorination reagent N-fluorobenzenesulfonimide (NFSI) and the corresponding
monofluorolactone 25. The latter is an important intermediate in the stereose-
lective synthesis of clofarabine [148] 2 and thus represents an example for early-step
fluorination (Scheme 1.4).
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Scheme 1.4: NSFI-mediated fluorination step within the stereoselective synthesis of
clofarabine 2.
Due to synthetic challenges in 18F-radiochemistry primarily caused by the
half-life of the 18F radionuclide, late-stage fluorination as an alternative strategy
for the introduction of a fluorine substituent will be presented in the following
section.
1.3.2 Late-stage fluorination
Organic deoxofluorination agents
Due to a high demand for powerful fluorination methods in pharmaceutical and
life sciences, deoxofluorination agents were developed that provide the accessibil-
ity of a variety of fluorinated organic compounds including nucleoside analogues.
Initially, it was found that the highly toxic and corrosive inorganic gas SF4 en-
abled deoxofluorinations of hydroxy-, carbonyl-, and carboxylic acid compounds
into the monofluoro, difluoromethylene, and trifluoromethyl derivatives, respect-
ively [150]. Regarding laboratory safety restrictions and common principles in
organic chemistry such as functional group interconversion (FGI), new organic
fluorination agents should be able to combine safe handling with efficient and con-
trollable reaction conditions. This led to the development of organic fluorination
agents with enhanced stabilities such as DeoxoFluor (26, bis(2-methoxyethyl)-
aminosulfur trifluoride) [151], DAST (27, diethylaminosulfur trifluoride) [152], Xtal-
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Fluor E (28, (diethylammino)difluorosulfonium tetrafluoroborate) and XtalFluor
M (29, difluoro(morpholino)sulfonium tetrafluoroborate) [151,153] (Figure 11).
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O O N
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26 27
N SF2
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N SF2
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28 29
Figure 11: Organic fluorination agents.
These SF4-based fluorination agents lead to deoxofluorinations according to
the following general mechanism [20] (Scheme 1.5).
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Scheme 1.5: General mechanism of deoxofluorination using SF4-based fluorination
agents.
As mentioned above DAST enables important functional group interconver-
sions that have already been applied to the synthesis of nucleoside analogues [154,155]
such as 2’-fluoro-2’-deoxyuridine (31 ,2’-FU) (Scheme 1.6).
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Scheme 1.6: DAST-promoted deoxofluorination towards 2’-FU (31).
Even though widely used in deoxofluorination reactions with a broad spec-
trum of different substrates [156] DAST was found to be thermally unstable and
highly explosive. Furthermore, DAST generates corrosive HF and often olefinic
elimination side products. The organic salts XtalFluorT M E (28) and M (29)
allow safer handling as well as high chemo - and stereoselectivities under specific
reaction conditions, whereas the reaction mechanism remains the same [153]. Even
deoxodifluorinations of aldehydes and ketones towards difluoromethylene com-
pounds are accessible in good yields with XtalFluor reagents [153] (Scheme 1.7).
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Scheme 1.7: XtalFluor E (28) and M (29) enable deoxofluorination reactions with
high chemoselectivities in good yields.
A more heat-stable alternative for various deoxofluorinations was reported
by using Fluolead [157] (32). Several hydroxy- and carbonyl compound could be
converted to the corresponding fluoro-, and difluoromethylene derivatives, respect-
ively (Scheme 1.8).
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Scheme 1.8: Fluolead-mediated deoxofluorinations.
Deoxodifluorination of the 2’- and 3’-position of nucleoside analogues
Deoxodifluorination of 5’-O-trityl-3’-ketothymidine 33 to give 5’-O-trityl-3’-deoxy-
3’,3’-dilfluorothymidine 34 has been reported [158] as a slow transformation with
low yields of the gem-difluorinated product using DAST (Scheme 1.9).
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Scheme 1.9: DAST-mediated 3’-deoxodifluorination of 3’-keto precursor 33.
Regarding the translation towards a deoxodifluorination of an appropriate
2’-keto precursor Kjell et al. [159] reported that a reasonable conversion rate could
be observed when pyridine/HF was used in addition to DAST. Conversion of
the triacetylated precursor 35 using DAST and pyridinium/HF in dry DCM
at r.t. gave the gem-difluoro derivative in 80% yield after 24 h. Subsequent
basic hydrolysis furnished gemcitabine (Scheme 1.10, top). The study states
the indispensable need for pyridine/HF (py/HF) as the first reagent. Hence, a
possible reaction mechanism may start with a fluoride anion (from py/HF) to
generate an oxyanion at the 2’-position that subsequently attacks DAST to form
a leaving group that can in turn be substituted by a second fluoride anion (Scheme
1.10, bottom).
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Scheme 1.10: Top: DAST promoted deoxodifluorination of 35 presents a convenient
method for the synthesis of gem-difluorinated compounds with commercial interest
such as gemcitabine (1). Bottom: The mechanism explains why an additional fluoride
source is needed. Fluoride (from pyridine/HF) attacks the 2’-carbonyl carbon first and
forms an oxyanion which in turn reacts with DAST to form a leaving group that can
be replaced by another fluoride anion.
The current literature does not provide a broad range of approaches concern-
ing late-stage deoxodifluorinations and thus limits assessments regarding poten-
tial applications in radiochemistry. Even though 18F-DAST has been successfully
synthesised [153,160] the application in radiosynthesis remains difficult [161–163].
Reactive fluoride salts
Cyclic 2,2’-anhydro precursors are convenient precursors for nucleophilic late-
stage fluorination reactions [164,165]. Fluoride salts such as KF, CsF or tetrabutyl-
ammonium fluoride (TBAF) can be used as a source for nucleophilic fluoride.
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However, the fluoride anion is a strong hydrogen bond acceptor and strong Lewis
base as well as a weak nucleophile so that extensive drying processes and anhyd-
rous reaction conditions are indispensable in order to enhance the nucleophilicity
of the fluoride anion and obtain reasonable conversion rates [166].
The first late-stage fluorination towards a 2’-fluorinated nucleoside was suc-
cessfully reported in 1963 [167] by using anhydrous HF (Scheme 1.11). Direct
fluorinations of 2,2’-anhydro-1(β-D-arabinofuranosyl)nucleosides 36-38 were car-
ried out in a stainless steel bomb.
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Scheme 1.11: First fluoride-mediated ring-opening reaction of 2,2’-anhydro com-
pounds 36-38 using anhydrous HF.
Mengel et al. [168] reported in 1978 the successful synthesis of 2’-deoxy-2’-
fluorocytidine (FC) 42 via 2,2’-anhydro precursor 41 under much milder con-
ditions using an anhydrous DMF/KF/crown-ether mixture for the nucleophilic
ring-opening reaction (scheme 1.12).
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Scheme 1.12: Fluoride-mediated ring-opening reaction of 2,2’-anhydrocytidine hydro-
chloride 42 under milder anhydrous conditions.
Even under strictly anhydrous conditions after azeotropic drying with ben-
zene the corresponding hydrolisation product 43 was still obtained illustrating
the importance of anhydrous reaction conditions for nucleophilic fluorination re-
actions.
Crown-ethers and cryptants such as [18]crown-6 or kryptofix-222 (K222) are
widely used not only in organic synthesis but also in radiosynthesis due to their
cation chelation properties and the generation of a ‘naked’ fluoride anion [169]. The
nucleophilicity of the fluoride anion can be additionally enhanced in polar aprotic
solvents. Altogether, anhydrous conditions, polar aprotic solvents and chelating
additives such as K222 are used in order to provide a nucleophilic fluoride anion.
Even though widely used in radiosynthesis, the incorporation of non-radio-
active fluoride into nucleosides using nucleophilic late-stage fluorination has only
been rarely reported. The synthesis of fluorinated nucleosides is rather carried
out using either early-stage fluorination or late-stage deoxofluorination procedures
based on DAST (27).
However, Alauddin and co-workers [170] reported the synthesis of FMXU 45
by late-stage fluorination of triflate precursor 44 using a 1 M TBAF solution
in dry MeCN (Scheme 1.13). They further reported similar conditions using
[18F]TBAF for the subsequent radiosynthesis of 18F-FMXU.
37
1 Introduction
N
O
ON
O
OMTrOTf
MTrO
Boc NH
O
ON
O
OH
HO Fi,ii
Reagents and conditions: i) 1 M TBAF/THF, MeCN, 72-74°C, 20 min, 46%; ii) 1 M HCl/MeOH, 
reflux, 10 min, 70%.
44 45
Scheme 1.13: Late-stage fluorination using an anhydrous TBAF/THF solution to give
FMXU 45.
1.4 Radiosynthesis using [18F]fluoride
This section will give an overview of relevant radiosynthetic approaches for the
synthesis of 2’- and 3’-18F-labelled nucleosides using [18F]fluoride after a brief
introduction to 18F-radiochemistry with 18F-FDG as the most widely used PET
tracer. Furthermore, the production of [18F]fluoride, radiochemical analysis, auto-
mated radiosynthesisers as well as radiation safety will be briefly introduced at
the end of this section.
The radiochemical synthesis of tracers for applications in PET imaging began
with the radiochemical synthesis of 18F-FDG [169] and subsequent cerebral glucose
imaging in humans in 1978 by Phelps et al. [115,116].
Despite the biological principle of 18F-FDG PET as outlined above (Sec-
tion 1.2.4), the broad application of 18F-FDG PET in clinical oncology today
is mainly due to its highly advanced radiochemical synthesis with radiochemical
yields (RCYs, activity of the final tracer divided by the starting activity) between
50-80% (decay-corrected) and specific activities ≥350 GBq/µmol using a broad
range of automated synthesis modules under good manufacturing practice (GMP)
guidelines for human clinical applications [111,171–173] (Scheme 1.14).
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Scheme 1.14: Radiochemical synthesis of 18F-FDG using mannose triflate 46 as pre-
cursor. Nucleophilic substitution of the triflate leaving group with [18F]fluoride gives
the [18F]fluorinated protected intermediate which is converted to 18F-FDG via basic
hydrolysis. Cartridge purification and sterilisation give 18F-FDG for clinical applica-
tions.
The complex and interdisciplinary nature of PET might be one of the main
reasons why the development of novel and more specific PET probes is resource-
intensive and time-consuming [94]. Another challenge of a more synthetic nature is
certainly the time limitation in synthesis, purification and quality control of PET
probes due to the radiochemical decay of the utilised radionuclides. However,
progress in information technology and process automation allowed the develop-
ment of innovative automated radiosynthesisers that enabled automated routine
production of several new tracers [174].
Multi-step syntheses towards non-radioactive fluorinated target compounds
utilise either fluorine containing starting materials or early-stage fluorinations [148]
due to the high C-F binding energy and the resulting chemical stability. However,
considering radioactive decay and safety restrictions, radiofluorinations have to
be carried out at a later stage of the synthesis of 18F-labelled tracers. Pharma-
ceutical standard radiolabelled tracers should be synthesised and purified within
three half-lives of the utilised radionuclide [53]. These restrictions led to the devel-
opment of new synthetic methods and the increased implementation of automated
synthesisers and modern synthetic techniques such as microwave assisted and flow
synthesis [112].
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1.4.1 Radiosynthesis of 2’- and 3’-18F-labelled nucleosides
Early-stage radiosynthesis implies that radiofluorination is carried out at the
sugar moiety before the appropriate nucleobase is attached at the 1-position of
the ribose moiety. Late-stage radiofluorination on the other hand uses an intact
and activated (protected) nucleoside for radiosynthesis [85].
Early-stage radiofluorination
Several 5-substituted uridine - and cytidine-based 2’-18F-arabino nucleosides have
been synthesised via early-step radiofluorination within the last 15 years. The
general approach starts with a [18F]fluoride-mediated nucleophilic substitution of
a leaving group at the 2-position of a protected ribose moiety followed by a base
coupling reaction that furnishes the desired nucleoside.
In 2003, Mangner et al. [175] reported the radiochemical synthesis of the ara-
bino nucleosides 18F-FAU, 18F-FMAU, 18F-FBAU, and 18F-FIAU based on the
route presented below with a synthesis time of ≈180 min (Scheme 1.15).
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Scheme 1.15: Radiosynthesis of uridine-based arabino nucleosides. Reported RCYs
(decay-corrected) of the desired β-isomer: 34.7±11.2% (18F-FAU), 42.1±2.1% (18F-
FMAU), 40.0±3.1% (18F-FBAU), and 34.6±7.3% (18F-FIAU).
The protected triflate precursor 47 reacted first with [18F]fluoride/kryptofix
to perform the nucleophilic substitution reaction at high temperatures. The 2-
18F-labelled compound 48 contains the 18F-substituent in the right stereochem-
ical orientation. Bromination and subsequent condensation with the appropri-
ate 2,4-bis-O-(trimethylsilyl)pyrimidines produced mixtures of β- and α-isomers
(β/α=6.6-8.6) of the nucleosides depending on reaction solvent and temperature
as reported by Howell et al [176]. Deprotection was followed by semi-preparative
HPLC purification which enabled the separation of the isomers. The labelling
reactions were carried out using a remote-controlled reactor.
Even though the nucleoside-based radiotracers were obtained in good RCY
and high purities, this synthetic approach could not be used for human tracer pro-
duction according to GMP regulations [177] mostly due to its complexity. In 2011,
Cai et al. [178] synthesised the uridine-based nucleosides 18F-FAU, 18F-FEAU,
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18F-FFAU, 18F-FBAU and 18F-FIAU in reasonable RCYs (4.1-10%) with high
radiochemical purity (≥99%) and specific activities (380±35 Ci/mmol) using a
novel one-pot strategy that may simplify their use in clinical routine production.
The main advantages of this approach were the removal of the bromination step
and the shorter synthesis time (≈150 min) (Scheme 1.16). However, the RCYs
and the selectivity for the desired β-isomers were lower.
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uracil (9), 2,4-bis-O-(trimethylsilyl)-5-ethyluracil (11),  2,4-bis-O-(trimethylsilyl)-5-fluorouracil (12), 2,4-bis-O-
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Scheme 1.16: Advanced one-pot radiosynthesis of pyrimidine nucleosides gave almost
a 1:1 mixture of the α- and β-isomers. The RCYs (decay-corrected, n = 4) of the desired
β-isomers were reported as 5.4±1.0% (18F-FAU), 4.1±0.8% (18F-FEAU), 5.5±0.9%
(18F-FFAU), 8.0±2.5% (18F-FBAU) and 9.9±0.4% (18F-FIAU).
Furthermore, Zhang et al. reported an improved radiosynthesis of the nuc-
leoside derivatives 18F-FIAU, 18F-FMAU and 18F-FEAU in terms of RCY by
using a microwave assisted synthesis. Their findings led to the conclusion that
the TMSOTf-catalysed coupling reaction of the sugar moiety and the protected
base can be accelerated by microwave assisted heating.
Despite significant improvements of the conditions of these labelling reactions
and the automated production of these uridine-based arabino nucleosides, their
use in routine clinical applications remains challenging.
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Radu et al. [16] reported the radiosynthesis of the cytidine-based nucleoside
18F-FAC (15) in good RCY (20-30%, decay-corrected) and high radiochemical
purities (≥99%). The synthesis scheme (Scheme 1.17) was similar to the route
towards 2’-18F-labelled uridine-based nucleosides presented above. Hence, radio-
fluorination was carried out first followed by bromination of the 1-position of the
sugar moiety and subsequent base coupling using the O- and N-TMS-protected
pyrimidine base. Amaraesekera et al. [179] developed a radiochemical approach to
give 18F-FAC using a newly developed radiosynthesis module with high-pressure
capabilities that furnished the tracer 18F-FAC in high RCYs (39±5%, decay-
corrected, n = 13), high radiochemical purities (≥99%) and specific activities
(≥37 GBq/µmol) with a synthesis time of 240 min.
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Reagents and conditions: i) [18F]fluoride, K222, DMF, 165°C, 15 min; ii) 30% HBr/AcOH, dichlorethane, 
80°C, 10 min;  iii) bis(trimethylsilyl)cytosine, dichlorethane, 160°C, 30 min; iv) NaOMe/MeOH, 100°C, 5 min.
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Scheme 1.17: Current radiochemical approach to give 18F-FAC.
The same synthetic route was tested by Lazari et al. [180] to synthesise the
18F-labelled nucleoside analogues 18F-FAC and 18F-FMAU using a specifically
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developed radiosynthesiser. In case of 18F-FAC, a decay-corrected RCY of 31±5%
(n = 6) with specific activities between 37-44 GBq/µmol were reported. The
synthesis time was 160 min. This method is currently used to produce 18F-
FAC for clinical trials to image the deoxycytidine kinase (dCK)-status of cancer
patients carried out by Michael Phelps and co-workers∗. Even though this method
is fully automated further studies have to show whether this method will be
applicable for clinical routine production.
Late-stage radiofluorination
A reproducible and efficient late-stage radiofluorination towards 2’- and 3’-labelled
nucleoside analogues may enable a faster transfer to routine production of these
PET probes [177]. In 2000, Machulla et al. [165] reported the synthesis of 18F-FLT
(8) via both the unprotected anhydro thymidine precursor 50 and the 5’-O-DMT-
protected precursor 51 (Scheme 1.18). Different radiochemical yields were repor-
ted for precursor 50 (5.3±1.2%) and precursor 51 (14.3±3.3%) with a synthesis
time of 90 min in case of precursor 51.
∗http://sofiebio.com/products/probes/
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Reagents and conditions: i) [18F]fluoride/K222, DMSO, 130 °C, 30 min; ii) [18F]fluoride/K222, DMSO, 
160 °C, 10 min; iii) 1 M HCl, 50 °C, 10 min.
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Scheme 1.18: Radiochemical synthesis of 18F-FLT 8 via the 2,3’-anhydro precursors
50 and 51.
In order to increase reactivity at the 3’-position, several 3’-activated precur-
sors with different leaving groups were synthesised by Martin et al. [128] in order
to reduce both the reaction temperature and the reaction time. The synthesis of
18F-FLT using a N3-Boc-5’-dimethoxytrityl-protected 3’-p-nitrobenzenesulfonate
(nosylate) precursor 52 (Scheme 1.19) gave 18F-FLT in 19.8% RCY (decay-
corrected) with a synthesis time of 85 min.
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Reagents and conditions: i) [18F]fluoride/K222, MeCN, 105 °C, 4 min;  ii) HCl,  100°C, 
4 min, then NaOH.
i,ii
52 8
Scheme 1.19: Advanced radiochemical synthesis of 18F-FLT (8) using the 3’-nosylated
precursor 52.
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The protected nosylate precursor 52 reacts with dried [18F]fluoride/K222 in
anhydrous acetonitrile. The deprotection step is carried out using a 1 M HCl-
solution at 105 ◦C for 4 minutes and subsequent HPLC purification yields 18F-
FLT in high radiochemical purity. Possible side products such as the 2’,3’-olefinic
elimination product can easily be separated from the 18F-labelled product [128,181].
In 2004, S.J. Oh et al. [129] presented a high-yielding radiochemical synthesis
of 18F-FLT using precursor 52 and a fully automated synthesis module. Decay-
corrected RCYs of up to 50.5±5.2% were reported with specific activities of 3.3-7.7
Ci/mmol after a synthesis time of 60±5 min. Even high starting activities (≈37
GBq) gave RCYs of 48% after HPLC purification. Additionally, full automation
made the synthesis suitable for clinical routine production [129].
A study by Javed et al. using microreactors [15] demonstrated the potential
of continuous-flow systems by obtaining 63% decay-corrected RCY for 18F-FLT
using the above described synthetic route [182]. Furthermore, purification using
custom-made solid-phase extraction cartridges furnished 18F-FLT in high purities
consistent with standards required by the U.S. Pharmacopeia [182].
At the present time, the proliferation marker 18F-FLT remains the only 2’- or
3’-18F-labelled nucleoside that is used routinely in human clinical applications [85].
The radiochemical synthesis of 18F-FLT that is currently used for clinical applic-
ations is based on the approach presented in scheme 1.19.
2’-18F-labelled arabino nucleoside analogues are of great interest in both pre-
clinical research and clinical oncology mainly due to their variable applicability as
outlined above (Section 1.2.5). For instance, 2’-18F-labelled arabino nucleosides
have been used as reporter gene probes for targets such as HSV-TK-1 and are
strong candidates for imaging other important biological targets such as dCK [124]
within the nucleoside salvage pathway [183,184]. However, introducing the 18F-
substituent in the 2’-arabino-position of an intact nucleoside was considered as
difficult, if not impossible [177]. The main reason for the difficulty is the high
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potential of 2’-activated labelling precursors to form the anhydro side product
due to the nucleophilicity of the C-2 carbonyl group of the pyrimidine moiety
after base-mediated N3-H deprotonation (Scheme 1.20).
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Scheme 1.20: Base-mediated formation of the anhydro side product under elimination
of the leaving group (exemplified by commonly used sulfonic ester derivatives) through
nucleophilic attack of the C-2 carbonyl oxygen at the 2’-position.
However, N3-protection with electron withdrawing groups such as tert-butyl-
oxycarbonyl (Boc) could successfully prevent 2’-activated precursor molecules
from forming 2,2’-cyclic compounds as it was shown by Alauddin et al. [177,185]
with the development a new radiosynthesis of 18F-FMAU (10, Scheme 1.21)
using precursor 53. Even though this is a low yielding labelling reaction (2.0%
RCY, decay-corrected), high specific activities (≥1.8 Ci/mmol) and radiochemical
purities (≥99%) with a synthesis time of 95-100 min were reported. Further
investigations carried out by Alauddin et al. [177] regarding the effect of different
2’-leaving and 3’,5-protection groups, however, could not improve the RCY of
18F-FMAU.
In contrast, the radiosynthesis of the ribo analogue 2’-[18F]fluoro-deoxy-uridine
using a 2’-nosylated precursor gave the 18F-labelled product in 26.5±1.4% RCY
and high radiochemical purities after a synthesis time of 70±10.5 min [186] exem-
plifying the difference in the syntheses of 2’-18F-labelled ribo and arabino nucle-
osides.
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Scheme 1.21: Late-stage radiofluorination gave 18F-FMAU (10).
1.4.2 Production of [18F]fluoride
In a cyclotron (cyclic particle accelerator) or linear particle accelerator 18O-
enriched water is bombarded with highly energetic protons (ca. 18 MeV) to
yield non-carrier-added [18F]fluoride present as [18F]-HF [187] and dissolved in 18O-
enriched target water via the 18O(p,n)18F nuclear reaction [188]. Specific activit-
ies of the produced [18F]fluoride may be ≥370 GBq/µmol [52]. Even though ra-
dioactivity levels can reach harmful thresholds (e.g. low milli-Sievert per hour
(mSv/h) levels) during a single cyclotron run, the concentration of [18F]fluoride
for the synthesis of PET tracers in routine production is still very low compared
to precursor concentrations [88]. The following equation 1.7 shows that the con-
centration of [18F]fluoride hardly exceeds low micromolar levels. For instance, an
initially delivered activity A of 80 GBq from the cyclotron dissolved in 1 mL of
18O-enriched water would lead to the following concentration of [18F]fluoride:
c([18F ]) =
A
NA
t(1/2)
ln(2) · V
= 1.261µmol/L (1.7)
This equation can be derived from equation 1.8 and the relation c = n/V.
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1.4.3 Specific activity
Since all radioactive atoms eventually decay the area under the time-activity
curve equals the total number N of radioactive atoms in the sample:
N = A
t1/2
ln(2)
(1.8)
Dividing N by Avogadro’s number NA (NA = 6.022×1023 mol−1) gives the molar
amount of 18F-labelled tracer in the sample. Together with the molar weight of
the radiotracer the specific activity (SA) of the sample can be calculated. The
SA is defined as the radioactivity per unit of material and is mostly given as the
radioactivity per gram or moles of tracer [188]. However, this approach assumes
that all molecules of the sample are labelled with 18F and hence gives the theor-
etical maximum SA. The actual specific activity of a synthesised tracer may be
lower as traces of 19F (carrier) might have been present during radiofluorination
even after a non-carrier-added (nca) production of [18F]fluoride. Possible sources
of carrier are Teflon tubing [189] and ion-exchange cartridges [190], among others.
The actual SA of a radiotracer can be calculated by determining the ratio
of 18F-labelled tracer to the total amount of tracer (sum of radioactive and non-
radioactive tracer) [187]. The total amount of tracer can be determined by HPLC
using a UV detector for UV-active compounds or refractive index-/conductivity
detectors for compounds with low molar absorptivities such as FDG [191,192]. As-
suming that the tracer is UV-active and sufficiently concentrated, the intensity
of the detected UV-signal that corresponds to the radiotracer during an HPLC
run would enable the calculation of the total amount of tracer by using a calibra-
tion curve previously determined with different concentrations of non-radioactive
standard [187].
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1.4.4 Automated synthesis modules
The production of radiopharmaceuticals is in many ways different to regular phar-
maceutical chemistry. Reaction time, purification and analysis of the final 18F-
labelled tracer have to be performed in a time frame according to the half-life of
the utilised radionuclide (rule of thumb is 3 times the half-life of the radionuclide).
Hence, the use of automated synthesis modules in radiochemistry laboratories is
advantageous. In particular, tracer production for pre-clinical and clinical applic-
ations requires fast and reproducible synthesis and purification procedures [193].
Computer-controlled reaction modules are placed in lead-shielded fume hoods or
hot cells for labelling reactions with high activities in order to minimise the radi-
ation exposure to staff. Graphic visualisation of the radiochemical synthesis on a
computer screen allows monitoring of the reaction sequences during radiotracer
production.
Several suppliers (General Electric, Eckert & Ziegler, IBA etc.) offer different
automated synthesis modules, either specifically developed for a particular tracer
or flexible to conduct radiochemical syntheses for different tracers utilising differ-
ent radionuclides. The IBA Syntherar module system, for instance (Figure 12)∗,
may be used for 18F-FDG production.
Figure 12: Synthera synthesis module (left) with the integrated fluidic processor (IFP)
(right) that carries out the labelling reaction.
∗taken from: http://www.iba-radiopharmasolutions.com/products/chemistry
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The development of automated synthesis modules has significantly contrib-
uted to the wide use and commercialisation of the radiotracer 18F-FDG. Other
clinically relevant radiotracers such as 18F-FLT [194] and 18F-FMISO [195] may
be synthesised in a 18F-FDG-like manner via nucleophilic radiofluorination and
subsequent hydrolysis/deprotection and can hence be produced using 18F-FDG-
based synthesis modules with appropriate modifications in programming and
hardware [196].
However, more complex radiochemical syntheses with more reaction and/or
purification steps require more advanced module systems in order to ensure the
automated procedure gives the particular tracer with the desired RCY and ra-
diochemical purity and in a fast and reproducible manner [111]. Examples for such
radiosynthesisers are the TracerLab FXr (GE Medical Systems, USA) (Figure
13, left)†, the FastLabr (GE Medical Systems, USA) for cassette-based produc-
tions as well as the All-in-Oner (Trasis S.A., Belgium) (Figure 13, right)‡ and the
Eckert & Ziegler module systems (Eckert & Ziegler Eurotope GmbH, Germany).
Figure 13: GE TracerLab FX N Pro module system (left) and the Trasis All-in-One
system (right).
†taken from: http://www3.gehealthcare.com/en/products/categories/pet-radiopharmacy/
‡taken from: http://www.trasis.com/
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1.4.5 Analysis and quality control of radiotracers
The analysis and quality control (QC) of radiopharmaceuticals is not only im-
portant for pre-clinical and clinical applications but also for the development of
PET probes and novel radiochemical syntheses. In order to ensure that a newly
developed synthetic route yields the desired radiolabelled product with the ap-
propriate RCY, (radio)chemical purity, specific activity and sterility, different
analytical techniques have to be performed. Table 2 gives an overview over the
most relevant test parameters and analytical methods. In case of PET radiophar-
maceuticals for clinical use, all synthetic methods and analytical tests have to be
validated according to the GMP guidelines of the appropriate country [57].
Table 2: Analysis and QC for PET radiopharmaceuticals
QC test Criteria/subject of test Test method
Sterility Batch needs to be sterile Bacteria growth
(incubation over 2 weeks
Pyrogenicity Batch needs to be apyrogenic Limulus amebocyte lysate
(LAL) test
Appearance Colour/clarity Visual inspection
Isotonicity Batch needs to be isotonic Osmometry (crysocopy)
pH 7.4 (ideal), pH-Meter
slightly higher or lower
Radionuclidic purity Radionuclides must be γ-spectroscopy
pure prior to use
Chemical purity Impurities/solvent traces HPLC/GC
must be reduced or harmless
Radiochemical purity Individual limits Radio-HPLC, radio-TLC
(set by national Pharmacopeia)
Radio-TLC and Radio-HPLC are routinely performed techniques in the de-
velopment of novel PET tracers that enable the characterisation of labelling re-
actions.
Radio-HPLC, for instance, allows the simultaneous detection of both the UV,
refractive index- or conductivity as well as the radioactivity profile of a radioactive
sample [197]. Flow-cell radioactivity analysis is the method of choice as it provides
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real-time analysis of the HPLC run. An alternative method is the analysis of
fractions by microplate scintillation counting. The detection of radioactivity in a
radio-HPLC detector may be conducted using NaI(Tl) or BGO scintillation crys-
tals that register the annihilation γ-photons and re-emit low energy photons that
can be converted into an electrical signal by coupled photomultiplier tubes [197].
The detection unit is usually shielded from background radiation and visible light
sources [198]. Certain radioactivity detectors in radio-HPLC systems use the 12 ns
coincidence time window in order to discriminate annihilation γ-rays from back-
ground radiation and hence increase sensitivity. Additionally, the tubing for the
mobile phase inside the detector unit can be coiled to form a helix in order to
reduce the effective velocity of the mobile phase and thus increase the length of
the active detector which may also lead to an increased sensitivity [198].
The radionuclidic purity of a synthesised PET tracer can be determined by
recording γ-spectra and only allowing the 511 keV peak as well as the 1022 keV
sum peak that are characteristic for PET tracer [171]. However, since most PET
radionuclides yield the same γ-spectra the physical half-life of the utilised radio-
nuclide can be calculated for radionuclidic purity confirmation by measuring the
activity of the sample at different time points using the following equation [199]:
t1/2 = −ln2(t2 − t1)/ln
A2
A1
(1.9)
1.4.6 Radiation safety and monitoring
Prior to any work involving radioactivity all personnel must complete a mandat-
ory radiation safety and monitoring training course. During work with radio-
activity personal film badges (finger, torso, head) must be worn in addition to
standard lab protective cloth in order to monitor and assess radiation doses. The
annual effective dose limit in accordance to the Ionising Radiations Regulations
1999 (IRR) for the whole body of a radiation worker of age 18 or above is 20
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mSv [200]. The annual dose limit for hands, forearms, feet and ankles is 500 mSv
and the dose limit for the lens of the eye is 150 mSv [200].
In general, radiation protection and monitoring in accordance to IRR aims
for a dose as low as reasonably achievable/practical (ALARA/ALARP) [57], and
ensures that exposure to ionising radiation of staff members does not exceed the
dose limits. This can be accomplished by spending a minimal amount of time near
the radiation source while keeping the greatest distance possible. Increasing the
distance between the radiation source and the staff member reduces the exposure
rate according to the inverse square law [201]. Furthermore, shielding devices are
used in order to minimise the radiation dose to staff members and patients. In
order to work in PET radiochemistry labs and hot cells, lead walls with a width
of ≥4 cm are required to effectively shield the 511 keV photons [201]. Altogether, a
good work practice is essential including the compliance with all radiation safety
regulations as well as the use of safety and radiation monitoring devices such as
electronic personal dosimeters (EPD) and personal film batch dosimeters.
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The overall aim of this research project is the radiochemical synthesis of 18F-
gemcitabine. Although several synthetic routes towards gemcitabine have already
been accomplished the radiochemical synthesis of 18F-labelled gemcitabine has
never been achieved. Therefore, 18F-gemcitabine poses serious challenges and an
entirely new synthetic approach due to the requirement for radiofluorination at a
late stage of the synthesis. It was envisaged that a 18F-gemcitabine PET probe
may enable the visualisation of the PK and PD of this important anticancer drug
in vivo. However, biological evaluations using appropriate cancer models would
have to be carried out in order to validate the clinical potential of this tracer.
The development of novel radiosynthetic routes to 2’-18F-labelled gemcitabine
analogues such as 18F-FAU and 18F-FAC is the primary objective of this research
project in order to establish routes that might enable a translation to the late-
stage synthesis of the gem-2’-difluoro system.
The figure below (Figure 14) shows the time line of this project together with
the 18F-labelled target compounds.
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Figure 14: 18F-labelled target molecules of this research project.
Once methods for non-radioactive late-stage synthesis of 2’-fluoro-nucleosides
are established, radiosynthesis of the correspondent mono-[18F]fluorinated ana-
logues 18F-FAU, 18F-FIAU and 18F-FAC (Figure 15) will be carried out at PETIC
(Wales Positron Emission Tomography Imaging Centre). The development of a
novel and efficient late-stage radiochemical synthesis of 18F-FAC is of particular
interest as the current radiochemical approach to this newly developed and clin-
ically relevant tracer is complex and hence difficult to translate to routine tracer
production.
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Figure 15: Structures of the mono-[18F]fluorinated target molecules 18F-FAU (9), 18F-
FIAU (14) and 18F-FAC (15) as well as the final target compound 18F-gemcitabine
(54).
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Finally, it will be investigated whether results obtained during late-stage
radiosynthesis of 2’-monofluorinated nucleosides can be applied to a synthesis
of the 2’,2’-difluoro system of gemcitabine. For this purpose, the synthesis of
an appropriate 2’-activated gemcitabine precursor will be pursued prior to com-
mencing non-radioactive fluorination and radiofluorination studies towards 18F-
gemcitabine as the final target of this research project.
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3.1 Non-radioactive late-stage fluorinations
3.1.1 Fluorination of protected 2,2’-anhydro uridines
Apart from the target molecules 18F-FAU and 18F-FAC that contain the fluor-
ine substituent in the 2’-arabino-position, the 2’-fluorinated nucleosides 2’-fluoro-
2’-deoxyuridine (31, 2’-FU) and 2’-fluoro-2’-deoxy-methyluridine (40, 2’-FMU)
(Figure 16) were considered as the first targets within this project. It was envis-
aged that these 2’-fluorinated nucleoside analogues could be accessible via fluor-
ination of appropriate 2,2’-anhydro precursors. Furthermore, fluoride-mediated
ring-opening reactions towards 2’-fluorinated nucleosides was of interest due to
possible applications in radiochemistry [164].
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Figure 16: Structures of 2’-FU (31) and 2’-FMU (40).
Mitsunobu reaction of uridine (55) and 5-methyluridine (56) using diisopro-
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pyl azodicarboxylate (DIAD) and triphenylphosphine [202] furnished 2,2’-anhydro-
β-D-arabinofuranosyluracil (57) and 2,2’-anhydro-β-D-arabinofuranosylthymine
(58), respectively, in moderate yields (Scheme 3.1). The absence of the amine
proton signal of the pyrimidine moieties at around 9.5 ppm in the 1H NMR
spectra confirmed that the anhydro compounds were formed.
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57 R = H 
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Reagents and conditions: i) DIAD, PPh3, MeCN, -20°C - 0°C, 5 h, 56%; ii) DIAD, PPh3, 
MeCN, -20°C - 0°C, 3 h, 51%
Scheme 3.1: Intramolecular cyclisation towards the anhydro derivatives (57) and (58).
Purification of the anhydro compounds 57 and 58 was carried out using silica
gel column chromatography and gradient elution with EtOAc/MeOH. Reaction
control by TLC indicated both full conversion of the starting compound and no
side product formation such as the 2,3’-anhydro compound. Subsequently, the
remaining hydroxy groups at the 3’- and 5’-positions were protected using differ-
ent protecting groups (Scheme 3.2) in order to study their impact on fluorination
reactions as well as to minimise side reactions during fluorination. The most com-
mon protecting group used in radiochemistry for late-stage fluorinations at the
2’-position is the 2-tetrahydropyranyl (THP)-group [185,186], mostly due to its ease
of removal through acidic hydrolysis. THP-protection of anhydro compounds 57
and 58 was carried out using an excess of 3,4-dihydro-2H -pyran and equimolar
amounts of p-toluenesulfonic acid in dry THF. Column chromatography furnished
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the protected compounds 59 and 60 in 77-84% yield. The reaction gave a clean
profile without side product formation according to TLC.
Although the THP protecting group can be attached and removed efficiently,
NMR analysis, however, remains difficult due to the formation of one additional
stereocenter per THP group. In this case, a mixture of four diastereomers was
obtained. Nevertheless, column chromatography purification of the crude product
using a low flow rate enabled separation of two pairs of diastereomers which could
be adequately analysed by NMR. Furthermore, product formation was confirmed
by mass spectrometry (ESI-MS).
In order to study whether silica based protecting groups allow simultan-
eous fluorination and deprotection or rather cause side effects during fluorin-
ation, anhydro compounds 57 and 58 were treated with 1,3-dichloro-1,1,3,3-
tetraisopropyldisiloxane [203,204] in a pyridine/DMF mixture at r.t. for 13-15 h.
The corresponding TIPDS-protected compounds 61 and 62 were obtained in
good yields (71-84%) after purification by column chromatography. Although
these reactions were carried out under anhydrous conditions it is worth noting
that around 10-12% of the hydrolysed disiloxane compound was recovered in both
cases which limited the yield of these reactions.
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Reagents and conditions: i) DHP, pTsOH, THF, 0°C - r.t., 3 h, 84%; ii) DHP, pTsOH, THF, 
0°C - r.t., 3 h, 77%;  iii) TIPDSCl2, pyridine, DMF, r.t., 16 h, 71%; iv) TIPDSCl2, pyridine, DMF,
 r.t., 12 h, 84%; v) acetone, conc. HCl, 0°C - r.t., 16 h, 85%; vi) acetone, conc. HCl, 0°C - r.t., 
15 h, 88%.
63 R = H
64 R = Me
N
O
N
O
O
O
Si
Si
O
O
R
N
O
N
O
O
O
O
R
N
O
N
O
O
O
R
O
O
O
59 R = H
60 R = Me
61 R = H
62 R = Me
iii,iv
v,vi
Scheme 3.2: Simultaneous protection of the remaining 3’ and 5’ hydroxy groups to-
wards first fluorination precursors 59-64.
The corresponding acetonides 63 and 64 were found to be stable and could
be synthesised in high yields (85-88%) by treating the 2,2’-anhydro precursors
57 and 58 with catalytic amounts of hydrochloric acid in acetone as solvent [205].
The amount of hydrochloric acid is obviously crucial in this reaction in terms of
product formation. It was found that addition of a catalytic amount (≈20 µL)
of 37% HCl furnished a clean reaction profile and high yields.
Table 3 gives an overview of the first fluorination reactions (Scheme 3.3)
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carried out with the protected precursors 59-64 as starting materials. Solvent,
reaction time and temperature as well as the fluoride salts were varied. All reac-
tions were carried out using anhydrous solvents under argon atmosphere. Each
reaction was performed on a 100 mg scale with 3 equivalents of the fluoride salt
and a solvent volume of 4 mL. A reaction time of 12 h was considered as the
maximum time.
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60 (ii) R = Me, PG = THP
61 (iii) R = H, PG = TIPDS
62 (iv) R = Me, PG = TIPDS
63 (v) R = H, PG = acetonide
64 (vi) R = Me, PG = acetonide
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Scheme 3.3: General scheme for the fluorination of compounds 59-64.
Table 3: Fluoride-mediated ring-opening reactions of anhydro compounds 59-64 tested
under different conditions.
starting fluoride solvent time yield comment
material source (T [◦C]) [h] [%]
59,60 CsF MeCN (85) 6-12 n/a SM recovered
59,60 CsF DMF (145) 3-12 n/a SM recovered
59,60 KF/K222 DMSO (180) 2-8 n/a SM recovered
61,62 KF/K222 MeCN (85) 6-10 n/a deprotection
61,62 CsF DMF (145) 3-12 n/a deprotection
61,62 KF/K222 DMSO (180) 2-6 n/a deprotection
63,64 KF/K222 MeCN (85) 4 n/a SM recovered
63,64 CsF DMF (145) 3-6 n/a SM recovered
63,64 KF/K222 DMSO (180) 1-2 n/a SM recovered
The desired 2’-fluorinated compounds could not be obtained under the above
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described conditions. The THP (59,60) and acetonide (63,64) protected precurs-
ors were recovered from the reaction mixture by column chromatography after
reaction times stated in table 3. The obtained NMR data for these compounds
and the starting materials were consistent. The TIPDS-protected compounds
61 and 62 were deprotected under these conditions. The corresponding anhydro
compounds 57 and 58 were recovered and confirmed by NMR spectroscopy. A
19F-signal with an estimated chemical shift of around -190 ppm, however, could
not be observed in any case confirming that nucleophilic ring-opening by fluoride
did not occur, at least not on a scale which was detectable by UV.
All solvents used in this reactions were dried in order to ensure anhydrous
reaction conditions. The fluorination agents, however, were used without perform-
ing azeotropic drying procedures prior to reactions which is a standard procedure
in radiochemical synthesis since [18F]fluoride is delivered in low quantities and as
an aqueous solution in 18O-enriched target water [128,170,177]. Properly dried fluor-
ide/kryptofix in combination with dry solvents could change the outcome of these
reactions significantly. Another reason for the observed results might be the high
stability of the anhydro compounds. Lewis-acid activation via the pyrimidine
moiety may increase the likelihood of the fluoride-mediated ring-opening event.
3.1.2 Nucleophilic fluorination of 2’-activated nucleoside
precursors
Since direct fluorination of the 2,2’-anhydro nucleoside precursors 59-64 could
not be achieved under the above stated conditions, the preparation and testing of
several nucleoside precursors containing a leaving group at the 2’-position seemed
to be the next reasonable step towards the 2’-fluorinated nucleosides 2’-FMU (40)
and FAU (65) as the first fluorinated arabino nucleoside (Figure 17).
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Figure 17: Structures of the target molecules 2’-FMU (40) and FAU (65).
For this purpose, hydroxide mediated ring-opening reaction of compounds 60
and 64 was performed using a 10 M sodium hydroxide solution in methanol at
reflux temperature for 4 h and 5 h, respectively (Scheme 3.4).
N
O
N
O
OPG
PGO
O
60 (i) PG = THP
64 (ii) PG = acetonide
NH
O
N
O
PGO
OPG
O
HO
66 PG = THP
67 PG = acetonide
Reagents and conditions: i) 10 M NaOH, MeOH, reflux, 4 h, 47%; ii) 10 M NaOH, MeOH, reflux, 5 h, 59%
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Scheme 3.4: Hydrolysis of compounds 60 and 64 gave the corresponding protected
2’-hydroxy arabino nucleosides 66 and 67.
The same reaction was reported for THP protected 2,2’-anhydro uridine (59)
and 2,2’-anhydro 5-methyluridine (60) using 1 M NaOH solution [206]. In the case
of 60 and 64, however, significant product formation only occurred using harsh
conditions with a 10 M NaOH solution in MeOH at reflux temperature. Addi-
tionally, these harsh conditions led to side product formation. In the case of THP
protected compound 60, the TLC showed full conversion of the starting material
64
3 Results and discussion
and two new spots corresponding to the desired product (66, 47%) and a side
product (35%) with Rf -values (5% MeOH/DCM) of 0.2 and 0.4, respectively. The
product was analysed and confirmed by both NMR spectroscopy as well as mass
spectrometry. Since a comparable reaction profile was observed for the reaction
of the acetonide protected compound 64 the side product was further studied
due to clean one- and two dimensional NMR spectra in the case of compound 64.
The 1H NMR spectrum gave signals corresponding to 21 instead of 18 protons
indicating an additional methyl group at 3.57 ppm. Finally, (1H,1H)-COSY and
HSQC spectra in combination with MS analysis led to the conclusion that the
methoxy-group acted as a competitive nucleophile which was generated under
these harsh conditions from solvent molecules. Methoxy-mediated ring-opening
furnished finally the observed 2-methoxy side product 67b with lower polarities
in comparison to the desired products (see Experimental Part).
The 2’-hydroxy arabino analogues (66) and (67) were converted to the cor-
responding 2’-(p-nitrobenzenesulfonyl) (-nosyl) compounds 68 and 69 using p-
nitrobenzenesulfonyl chloride (NsCl) and dry pyridine in anhydrous DCM at r.t.
in good yields (68-84%, Scheme 3.5). The nosylate precursor 51 furnished good
RCY (14-18 %, decay-corrected) in case of 18F-FLT [128,162] as presented in section
1.4.1.
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Reagents and conditions: i) NsCl, pyrdine, DCM, r.t., 15 h, 68%; ii) NsCl, pyrdine, 
DCM, r.t., 8 h, 84%.
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Scheme 3.5: Nosylation of compounds 66 and 67 furnished the nosylate precursor 68
and 69.
The nosylate precursors 68 and 69 were treated with KF/K222 in either dry
MeCN or DMF at appropriate reflux temperatures for different reaction times
(2-12 h) as shown below (Scheme 3.6, table 4).
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Scheme 3.6: Fluoride-mediated nucleophilic substitution using nosylate precursor 68
and 69 did not occur. Instead, the appropriate anhydro intermediates were obtained.
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Table 4: Results of the fluoride-mediated nucleophilic substitution of the nosylate
precursors 68 and 69.
starting fluoride solvent time yield comment
material source (T [◦C]) [h] [%]
68 KF/K222 MeCN (85) 3-12 n/a anhydro cmpd 60
68 KF/K222 DMF (145) 3-12 n/a anhydro cmpd 60
69 KF/K222 MeCN (85) 4-12 n/a anhydro cmpd 64
69 KF/K222 DMF (145) 4-12 n/a anhydro cmpd 64
In place of the 2’-fluorinated compounds the corresponding anhydro interme-
diates 60 and 64 were obtained and confirmed by NMR and MS. That led to
the conclusion that the reaction stopped at the stage of the anhydro intermedi-
ate. However, since the leaving group is in an unfavoured "up" (arabino)-position
regarding a nucleophilic attack of the carbonyl oxygen of the pyrimidine moiety,
the anhydro formation reaction most likely follows a SN1-mechanism as illustrated
below (Scheme 3.7). A SN1-mechanism was additionally supported by the use
of polar aprotic solvents, high reaction temperatures and a good leaving group.
Furthermore, the fluoride anion competes with the 2-carbonyl oxygen to attack
the activated 2’-position. Hence, reducing the nucleophilicity of the 2-carbonyl
oxygen could increase the likelihood of a fluoride attack. In fact, Turkman et
al. [185] reported that Boc-protection of the N3 of the base moiety successfully
prevented the formation of the anhydro derivative during radiosynthesis.
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Scheme 3.7: Possible mechanism that explains the results obtained during the fluor-
ination of the nosylate precursors 68 and 69. The fluoride anion can also act as a base
and hence trigger anhydro formation through NH-deprotonation.
The next logical step was Boc-protection of the nosylate precursors 68 and
69 following reported procedures [162]. For this purpose, compounds 68 and 69
were treated with Boc2O and 4-DMAP in dry THF at r.t. for 14 h (Scheme 3.8).
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Reaction conditions: i) Boc2O, DMAP, THF, r.t., 14 h.
Scheme 3.8: Anhydro formation triggered under basic conditions.
In both cases, however, anhydro compounds 60 and 64 were obtained and
thus Boc-protection did not occur. Based on that results, it was assumed that
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a base-mediated cyclisation towards the corresponding anhydro compounds took
place, which seems reasonable due to the proposed mechanism of the anhydro
formation (Scheme 3.7). Thus, N3-Boc-protection had to be carried out before
leaving group introduction at the 2’-position in order to prevent the formation of
anhydro compounds.
Therefore, TMS-protection of the 2’-OH group was accomplished first before
the N3-position was Boc-protected. TMS-protected compound 70 was obtained
in 73% yield. Additionally, it is worth noting that addition of Et3N (1%) prevents
the TMS-group from being hydrolysed on the silica gel column during purification.
Boc-protection was carried out directly followed by selective deprotection of the
TMS-group through addition of pTsOH (2 eq.) to the reaction mixture. Column
purification furnished compound 71 in an good overall yield (53%). Nosylation
of the free 2’-OH group of the Boc-protected compound 71 was carried out using
nosyl chloride and pyridine in anhydrous DCM. Fluorination precursor 72 was
obtained after purification in an acceptable yield (53%) (Scheme 3.9).
69
3 Results and discussion
NH
O
N
O
THPO
OTHP
O
HO
66
i
Reagents and conditions: i) TMSCl, Et3N, DCM, 0°C - r.t.,  2.5 h, 73%;  ii) Boc2O, DMAP, THF, r.t., 14 h, 
then pTsOH, 0°C - r.t., 40 min, 53%; iii) NsCl, pyrdine, DCM, r.t., 3 h , 53%.
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Scheme 3.9: Synthetic scheme to give the fluorination precursor 72.
Prior to nucleophilic fluorination of the nosylate precursor 72, XtalFluor-
mediated deoxofluorination of Boc-protected hydroxy compound 71 was per-
formed in order to obtain the reference compound for the purpose of comparison.
The treatment of compound 71 with a freshly prepared mixture of XtalFluor M
and Et3N/HF in anhydrous DCM at -78 ◦C led to the desired product 2’-FMU.
After full conversion of the starting material an aqueous HCl/MeOH solution was
added furnishing the fully deprotected fluorinated compound 2’-FMU (40) in 25%
yield (Scheme 3.10). Target compound 40 was fully characterised and confirmed
by analytical comparison with commercially available 2’-FMU. This is the first
time that deoxofluorination was performed using the new DAST-derivative Xtal-
Fluor M (29).
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Reagents and conditions: i) XtalFluor M, Et3N/HF, DCM, -78°C - r.t., 3 h, then HCl/MeOH, r.t., 1 h, 25%.
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Scheme 3.10: XtalFluor M enabled fluorination of hydroxy precursor 71. Subsequent
deprotection furnished 2’-FMU (40).
However, when treated with KF/K222 or TMAF in dry MeCN at reflux tem-
perature (Scheme 3.11, table 5) nosylate precursor 72 did not lead to the desired
2’-fluoro compound. Reaction control using LC-MS did not show any evidence
for the formation of the fluorinated derivative.
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Scheme 3.11: Fluoride-mediated nucleophilic substitution towards 40 did not occur.
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Table 5: Fluorination results using precursor 72.
starting fluoride solvent time yield (40) comment
material source (T [◦C]) [h] [%]
72 KF/K222 MeCN (85) 3-6 n/a decomposition
72 KF/K222 DMF (145) 2-4 n/a decomposition
72 TMAF MeCN (85) 8-12 n/a SM recovered
72 TMAF DMF (145) 2-4 n/a decomposition
Although tetramethylammonium fluoride (TMAF) [20] was considered as a
milder and more soluble fluorination agent it did not lead to the formation of the
desired compound 2’-FMU. Hence, it was assumed that the nosyl group may be
replaced by another less reactive leaving group in order to accomplish a better
stability-to-reactivity ratio of the corresponding fluorination precursor.
For this purpose the arabino analogue of 2’-FU, 2’-fluoro-2’-deoxy-arabino-
uridine (FAU) 65, was synthesised using a mesylate precursor based on a pro-
cedure reported by Turkman et al. [185] for the radiosynthesis of the 5-methylated
analogue 18F-FMAU. The corresponding mesylate precursor 79 was synthesised
via the route shown in scheme 3.12. TIPDS-protection of commercially available
uridine (55) was carried out using dichloro-1,1,3,3-tetraisopropyldisiloxane in dry
pyridine/DMF. 3’,5’-TIPDS-protected uridine (73) was furnished in 88% yield
after column purification. TMS-protection of the remaining 2’-hydroxy group
gave compound 74 in 79% yield. N3-Boc-protection and subsequent selective
deprotection of the TMS-group furnished hydroxy compound 75 in 63% overall
yield. Mesylation of the free 2’-OH group using mesyl chloride and Et3N in dry
DCM gave 76 in 82% yield. Tosylation product 77 was obtained in 44% yields,
however, it did not prove to be stable when stored at r.t. for longer then 24 h.
Hence, the synthesis of a tosylate precursor was discontinued.
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Reagents and conditions: i) TIPDSCl2, pyridine, DMF, 0°C - r.t., 14 h, 88%; ii) TMSCl, Et3N, DCM, 
0°C - r.t., 2 h, 79%;  iii) Boc2O, DMAP, THF, r.t., 16 h then pTsOH, 1 h, 63%; iv) MsCl, Et3N, DCM, 0°C - r.t., 3 
h, 82%; v) TsCl, Et3N, DCM, r.t., 24 h, 44%; vi) TBAF, THF,r.t., 40 min, 90%; vii) DHP, pTsOH, THF, 0°C - r.t., 
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Scheme 3.12: Synthetic scheme towards the mesylated fluorination precursor 79.
Tetrabutylammonium fluoride (TBAF) mediated deprotection of the bident-
ate protection group furnished compound 78 in 90% yield. THP-protection of
the 3’- and 5’-hydroxy groups was carried out using an excess of 3,4-dihydro-2H -
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pyran and an equimolar amount of pTsOH to obtain mesylate precursor 79 in
65% yield and high purities. Mesylate precursor 79 was tested using several flu-
oride salts and different reaction conditions as summarised below (Scheme 3.13,
table 6).
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Scheme 3.13: Fluoride-mediated nucleophilic substitution towards the protected 2’-
fluoro-arabinonucleoside 80.
Table 6: Fluorination results using mesylate precursor 79.
starting fluoride solvent time yield (80) comment
material source (T [◦C]) [h] [%]
79 KF/K222 MeCN (85) 8-12 n/a SM recovered
79 KF/K222 DMF (145) 3-5 n/a decomposition
79 TMAF MeCN (80) 8-12 n/a SM recovered
79 TMAF DMF (145) 4-8 n/a SM recovered
79 TBAF/THF MeCN (80) 2.5 51 -
Fluorinated intermediate 80 was obtained in MeCN at 80 ◦C for 2.5 h using
TBAF/THF (3.0 eq.) and confirmed by NMR and ESI-MS. Since TBAF is only
available as the trihydrate and very difficult to dry [207,208], the anhydrous solution
of TBAF in THF was considered as a reasonable option since it was already
successfully used in the synthesis of FMXU [170] (46, scheme 1.13). Acid mediated
hydrolysis of protected intermediate 80 using 1 M HCl/MeOH solution furnished
the target compound FAU 65 in acceptable yield (62%) (Scheme 3.14) after
column purification.
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Reagents and conditions: i) 1 M HCl/MeOH, reflux, 1 h, 62%.
Scheme 3.14: Acidic deprotection of 80 furnished the final compound FAU (65).
Full NMR characterisation in combination with MS and melting point (mp)
determination confirmed the desired product. The correct conformation of the
fluoro-substituent was derived from the coupling constants of the ribose protons
according to the Karplus relation. The corresponding 1H and 19F NMR spectra
of the mesylate precursor 79, the fluorinated intermediate 80 and FAU 65 are
shown in the appendix. The absence of the characteristic mesyl group singlets at
around 3.25 ppm illustrate the successful substitution by the fluoride nucleophile.
3.2 Radiochemical synthesis of 18F-FAU and
18F-FIAU
In this section the results regarding a novel late-stage radiofluorination approach
towards the 2’-18F-labelled uridine analogues 18F-FAU (9) and 18F-FIAU (14)
are presented.
The current radiochemical approach to give the uridine-based nucleosides
18F-FAU (9) and 18F-FIAU (14) is based on the early radiofluorination method
reported by Cai et al. [178] (Scheme 3.15):
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Reagents and conditions: i) [18F]fluoride/K222 or [18F]TBAF, MeCN, 85°C, 20 min;  ii) 2,4-bis-O-(trimethylsilyl)uracil (9), 
2,4-bis-O-(trimethylsilyl)-5-Iodouracil (14), HMDS, TMSOTf, MeCN, 85 °C, 1 h; iii) KOMe, MeOH.
O
47 48 9   R = H
14 R = I
Scheme 3.15: Current radiosynthesis of the uridine-based nucleoside analogues 18F-
FAU (9) and 18F-FIAU (14).
Decay-corrected RCYs of 5.4±1.0% (18F-FAU) and 9.9±0.4% (18F-FIAU)
with specific activities of 380±35 Ci/mmol and high radiochemical purities (≥99%)
were reported. The synthesis time was 150 min. The radiochemical syntheses of
these tracers were carried out on automated synthesis modules. Routine produc-
tion of these tracers, however, remains challenging.
3.2.1 18F-FAU
Since the late-stage fluorination of FAU-precursor 79 could be successfully demon-
strated, the subsequent radiochemical synthesis of its labelled analogue 18F-FAU
was carried out. First, the radiochemical synthesis of the 18F-labelled interme-
diate 81 was conducted in order to investigate whether [18F]fluoride could be
incorporated by nucleophilic substitution (Scheme 3.16).
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Scheme 3.16: [18F]fluoride-mediated nucleophilic substitution towards the protected
2’-18F-labelled FAU-intermediate 81.
Radiofluorinations were carried out using 3 GBq activity (≈5 nmoles of
[18F]fluoride) which was delivered from the cyclotron as an aqueous solution.
Hence, a drying procedure was carried out (ca. 20 min) after [18F]fluoride was
released from the ion-exchange (QMA) cartridge. Various polar aprotic solvents
such as MeCN, DMF and DMSO and different reaction temperatures (90-140 ◦C),
with reaction times no longer than 30 min were tested regarding radioactive decay.
Table 7 gives an overview of the results from conducted radiofluorinations using
different reaction conditions.
Table 7: Analytical radiochemical yields of 81 using different reaction conditions.
run solvent T [◦C] t [min] RCY [%] (n = 3)
1 MeCN 90 20 0.7±0.5
2 MeCN 90 30 0.9±0.3
3 DMF 100 20 2.3±0.7
4 DMF 120 20 8.7±1.1
5 DMF 120 30 5.2±0.9
6 DMF 140 20 3.9±1.0
7 DMSO 120 20 2.3±0.6
8 DMSO 140 20 1.4±0.6
The analytical RCY of compound 81 was determined using radio-TLC. The table
shows that maximum yields were found with DMF, 120 ◦C and 20 min reaction
time.
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The peak width of the radio-TLC experiment using the crude reaction mixture
(Figure 18) is most likely due to incomplete evaporation of high boiling reaction
solvents such as DMF and DMSO prior to the TLC experiment.
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Figure 18: Radio-TLC of the crude reaction mixture showing the radioactivity sig-
nal of the fluorinated intermediate (Rf=0.65; 5% MeOH/DCM) and the unreacted
[18F]fluoride near the baseline.
Labelling reactions were carried out using [18F]fluoride/K222/K2CO3 instead
of [18F]TBAF since the drying procedure was easier to perform (less prone to
decomposition [207,209]) in the module system and the conditions were adjusted
for [18F]fluoride/K222/K2CO3. Consequently, precursor 79 (10 mg) was dis-
solved in dry DMF under a flow of nitrogen. The solution was then added to
[18F]fluoride/K222 in a V-vial under a nitrogen atmosphere. The resulting mix-
ture was stirred at the appropriate temperature (90-140 ◦C) for the given time
(20-30 min). Table 7 shows that the highest RCY (8.7%) for 81 was obtained at
120 ◦C for 20 min in dry DMF. The crude reaction mixture was purified using
AL (Normal-phase alumina) and C18 (Reversed-phase C-18) cartridges to trap
unreacted [18F]fluoride and organic residues, respectively. The radioactive inter-
mediate 81 was released with EtOAc (2 mL) into a V-vial containing water (2
mL). The mixture was extracted to further remove unreacted [18F]fluoride from
the organic layer. Subsequently, radio-TLC (Figure 19) and radio-HPLC (Figure
20) samples spiked with non-radioactive reference compound 80 for co-elution
were analysed.
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Figure 19: Radio-TLC of the purified reaction mixture using pre-conditioned Al and
C18 cartridges for purification. The radioactive intermediate could be identified at
around 57 mm by co-elution with the non-radioactive reference standard.
Radio-HPLC with isocratic co-elution (20% H2O/MeCN) of both the non-
radioactive and the radioactive compound at approx. 6.3 min further confirmed
that the 18F-labelled intermediate 81 was obtained (Figure 18). Additionally, 81
was confirmed by LC-MS where the Na+-adduct with a mass to charge ratio of
535.79 ([M + Na]+)) was found indicating the intermediate ion with a mass of
513.54 ([M+]).
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Figure 20: Superimposed radioactivity and UV traces of the purified 18F-labelled
intermediate (Al and C18 cartridge followed by extraction) using analytical radio-HPLC
and non-radioactive reference standard, respectively (isocratic 20% H2O/MeCN; 1.0
mL/min flow rate).
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The next step involved acid-catalysed deprotection to give the nucleoside
tracer 18F-FAU (Scheme 3.16).
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Reaction conditions: i) 1 M HCl/MeOH, 70°C, 8 min.
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Scheme 3.17: Acid-catalysed deprotection gave 18F-FAU 9.
The radiofluorination step was carried out using optimal conditions (run 4,
Table 7). The eluted EtOAc-solution from the cartridge containing 81 was flushed
back into the reactor. The solvent was then removed under a stream of nitrogen
at 80 ◦C before 1 M HCl/MeOH-solution (0.4 mL) was added to the reaction
vial. The reactor was heated up to 70 ◦C for 8 min. A test reaction carried
out using an appropriate amount of the non-radioactive reference compound 80
indicated that deprotection is complete after 5 min under these conditions. The
mixture was subsequently neutralised with 1 M NaOH solution (0.5 mL). The
reaction mixture was then loaded onto a semi-preparative HPLC column via a 10
mL injection-loop. The product fraction was collected after 13.5 min of isocratic
elution (10% MeCN/H2O, 3 mL/min flow rate) in a vial containing isotonic NaCl-
solution. The product solution was then flushed through a sterility filter into the
final product vial.
Analytical radio-HPLC (10% MeCN/H2O, 1 mL/min flow rate) of the final
product confirmed 18F-FAU was furnished by co-elution with the non-radioactive
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reference compound FAU (Figure 19). 18F-FAU was obtained with a RCY of 2.8-
3.9% (decay-corrected, n = 3) in high radiochemical purities (≥95%) and specific
activities ≥42 GBq/µmol with a synthesis time of 178 min.
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Figure 21: Superimposed radioactivity and UV traces of analytical radio-HPLC of pur-
ified 18F-FAU and non-radioactive reference standard FAU (65), respectively (isocratic
elution with 10% MeCN/H2O; 1.0 mL/min flow rate).
This was the first time that 18F-FAU was synthesised via a late-stage fluorin-
ation procedure. This approach was based on previously published data for the
radiosynthesis of the uridine analogue 18F-FMAU by Alauddin et al. [177,185]. How-
ever, due to the proof-of-principle character of this reaction further optimisations
towards an improved radiosynthesis of 18F-FAU were not carried out.
3.2.2 18F-FIAU
In collaboration with Dr. Steven Paisey from PETIC at the Cardiff University
Hospital, we aimed to synthesise the FAU-analogue 18F-FIAU (14) via a novel
synthetic route based on the results obtained from the previously described 18F-
FAU study. Ultimately, 18F-FIAU was supposed to be tested as a PET reporter
probe for herpes simplex virus thymidine kinase 1 (HSV-TK-1) in a newly de-
veloped cancer model at the Cardiff School of Medicine. As FIAU and thus
18F-FIAU are substrates for HSV-TK-1 but not substrates of the mammalian
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thymidine kinase 1 (TK-1) [210], genetically engineered stem cells that express the
HSV-TK-1 gene could selectively trap 18F-FIAU in the cell through phosphoryla-
tion [211]. It was envisaged that in vivo imaging of stem cell localisation and, if
enzyme expression is conditional, cell differentiation could be monitored by PET
with potential applications in stem cell therapy [212].
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Reagents and conditions: i) TIPDSCl2, pyridine, 0°C - r.t., 24 h, 77%;  ii) TMSCl, Et3N, DCM, 0°C - r.t., 2 h, 
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Scheme 3.18: Synthetic scheme towards the mesylated fluorination precursor 88.
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The precursor synthesis was performed according to the FAU-precursor syn-
thesis. Starting with commercially available 5-iodouridine (82) the first step
involved the 3’,5’-TIPDS-protection in dry pyridine at ambient temperature fur-
nishing compound 83 [213] in 77% yield followed by TMS-protection of the remain-
ing hydroxy group at the 2’-position. It is noteworthy that the yield of the TMS-
protection could be significantly improved (≥30%) by slow and dropwise addition
of the TMSCl at low temperatures (≤-5 ◦C). Subsequent N3-Boc-protection and
pTsOH-mediated TMS-deprotection gave compound 85 as a white foamy solid in
58% yield. Mesylation was carried out in dry DCM using MsCl and Et3N. The
reaction profile was clean and full conversion of the starting material could be ob-
served after 3 h. TBAF-mediated deprotection of the bidentate protecting group
occurred within 45 min at ambient temperature. The resulting crude oil was
used without further purification for reaction scales ≥500 mg for the subsequent
THP-protection step. The dried crude mixture was dissolved in dry DCM under
inert atmosphere followed by the addition of an excess of 3,4-dihydro-2H -puran
and an equimolar amount of pTsOH. Full conversion of the starting material was
observed after 4 h. The THP-protected product 88 was detected by TLC as
two close spots under UV-light (254 nm), each spot corresponding to one pair of
diastereomers. The two pairs of diastereomers could be separated and purified
by column chromatography using an EtOAc/hexane gradient. Analytical HPLC
gave a purity of ≥97% with a yield of 55% for precursor 88.
The radiochemical synthesis was performed based on the 18F-FAU-synthesis.
However, the non-radioactive reference standard 89 for the radiolabelled 18F-
FIAU-intermediate was not available as non-radioactive fluorinations proved to
be challenging (Scheme 3.19, top). Different reaction conditions were tested us-
ing either KF/K222 or TBAF as fluorination agent and MeCN or DMF as solvents
at reflux temperatures (90-160 ◦C) for 1-2 h. However, analytical evidence for
the fluorinated intermediate 89 could not be provided. Consequently, radiofluor-
inations with subsequent deprotection were carried out (Scheme 3.19, bottom)
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as the non-radioactive reference standard FIAU was commercially available and
thus enabled analysis of the reaction mixture with radio-HPLV and radio-TLC
via co-elution.
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HO
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I I
Reaction conditions: i) KF/K222 or TBAF, MeCN/DMF, 90-140°C, 1-2 h; ii) [18F]fluoride/K222, 
DMF/DMSO, 100 - 140°C, 20 min, iii) 1 M HCl/MeOH, 70°C, 8 min.
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Scheme 3.19: Non-radioactive fluorination did not yield the intermediate 89. Fur-
thermore, the radiochemical approach as outlined above to give 18F-FIAU 14 was not
successful.
Radiofluorination and subsequent deprotection were carried out in the same
reaction vial. Reaction solvent and temperature were varied. The reaction time
as well as the conditions for the deprotection step (1 M HCl, 80 ◦C, 10 min) were
not changed (Table 8).
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Table 8: Tested radiofluorination conditions to give 18F-FIAU
run solvent T [◦C] t [min] RCY [%] (n = 2)
1 DMF 100 20 n/a
2 DMF 120 20 n/a
3 DMF 130 20 n/a
4 DMF 140 20 n/a
5 DMSO 130 20 n/a
6 DMSO 140 20 n/a
The target compound 18F-FIAU (14) could not be obtained using different reaction
conditions.
Radio-TLC as well as radio-HPLC experiments were carried out using co-
elution with the non-radioactive reference compound FIAU. However, 18F-FIAU
could not be obtained under the reaction conditions shown in table 8. The only
observed radioactivity peak was due to unreacted [18F]fluoride.
Further investigations regarding the late-stage synthesis of 18F-FIAU were
discontinued, mainly due to reasons of time but also because the stem cells could
not be provided. The translation of the findings from the 18F-FAU synthesis to
18F-FIAU proved to be more challenging then expected even though the target
molecules are similar in their chemical structure. That is an indicator for the
general complexity of radiochemistry.
85
3 Results and discussion
3.3 Radiochemical synthesis of 18F-FAC
As outlined in section (1.4.1), 18F-FAC is currently synthesised via the following
route [180] (Scheme 3.20):
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OBz
O
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OBz
i
18F
ii
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BzO
OBz
18F
Br iii, iv
N
ON
O
OH
HO 18F
Reagents and conditions: i) [18F]fluoride, K222, DMF, 165°C, 15 min; ii) 30% HBr/AcOH, dichlorethane, 
80°C, 10 min;  iii) bis(trimethylsilyl)cytosine, dichlorethane, 160°C, 30 min; iv) NaOMe/MeOH, 100°C, 5 min.
47 48
49 15
NH2
Scheme 3.20: Current radiochemical approach to give 18F-FAC.
A novel automated radiosynthesis module (ELIXYS) was developed in order
to synthesise 18F-FAC following the route in scheme 3.20 and suitable for clinical
application [180]. Decay-corrected RCY of 31±5 (n = 6) with specific activities
between 37-44 GBq/µmol and a synthesis time of 160 min were reported. Clinical
routine production of this radiotracer, however, has not been reported so far.
A late-stage and FDG-like radiosynthesis may simplify the application of 18F-
FAC in clinical routine production and hence could have a significant impact on
the availability of 2’-[18F]fluorinated arabino cytidine derivatives such as 18F-FAC
and 18F-FIAC in clinical use. The following section describes a novel late-stage
radiofluorination approach to give 18F-FAC.
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3.3.1 Precursor development
The greatest challenge from a synthetic point of view is the rational design and
synthesis of an appropriate fluorination precursor which combines an activated,
electrophilic position at the 2’-position of the sugar moiety with stability against
decomposition when handled at high temperatures (≥100 ◦C) and under basic
conditions.
The development of a novel late-stage radiochemical approach towards 18F-
FAC (15) was based on the idea that a rational design of a potential precursor
may be advantageous prior to 18F-labelling reactions. In order to develop a
novel precursor for the radiofluorination of the 2’-arabino position of cytidine
derivatives the idea of radiofluorination of an intact nucleoside moiety was applied.
The main challenge of this new approach was the rational design of a precursor
that combined reactivity and stability in a way that radiofluorination at high
temperatures could be carried out with acceptable conversion rates while the
heat- and base-mediated anhydro-formation was kept at a minimum.
Despite experimental data, a quantitative method for the characterisation of
the thermal stability of precursors was desirable. Next to base-mediated N3/N4-
H deprotonation, the electric charge density of the 2-carbonyl oxygen of the
pyrimidine moiety was considered as a measurement for the potential to undergo
an intramolecular nucleophilic attack at the 2’-position to form undesired an-
hydro side products. Hence, the electric charge density of a family containing
N4-substituted cytidine derivatives was calculated. Base-mediated N-H depro-
tonation, however, was not considered for the calculations. Molecular dynamic
calculations were performed to yield energetically minimised conformations from
which sixteen were selected in order to cover the conformational space. The
net electric charge of all atoms of these compounds were calculated using the
GAMESS [214] software with support from Dr. Andrea Brancale and Iuni Trist.
The net electric charge of the 2-carbonyl oxygen was subsequently averaged for
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each compound. In addition to the cytidine derivatives 90-94, selected uridine
derivatives were included to give a reference value as well as to show the impact
of the 4-amino group on the electric charge density of the 2-carbonyl oxygen
(Table 9). The N-substituents were chosen with regard to their synthetic access-
ibility and deprotection mechanisms that are suitable for radiochemical syntheses
and GMP environments in terms of efficient removal and the use of hazardous
chemicals, respectively (Figure 23).
Furthermore, the N3−nitro-2’-(methanesulfonyl)uridine 96 was considered
as a standard value since the N3−nitro-2’-(trifluoromethanesulfonyl)uridine de-
rivative 97 (Figure 22) was previously reported as successfully synthesised and
thermally stable [215]. Thus, N-nitro-substitution decreases the electron density
on the 2-carbonyl oxygen and prevents base-mediated N-H deprotonation to an
extent which allows the conversion of the 2’-hydroxy group into a triflate group (a
very good leaving group) without formation of the cyclic 2,2’-anhydro compound.
N
O
ON
O
HO
OH O
NO2
S
O
O
CF3
97
Figure 22: Compound 97 was found to be stable even though the triflate group
represents a good leaving group. Hence, the N3-nitro substituent withdraws enough
electron density and prevents base-mediated N-H deprotonation so that the 2-carbonyl
oxygen is not attacking the 2’-position.
However, according to the existing literature [215] no radiofluorination method
could be applied to a N3−nitro uridine-based precursor. Hence, N-nitro protec-
tion was not considered as a potential protecting group strategy.
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90 R1 = R2 = H    
91 R1 = H, R2 = Ac
92 R1 = H, R2 = Boc
93 R1 = R2 = Boc
94 R  = phthalimide
phthalimide:
95 R3 = H
78 R3 = Boc 
96 R3 = NO2
NO O
Figure 23: Selected cytidine- (90-94) and uridine-based (95,78,96) nucleosides for
electric charge density calculations.
Table 9: Net electric charge densities Ω calculated for the 2-carbonyl oxygen.
Compound R1 R2 R3 Ω
90 H H -0.911±0.09
91 H Ac -0.901±0.05
92 H Boc -0.860±0.01
93 Boc Boc -0.825±0.06
94 phthalimide phthalimide -0.814±0.08
95 H -0.838±0.02
78 Boc -0.770±0.03
96 NO2 -0.589±0.10
The results shown in table 9 indicated that the net electric charge at the
2-carbonyl oxygen was reduced when H-substitution at the N4 (N3 for uridine
derivatives) with an electron-withdrawing group was performed. Furthermore,
it showed that the stronger the electron-withdrawing effect of the substituent(s)
the lower the calculated electron density at the 2-carbonyl oxygen. For instance,
double N4-Boc-protection (93) decreased the electron density more then single N4-
Boc-protection (92) and N4-acetylation (91), respectively. In order to translate
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the difference of the calculated electric net charge into a measurable dimension,
compounds 91 and 93 were tested for their ability to decompose and to form the
appropriate cyclic anhydro compounds. Intramolecular cyclisation of compound
91 is shown in scheme 3.21.
N
HN
N
O
HO
OMsOH
O
N
N
N
O
HO
OH
O
91 98
O
1. deprotonation
2. intramolecular
    cyclisation
50°C, 2 h
O
- MsOH
Scheme 3.21: Intramolecular cyclisation of compound 91 gave the cyclisation product
98
Therefore, a NMR sample of compound 91 was heated up to 50 ◦C. 1H NMR
spectra were recorded hourly. Figure 24 shows that almost full conversion to
anhydro compound 98 occurred within 2 h.
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Figure 24: Decomposition of compound 91. The signals in red correspond to com-
pound 91, the signals in blue to the anhydro compound 98.
Chemical shifts of the amino proton (11.5 to 12.25 ppm) and the ribose pro-
tons showed the conversion into the cyclic nucleoside compound. Furthermore,
the vanishing signal of the mesyl group at 3.5 ppm also indicated the decompos-
ition since the free mesylate should show a different chemical shift which indeed
was observed at around 2.3 ppm next to the methyl-signal of the acetamide.
13C-NMR chemical shifts also indicated anhydro formation. Additionally,
ESI-MS was performed in order to show the change in the molecular mass. In fact,
the increasing intensity of the m/z-signal 268 ([M + H]+) further confirmed the
formation of compound 98. The same results were obtained for the benzoylated
derivative 106. Subsequent THP-protection of the 3’- and 5’- hydroxy groups
of 91 increased its thermal stability, presumably due to steric hindrance of the
intramolecular nucleophilic attack. However, temperatures ≥80 ◦C also led to
decomposition, which was reliably monitored by TLC.
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The double N4-Boc-protected compound 93, however, indicated a signific-
antly increased stability as shown in figure 25. Recorded proton NMR spectra
did not show the formation of the cyclic compound 99 after 2 h at 80 ◦C (Fig-
ure 25). the observed stability of compound 93 looked promising with regard to
radiofluorination reactions. Additionally, carbon NMR spectra and recorded MS
data supported the stability of compound 93.
N
N
N
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HO
OMsOH
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N
N
N
O
HO
OH
O
93 99
80°C, 2 h
- MsO
Boc Boc Boc Boc
Scheme 3.22: Compound 93 did not form the cyclisation product 99 after 2 h at
80 ◦C.
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Figure 25: Even after 2 h at 80 ◦C compound 93 was not converted into the cyc-
lic species 99. The increased stability led to the synthesis of fluorination precursor
119. Additionally, acid-labile N4-Boc-protection was the protection strategy of choice
regarding a possible THP-protection of the hydroxy groups.
Hence, both the calculated and experimental data led to the conclusion that
N4/N3-electron withdrawing groups have a measurable and quantifiable effect on
the electron density at the 2-carbonyl oxygen. Depending on the strength of its
electron withdrawing nature a N4/N3-protecting group may influence the stability
of a 2’-activated nucleoside analogue regarding 2,2’-intramolecular cyclisation.
However, these results did not explain to what extend the electron withdraw-
ing effect of the Boc-protecting groups contributed to the observed stability of
compound 93, or whether it was a result of the disubstitution of both amino
protons preventing base-mediated cyclisation. Hence, it was assumed that the
disubstituted N4-diacetyl- and N4-dibenzoyl compounds might have similar sta-
bilities. Their synthesis, however, proved not to be successful and thus appropri-
ate stability experiments could not be carried out. The inaccessibility of these
93
3 Results and discussion
compounds was a surprising result as double N4-Boc-protection was performed
in good yields.
Finally, compound 93 was selected for further studies. In accordance to
previous experiments, the combination of N-Boc-protection with 3’/5’-O-THP-
protection was the protection strategy of choice. This led to the development of
precursor 119 (Scheme 3.28).
3.3.2 Precursor synthesis
TIPDS-protection of the 3’- and 5’-OH groups of N4-acetylcytidine (100) and N4-
benzoylcytidine (101) furnished compounds 102 and 103 in good yields (67-77%).
Coevaporation with dry pyridine prior to the reaction was found to be crucial for
yields ≥60%. Subsequent mesylation was carried out using mesyl chloride and
Et3N in anhydrous DCM under inert atmosphere and furnished compounds 104
and 105 in yields between 82-88%. TBAF-mediated deprotection of the TIPDS-
group furnished compounds 91 and 106 which were used for stability experiments
(Scheme 3.23).
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104 R = Me
105 R = Ph
 91  R = Me
106 R = Ph
Reaction conditions: i)  TIPDSCl2, pyridine, 0°C - r.t., 18 h, 67-77%;  ii) MsCl, Et3N, DCM, 0°C - r.t., 
2 h, 82-88%; iii) TBAF, THF, r.t., 30 min, 57-63%.
Scheme 3.23: Synthetic scheme towards the mesylated compounds 91 and 106.
As a proof-of-principle study, the influence of a better leaving group at the 2’-
position of the N4-acetyl cytidine derivative 91 was investigated by synthesising
the 2’-tosylated compound 107. Compound 107, however, was found to be even
less thermally stable than the 2’-mesylated counterpart (Scheme 3.24).
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H
Scheme 3.24: The 2’-tosylated derivative decomposed even faster than compound 91
supporting previous assumptions about leaving group abilities and their influence on
2,2’-intramolecular cyclisations.
Double N4-acetylation/benzoylation was investigated using compounds 108
and 109 as starting materials according to published results [216]. However, the
disubstituted products could not be observed. Reaction time and temperature
were varied as well as higher amounts of the acetylating agent were tested (Scheme
3.25).
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Reaction conditions: i)  TMSCl, Et3N, DCM, 0°C - r.t., 3 h, 73-82%; ii) either AcCl, Ac2O or BzCl in 
DCM/THF/dioxane, 0°C/r.t./reflux, 2-12 h.
Scheme 3.25: N4-acetylation/benzoylation of 108 and 109 could not be achieved
using different reaction conditions.
Starting from commercially available cytidine (110) compounds 113 and 114
could be successfully synthesised. Phthalimide 113 was obtained by converting
the 4-amino-group of compound 112 into the cyclic diamide using phthaloyl chlor-
ide and DMAP in dry pyridine [217]. The desired product gave a strong UV signal
(254 nm) with Rf=0.8 (DCM/MeOH=94/6). Coevaporation with dry pyridine
prior to the reaction and dropwise addition of a phthaloyl chloride solution in
DCM furnished 113 in 69% yield. Additionally, compound 114 was successfully
synthesised using similar conditions as for compounds 75 and 85 except a higher
excess of di-tert-butyl dicarbonate. The starting material was completely con-
verted after 5 h and no other spot on the TLC according to the mono-protected
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intermediate could be found. NMR and ESI-MS confirmed that compound 114
was successfully obtained in 77% yield (Scheme 3.26).
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Reaction conditions: i) TIPDSCl2, pyridine, 0°C - r.t., 18 h, 81%;  ii) TMSCl, Et3N, DCM, 0°C - r.t., 2 h, 
83%; iii) phthaloyl chloride, DMAP, pyridine, 0°C - r.t., 4 h, 69%; iv) Boc2O, DMAP, DCM, r.t., 5 h, 77%.
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Scheme 3.26: Formation of the 4-amino-protected compounds 113 and 114. TIPDS
and subsequent TMS protection starting from commercially available cytidine furnished
112 which was then converted to the 4-amino-protected derivatives 113 and 114.
Di-tert-butyl dicarbonate had to be used in 5 equivalents or higher in order
to fully convert the starting material into the di-Boc protected compound 114.
Otherwise both the single (114b) and double 114 Boc-protected compounds
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were isolated. The straightforward synthesis of 114 is surprising considering
the unsuccessful attempts to synthesise the double acetylated- and benzoylated
derivatives. Compounds 113 and 114 were then treated with pTsOH in dry
DCM at 0 ◦C in order to selectively deprotect the 2’-position. In case of 114,
the addition of pTsOH was performed slowly over a time period of 15 min in
order to avoid cleavage of the Boc-groups. Subsequent mesylation of 115 and
116 furnished 117 and 118 in good yields (65-71%) (Scheme 3.27).
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Reaction conditions: i) pTsOH, DCM, 0°C, 30 min, 62-66%; ii) MsCl, Et3N, DCM, 0°C - r.t., 2 h, 65-71%
O
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Scheme 3.27: Selective 2’-deprotection and subsequent mesylation furnished com-
pounds 117 and 118.
The Boc-protected precursor was considered as more suitable for automated
synthesis modules as N4-deprotection should be more straight forward compared
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to the phthalimide which usually involves chemicals such as NaBH4 or methyl
amine and long reaction times [218,219]. Furthermore, treating compound 117 with
fluoride-containing agents for deprotection did not lead to the desired compound
94.
N
N
ON
O
OO
O
Si
Si
O
S
O
O
N
N
ON
O
OOH
HO
S
O
O
117 R = pthtalimide
118 R = Boc
Reagents and conditions: i) TBAF, THF, -10 °C, 40 min, 56% (only for 93); ii) DHP, pTsOH, 
DCM, 0 °C - r.t., 5 h, 47%.
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Scheme 3.28: Selective TIPDS-deprotection gave the intermediate 93 which was used
for stability studies. Subsequent THP-protection furnished FAC-precursor 119 as a
mixture of four diastereomers in moderate yields and high purities.
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Based on these results, the corresponding fluorination precursor 119 was
synthesised. Precursor 119 was obtained in good yield (47%), as an off-white
powder and as a mixture of four diastereomers with coincidental ratios. The
purity was determined using analytical HPLC and calculated for ≥98% (Scheme
3.28).
The non-radioactive reference compound 120 was obtained by treating pre-
cursor 119 with an anhydrous 1 M TBAF/THF solution in DMF at 110 ◦C for
2 h according to the method previously described for the FAU-intermediate 80
(Scheme 3.29). The accessibility of this compound was crucial as it allowed iden-
tification of the 18F-labelled intermediate after radiofluorination via co-injection.
Despite ESI-MS, 19F NMR was used to confirm the product by showing four
distinguishable fluorine signals each corresponding to one of the four diastereo-
mers that are present due to the THP-protecting groups (see Appendix). Inter-
mediate 120 was obtained in moderate yields (29%) and high purities (≥98%)
which was considered as the most important factor for HPLC purposes.
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Reagents and conditions: i) 1 M TBAF/THF, DMF, 110°C, 100 min, 29%
Scheme 3.29: TBAF-mediated fluorination furnished the FAC-intermediate 120 as a
mixture of four diastereomers in moderate yields.
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3.3.3 Radiochemistry
Subsequent radiofluorinations to give the 18F-FAC-intermediate 121 were carried
out using dried [18F]fluoride/K222/KHCO3 in different solvents and at various
temperatures (Scheme 3.30). [18F]fluoride was released from the QMA cartridge
using a K222/KHCO3-solution. Table 10 shows the analytical RCYs calculated
using radio-TLC.
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18F
FAC-precursor (119) 18F-FAC-intermediate (121)
Reaction conditions: i) [18F]fluoride/K222, 90-130°C, solvent, 20-30 min.
Scheme 3.30: Radiofluorination of precursor 119 furnished the radioactive intermedi-
ate 121.
The highest RCY (9.4%) of 121 was obtained using DMF at 110 ◦C for 20
minutes (Table 10, Figure 26). MeCN or tBuOH as solvent did not show any
conversion. However, higher temperatures and longer reaction times led to de-
creased RCY, presumably due to increased formation of the anhydro intermediate.
Furthermore, less basic reaction conditions by using KHCO3 instead of K2CO3
led to an improved RCY.
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Table 10: Analytical radiochemical yields of 121 using different reaction conditions.
run solvent T [◦C] t [min] RCY [%] (n = 3)
1 tBuOH 95 20 n/a
2 MeCN 90 20 n/a
3 DMF 90 20 1.3±0.3
4 DMF 95 20 2.6±0.2
5 DMF 100 20 4.9±0.6
6 DMF 105 20 7.7±0.8
7 DMF 110 20 9.4±0.8
8 DMF 110 30 7.9±0.6
9 DMF 115 20 6.9±0.5
10 DMF 120 20 4.1±0.4
11 DMF 125 20 2.3±0.2
12 DMF 130 20 1.8±0.2
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Figure 26: Analytical RCY of precursor 119 plotted against the reaction temperature.
The reactions were carried out in DMF with 20 min reaction time. Despite the balance
between precursor stability and reactivity, the reaction temperature displays another
crucial parameter for radiofluorination.
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Figure 27: Radio-TLC chromatogram of the crude reaction mixture after radiofluor-
ination.
After trapping unreacted [18F]fluoride on an Al cartridge and organic residues
on a C18 cartridge, the 18F-labelled intermediate 121 was released using EtOAc
(3 mL). Product confirmation was carried out by radio-TLC and radio-HPLC
with co-injection of the non-radioactive reference standard 120 (Figure 28,29).
Figure 28: Radio-TLC chromatogram of the EtOAc-phase after purification of the
[18F]fluorinated intermediate 121 using Al and C18 cartridges.
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Figure 29: Radio-HPLC chromatogram of the purified (Al/C18 cartridge)
[18F]fluorinated intermediate 121 (red trace) with co-injected reference compound 120
(blue (UV) reference peak)
After elution of the labelled intermediate from the Al cartridge with EtOAc
into a clean V-vial, the solvent was removed at 90 ◦C under a stream of nitrogen
in a separate heating module. 2 M HCl solution was added to the dried residue
and then stirred at 95 ◦C for 20 min (Scheme 3.31, top). Neutralisation with 2
M NaOH solution was followed by semi-preparative HPLC purification. 18F-FAC
was eluted after 22.5 minutes at a flow rate of 3.5 mL/min using 3% MeCN/H2O
as the mobile phase. After collection of the product the HPLC solvent was re-
moved under reduced pressure and a stream of nitrogen. The radioactive product
was taken up in saline and subsequently flushed through a sterility filter to obtain
a sterile and clean aqueous solution of 18F-FAC.
An aliquot of the purified sterile sample was analysed by HPLC (Figure 30)
via co-elution of both possible 2’-19F-isomers FC and FAC (Scheme 3.31, bottom)
as reference. The obtained 18F-labelled product was confirmed as the desired tar-
get compound 18F-FAC. Radiochemical reactions were carried out using starting
activities between 2.5-55 GBq. Final product activities of 134-1045 MBq were
obtained resulting in RCY of 4.3-5.5% (n = 6, decay-corrected from end of bom-
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bardment (EoB)) with high radiochemical purities (≥98%) and specific activities
≥1700 mCi/µmol. The total synthesis time was 168 min after the end of bom-
bardment (EoB).
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Scheme 3.31: top: deprotection scheme towards the 18F-labelled nucleoside 18F-FAC;
bottom: structure of the two possible 2’-fluoro stereoisomers 2’-fluorocytidine (FC, 42)
and 2’-fluoroarabinocytidine (FAC, 5).
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Figure 30: The purified and sterilised product solution was analysed by radio-HPLC
and co-elution of both stereoisomers and reference standards FC (Rt=11.7 min) and
FAC (Rt=13.1 min) showing that the correct stereoisomer was obtained.
A carrier-added synthesis was performed and the resulting product solution
stored for 48 h for decay. Subsequently, the sample was characterised by LC-MS
showing a single signal with the m/z-values of 245.4 (5%) [(M + H)+] and 267.7
(95%) [(M + Na)+] , respectively. Furthermore, the influence of reaction time and
temperature on the stereospecific outcome of this radiofluorination reaction was
studied. The diagrams below show radioactivity traces recorded after different
reaction temperatures and reaction times (Figure 31).
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Figure 31: Increased reaction temperature and longer reaction times led to anhydro
formation and subsequently to the formation of 2’-18F-FC shown by the increasing
intensity of the radioactivity signal at ≈11.8 min. That may explain the decrease in
the observed RCY for the desired arabino compound (Table 10). Both radioactive iso-
mers 18F-FAC to 18F-FC were collected in one fraction during semi-preparative HPLC
purification.
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The chromatograms above (Figure 31) show the temperature and reaction
time dependence of the stereochemical outcome of the radiofluorination reaction
and hence support previous assumptions regarding the 2,2’-intramolecular cyclisa-
tion (Scheme 3.32). Increased reaction temperature and longer reaction times
led to the formation of the 2,2’-cyclic anhydro side product which in turn gave
the 2’-[18F]fluoro-ribo isomer. Hence, the ratio of 18F-FAC to 18F-FC decreases
when reaction temperature and time increase which is indicated by the consec-
utively increasing radioactivity signal at ≈12 min, which, as co-injection shows,
corresponds to the 2’-[18F]fluoro-ribo-isomer.
Due to the instability of Boc-protecting groups during radiofluorinations,
most likely due to in situ generation of hydrogen fluoride from remaining trace
water, the cleavage of a Boc group may lead to the formation of a N4-mono-
Boc protected intermediate (122) which in turn may undergo base-mediated
intramolecular cyclisation as shown in Scheme 3.32. Subsequent nucleophilic
attack of [18F]fluoride at the 2’-position would lead to the formation of the 2’-
[18F]fluoro-ribo isomer 18F-FC.
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Scheme 3.32: Single (or double) deprotection of the Boc groups would enable base-
mediated intramolecular cyclisation of N4-single Boc-protected compound 122. 18F-
mediated nucleophilic attack of the 2’-position would lead to the observed 2’-[18F]fluoro-
ribo isomer 18F-FC.
This newly developed radiochemical approach to give 18F-FAC applied the
principle of a late-stage radiofluorination for the first time to a cytidine-based nuc-
leoside. Even though the RCY of this method is low compared to the reported
RCY of the latest method (31±5%) [180], less steps after radiofluorination and an
18F-FDG-like synthetic route (radiofluorination followed by deprotection) using
an intact nucleoside moiety may simplify the use of this tracer in routine produc-
tion. However, the results presented in this section concerning 18F-FAC should
be regarded as first trials. Further investigations using different radiochemistry
set-ups (e.g. different radiosynthesisers, microwave-assisted synthesis, continuous-
flow systems) have to be carried out in order to validate the clinical potential of
this method.
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3.4 Radiochemical approach towards
18F-gemcitabine
2’-carbonyl nucleosides were the only reported 2’-activated nucleoside analogues
that enabled a late-stage formation of the gem-difluoro system. Consequently, the
proposed synthetic approach (Scheme 3.33) towards 18F-gemcitabine (54) was
based on previously published data [159] concerning a 2’-deoxodifluorination as
presented in section 1.3.2. Considering the mechanism (Scheme 3.34, top) of the
2’-deoxodifluorination of a 2’-keto nucleoside, it was assumed that [18F]fluoride
could replace pyridine/HF as an additional fluoride source in a labelling reaction
(Scheme 3.34, bottom). [18F]fluoride would hence be incorporated first by form-
ing an oxyanion at the 2’-position which then could react with DAST. Subsequent
nucleophilic substitution of the generated leaving group by fluoride may lead to
the 2’-difluorinated and 18F-labelled gemcitabine intermediate 123 (Schemes 3.33
and 3.34).
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Scheme 3.33: Proposed synthetic scheme towards a 18F-labelled gem-difluoro system
as present in the 18F-gemcitabine intermediate 123. In comparison to the reported
non-radioactive deoxodifluorination carried out at r.t. for 24 h in anhydrous DCM
with 80% conversion, the time of the labelling reaction is restricted due to the half-life
of 18F. Thus, higher reaction temperatures in higher boiling polar aprotic solvents were
used in order to compensate shorter reaction times.
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Scheme 3.34: Top: Mechanism of the reported non-radioactive deoxodifluorination
towards gemcitabine. Bottom: Hypothetical mechanism of a labelling reaction to give
intermediate 123 using [18F]fluoride as an additional fluoride source.
Based on the results from the previous chapter involving the radiosynthesis of
18F-FAC, the first thoughts regarding an appropriate precursor with an activated
2’-position for deoxodifluorination resulted in structure 124 (Figure 32).
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Figure 32: Proposed structure of a novel gemcitabine precursor based on previous
results.
Consequently, 2’-oxidation of compound 116 using DMP-oxidation condi-
tions was successfully carried out furnishing 2’-keto compound 125 in 57% yield
(Scheme 3.35).
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Reaction conditions: i) DMP, DCM, r.t., 24 h, 61%
Scheme 3.35: 2’-oxidation of 116 was successful using DMP.
However, all attempts to cleave the 3’,5’-protecting group failed. Compound
125 formed side products such as the fully deprotected nucleoside when treated
with TBAF or related fluoride containing reagents. The second reason why this
approach was finally abandoned was the fact that acid-labile protecting groups
such as Boc and THP might be cleaved during the reaction with HF-generating
agents such as DAST and Fluolead.
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Precursor 35 was adopted from previously published data [159] as outlined in
section 1.3.2 and synthesised by using the TIPDS-protected cytidine derivative
102. Subsequent 2’-oxidation to give the 2’-carbonyl compound 126 was carried
out using both Dess-Martin Periodinan (DMP) reagent and classic Swern oxida-
tion conditions (Scheme 3.36). Both methods furnished the desired 2’-carbonyl
compound 126 in moderate yields (49-55%). Swern oxidation was preferred due
to less costly material and shorter reaction times.
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Reagents and conditions: i) DMP, DCM, r.t., 24 h, 55%; ii) oxalyl chloride, DMSO, Et3N, DCM, 
-78°C - r.t., 1 h, 49%.
102 126
Scheme 3.36: Synthetic scheme towards the 2’-carbonyl compound 126. Both DMP
and Swern oxidation furnished 126 in 49-55% yield.
According to published data [159], TIPDS deprotection and subsequent acetyla-
tion of the 3’- and 5’-hydroxy groups were carried out using anhydrous Et3N/HF
in DCM for deprotection followed by acetylation using acetyl chloride in dry DCM
at r.t. After basic work-up of the reaction mixture, two consecutive column puri-
fications were required in order to obtain precursor 35 in high purities (≥98%)
and moderate overall yield (32%) (Scheme 3.37).
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Reagents and conditons: i) Et3N/HF, DCM, r.t., 45 min; ii) AcCl, Et3N, DCM, 0°C - r.t., 24 h, 
32% overall yield.
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Scheme 3.37: Et3N/3HF-mediated deprotection and subsequent acetylation furnished
gemcitabine precursor 35.
The alternative route towards precursor 35 via cyclic anhydro compound 127
was investigated by my 4th year MPharm project student Josephine Sze. It was
found that this route is faster but furnishes lower overall yields (Scheme 3.38).
127 is hydrolised under basic conditions and the 2’-hydroxy product was filtered
off and purified. Oxidation of compound 128 furnished precursor 35 in 43% yield
and high purities (≥98%).
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Scheme 3.38: Alternative synthetic route to give gemcitabine precursor 35.
After successful synthesis of precursor 35, the 2’-difluorinated reference com-
pound 129 for the analysis of labelling reactions with radio-TLC and radio-HPLC
was synthesised via acetylation of all available hydroxy and amino groups of com-
mercially available gemcitabine. Compound 129 was obtained in high yield (93%)
(Scheme 3.39).
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Scheme 3.39: Synthesis of the gem-2’-difluoro reference standard 129 starting with
commercially available gemcitabine.
Prior to labelling reactions, non-radioactive test reactions were carried out in
order to investigate whether the 2’-difluorinated intermediate 129 could be syn-
thesised using an organic fluorination agent such as DAST and an additional
fluoride source such as pyridinium hydrogen fluoride at higher temperatures
and shorter reaction times with regard to subsequent radiofluorinations (Scheme
3.40).
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Scheme 3.40: Non-radioactive fluorination of precursor 35 to give the gem-2’-difluoro
reference standard 129.
Precursor 35 was treated with different organic fluorination agents (OFA) in
combination with either KF/K222 or pyridinium hydrogen fluoride (py/HF) as
summarised in table 11. In general, precursor 35 (20 mg) was dissolved in the
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reaction solvent (1 mL) under inert atmosphere before either KF/K222 or py/HF
(1 eq.) was added to the mixture. A solution of the organic fluorination agent
(10 eq.) in the reaction solvent (0.2 mL) was then added dropwise to the reaction
mixture before heating.
Table 11: Results of the non-radioactive 2’-deoxodifluorinations using precursor 35.
run OFA add. fluoride solvent t [h] yield (129)
source (T [◦C]) [%] (n = 1)
1 DAST KF/K222 MeCN (60) 3 n/a
2 DAST py/HF MeCN (90) 2 n/a
3 DAST KF/K222 DMF (60) 3 n/a
4 DAST py/HF DMF (90) 2 n/a
5 XtalFluor M KF/K222 MeCN (60) 3 n/a
6 XtalFluor M py/HF MeCN (90) 2 n/a
7 XtalFluor M KF/K222 DMF (60) 3 n/a
8 XtalFluor M py/HF DMF (90) 2 n/a
9 Fluolead KF/K222 MeCN (60) 3 n/a
10 Fluolead py/HF MeCN (90) 2 n/a
11 Fluolead KF/K222 DMF (85) 3 n/a
12 Fluolead py/HF DMF (145) 2 n/a
Deoxodifluorinations in presence of an organic fluorination agent (OFA = DAST,
XtalFluor M, Fluolead; 10 eq. relative to precursor) and either py/HF or KF/K222
(1 eq.) using precursor 35 (20 mg, 51.4 µmol) in 1.2 mL solvent. However, the
gem-difluoro intermediate 129 could not be observed.
Evidence for compound 129 could not be provided under the reaction con-
ditions shown in table 11. The crude reaction mixtures were analysed by TLC,
ESI-MS and HPLC. Even though the starting material was fully converted after
the given reaction time side products could not be identified.
Although non-radioactive test reactions did not yield the 2’-difluorinated in-
termediate 129, a series of radiofluorination reactions was carried out (Scheme
3.41). The radiochemistry set-up in the hot cells as well as the Eckert & Ziegler
module system enabled more reproducible reaction conditions. Furthermore, the
detection of radioactivity by using radio-TLC and radio-HPLC systems offered a
higher sensitivity in comparison to UV detectors. Consequently, lower concentra-
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tions of 18F-labelled compounds can be detected. Table 12 shows the conditions
of the labelling reactions carried out using the Eckert & Ziegler module system.
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Reaction conditions: i) [18F]fluoride/K222, DAST/XtalFluor/Fluolead, MeCN/DMF,
30-120 °C, 60-90 min.
Scheme 3.41: Labelling reaction to give the radioactive gemcitabine intermediate 123.
Table 12: [18F]fluorination reactions using precursor 35.
Run OFA (eq.) [18F]fluoride T t solvent RCY [%]
[GBq] [◦C] [min] (n = 1)
1 Fluolead (5.0) 5 70 60 MeCN n/a
2 Fluolead (5.0) 5 90 60 MeCN n/a
3 Fluolead (10.0) 8 60, 100 30, 30 DMF n/a
4 Fluolead (10.0) 8 60, 120 30, 50 DMF n/a
5 Fluolead (10.0) 10 50, 85 30, 50 MeCN n/a
6 XtalFluor (10.0) 8 40, 80 30, 50 MeCN n/a
7 XtalFluor (10.0) 8 50, 90 30, 60 MeCN n/a
8 DAST (5.0) 8 30, 50 30, 30 MeCN n/a
9 DAST (10.0) 8 30, 50 30, 50 MeCN n/a
10 DAST (5.0) 8 50, 85 30, 30 MeCN 0.2±0.1*
11 DAST (10.0) 8 50, 85 30, 60 MeCN 0.3±0.05*
control DAST (10.0) 8 50, 85 30, 60 MeCN n/a
*n = 3; Deoxodifluorination reactions in presence of an organic fluorination agent
(OFA = DAST, XtalFluor M, Fluolead; eq. relative to precursor) and 5-10 GBq of
[18F]fluoride. Each run was carried out using a total solvent volume of 400 µL and
precursor 35 (10 mg, 2.7 µmol). The control run was performed without precursor
35 present. The influence of temperature and reaction time on the formation of the
18F-labelled gemcitabine intermediate 123 was investigated using radio-HPLC by
co-elution with the non-radioactive reference standard 129. Radio-HPLC provided
evidence that experiments 10 and 11 furnished intermediate 123 in very low RCY
(0.2-0.3%, decay-corrected).
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After azeotropic drying of [18F]fluoride/K222, precursor 35 (10 mg) dissolved
in reaction solvent (0.2 mL) was added. Subsequently, the organic fluorination
agent dissolved in reaction solvent (0.2 mL) was added to the reaction mixture.
The reaction was stirred (60-90 min) at temperatures between 30-120 ◦C before
the reaction mixture was analysed using radio-HPLC.
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Figure 33: Radioactivity-trace (top) and UV-trace (bottom) of the HPLC chroma-
togram of run 11. The 18F-labelled gem-difluoro intermediate 123 was co-eluted
(isocratic, 50% MeCN/H2O) with the non-radioactive reference compound at Rt=7.9
minutes.
Analytical radio-HPLC (60% MeCN in H2O) of the crude reaction mixture
with co-elution of the non-radioactive standard 129 gave the chromatograms
shown above (Figure 33) for run 11. Figure 33 showed that the UV signal of
the reference standard (bottom) matched a radioactivity signal of the reaction
mixture (top) providing evidence that the [18F]fluorinated intermediate 123 had
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been formed. HPLC experiments without co-elution of 129 did not show a corres-
ponding UV signal which excluded the possibility of the formation of considerable
amounts of non-radioactive intermediate 129 during the reaction. The radioactiv-
ity signal at ≈3.2 min was due to unreacted [18F]fluoride. The radioactivity signal
at ≈12 min was observed in all runs including the control reaction without pre-
cursor 35 present. Thus, it was assumed that the radioactivity peak at ≈12 min
could correspond to a 18F-labelled DAST species. The [18F]fluorinated interme-
diate 123 could be purified using Al and C18 cartridges.
One explanation for the low RCY (0.2-0.3%) may be the complex mechanism
of the deoxodifluorination that was proposed in scheme 3.34. The non-radioactive
difluorination reaction reported by Kjell et al. [159] (Scheme 1.10) indicated 80%
conversion after 24 h at r.t. Hence, it was assumed that higher temperatures
during radiofluorination were needed in order to compensate a shorter reaction
time due to radiochemical decay. However, DAST is not stable at high temper-
atures [151] which led to the assumption that DAST was decomposing during the
labelling reaction resulting in a low yield of the desired product 123. Furthermore,
treating carbonyl compounds with DAST can lead to side product formation due
to elimination reactions [220,221]. Longer reaction times were tested (up to 3 h at
80 ◦C) but no significant improvement of the RCY could be observed.
Even though the calculated RCY of the 18F-labelled gemcitabine intermedi-
ate 123 is very low a deoxodifluorination with incorporation of [18F]fluoride at
the 2’-position of an intact nucleoside could be demonstrated for the first time.
The detection of the radioactive intermediate 123 provided supporting evidence
for the mechanism that was proposed in scheme 3.34. However, in order to eval-
uate the relevance of this approach for future biological applications of the final
tracer 18F-gemcitabine (54) test reactions to improve the RCY as well as the
deprotection step to give the final compound 54 have to be investigated.
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The objective of this research project was the development of novel and efficient
radiosynthetic routes to 18F-labelled gemcitabine and related 2’-18F-labelled nuc-
leosides for applications in positron emission tomography (PET) imaging. Cur-
rently, the synthetic accessibility of 18F-labelled uridine- and cytidine-based nuc-
leosides is limited [177,178]. The clinical potential and broad applicability of these
tracers, ranging from reporter gene imaging [212] to the assessment of nucleoside
salvage pathway activity [147], justify the need of new and efficient radiosynthetic
procedures. In order to address this demand, the presented research project
focused on nucleophilic late-stage radiofluorinations with the intention to de-
velop novel and fast radiochemical approaches towards 2’-18F-labelled nucleosides.
Proof-of-concept studies based on uridine-derived 2’-18F-labelled nucleosides were
followed by the development of novel late-stage radiofluorination approaches to-
wards the cytidine-based nucleosides 18F-FAC and finally 18F-gemcitabine. The
latter is a new PET probe which has not yet been synthesised and thus posed
serious challenges and an entirely new synthetic approach.
Non-radioactive late-stage fluorination reactions as proof-of-principle studies
were initially performed, which led to a solid understanding of the reactivity and
stability of different precursors for 2’-fluorinated nucleosides. The major finding
was that an optimal balance between precursor reactivity and stability is key
in order to successfully conduct nucleophilic late-stage fluorinations. This was
demonstrated by the non-radioactive late-stage synthesis of FAU (65) which in
turn enabled late-stage radiofluorinations carried out at the Wales Research and
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Diagnostic Positron Emission Tomography Centre (PETIC) at Cardiff University
Hospital. Radiofluorination reactions towards 18F-FAU (9) were performed us-
ing the Eckert & Ziegler module system with highest RCYs in DMF at 120 ◦C.
18F-FAU was purified and identified via both radio-TLC and radio-HPLC using
co-injected non-radioactive reference compound as internal standard. RCYs were
calculated to 2.8-3.9% (decay-corrected, n = 3) with high radiochemical purit-
ies (≥95%) and specific activities ≥42 GBq/µmol after a synthesis time of 178
min. This was the first time that 18F-FAU was synthesised via late-stage ra-
diofluorination. However, due to the proof-of-principle character of this study
further investigations towards an improved radiochemical synthesis were discon-
tinued. Instead, the findings of the 18F-FAU synthesis were used as a template
for a novel radiosynthetic approach to the structurally related uridine analogue
18F-FIAU with regard to potential applications in reporter gene imaging. Despite
the structural similarity of both compounds, which justified comparable reaction
conditions and set-ups, non-radioactive fluorinations as well as radiofluorinations
using the 2’-mesylated precursor 88 were not successful under the tested condi-
tions.
Previous results and experiences with radiofluorinations could subsequently
be used to develop a novel late-stage radiochemical approach to give 18F-FAC
(15), a PET probe previously developed by Radu et al. and currently in clin-
ical trials. This methodology involved computational and experimental analysis
of the precursor stability followed by an extensive investigation of the RCY of
the labelling reactions and proof of the correct stereochemical outcome of this
reaction. The final product 18F-FAC was obtained with RCYs between 4.3-5.5%
(n = 6, decay-corrected), high radiochemical purities (≥98%) and specific activ-
ities ≥1700 mCi/µmol. The total synthesis time was 168 min after the end of
bombardment (EoB) [222]. Future studies regarding an improved radiosynthesis of
18F-FAC should include test reactions using simplified and cassette-based radio-
synthesisers such as the IBA SynthERA or the GE FastLab/TracerLab module
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systems. This would be a crucial step forward in terms of the translation of this
radiochemical approach to a GMP facility. The reaction could then be further
tested regarding reproducibility and RCY. Furthermore, [18F]TBAF should be
used in continuing investigations as an alternative fluorination agent to evalu-
ate improvements in RCY. The newly developed route offers an advantage over
the latest reported synthetic method as it utilises a ‘FDG-like’ radiochemical ap-
proach with radiofluorination and subsequent deprotection. The reaction started
with an intact (protected) nucleoside avoiding base coupling reactions and sub-
sequent separations of the α- and β-stereoisomers after radiofluorination. Hence,
this approach may simplify the production of 18F-FAC in GMP hot cells. How-
ever, the RCY is still low compared to reported RCYs for 18F-FAC (31±5%) [180]
and thus further testing is needed to demonstrate the actual clinical potential of
this synthetic approach.
Considering the final target of this research project it was envisaged that a 18F-
gemcitabine PET probe may enable the evaluation of pharmacokinetic and phar-
macodynamic parameters of this widely applied anticancer drug in vivo, which
may have significant impact on future treatment planning using nucleoside-based
chemotherapy. However, the clinical relevance of 18F-gemcitabine as a PET probe
would have to be evaluated using appropriate in vivo cancer models.
3’,5’-O-diacetyl-N4-acetyl-2’-ketocytidine (35) was used as a precursor for
first radiochemical approaches towards the target molecule 18F-gemcitabine (54).
Compound 35 was based on previously published data [159] demonstrating that
deoxodifluorination of 35 can be achieved when treated with DAST and pyridinium
hydrogen fluoride. Based on that finding, it was assumed that [18F]fluoride/K222
could substitute pyridinium hydrogen fluoride as the additional fluoride source
in a radiosynthetic approach. Consequently, radiofluorination reactions using
precursor 35 were carried out under different conditions testing several organic
fluorination agents (DAST, XtalFluor M, Fluolead), varying reaction times (1-
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2 h) and temperatures (40-90 ◦C). Radio-HPLC experiments provided evidence
that the 18F-labelled gemcitabine intermediate 123 was obtained in very low
RCY (0.2-0.3%, decay-corrected) after a synthesis time of 212 minutes. That
finding provided supporting evidence for the proposed mechanism of this radio-
active deoxodifluorination. However, the reaction mechanism included that the
incorporation of [18F]fluoride and [19F]fluoride occurred in distinct steps during
the reaction implying that each 18F-gemcitabine molecule would be single la-
belled. Considering the presence of organic fluorination agents such as DAST,
it seemed reasonable to assume that [18F]fluoride competed with [19F]fluoride in
both incorporation steps potentially leading to non-radioactive, single and double
18F-labelled compounds. Hence, future tests including the determination of the
specific activity as well as the improvement of the RCY are indispensable in or-
der to make this approach significant for future applications. Furthermore, the
subsequent deprotection step to give the final compound has to be carried out
to produce a sufficient amount of 18F-gemcitabine needed for biological evalu-
ations. Altogether, extensive investigations have yet to be conducted in order to
identify the potential of this synthetic approach. Further radiosynthetic improve-
ments should include the use of simplified synthesisers (e.g. GE TracerLab) and
cassette-based synthesis modules in order to reduce potential sources of error. In
addition, the application of this radiochemical approach using microwave-assisted
radiosynthesis and mircoreactor technology [223,224] could lead to higher RCYs and
cleaner reaction profiles due to milder and more controllable reaction conditions.
Altogether, it could be demonstrated that rationally designed radiochemical
approaches are capable of providing new synthetic routes towards challenging
PET probes such as 18F-labelled nucleoside analogues that were the focus of this
research project. In particular, the newly developed radiosynthesis of 18F-FAC
may prove useful in future routine applications providing that an improved syn-
thetic procedure is transferable to GMP facilities. Despite considerable advances
in the synthesis of 18F-labelled nucleosides within the last decade, further invest-
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igations have to be carried out in order to make 18F-labelled nucleosides such
as 18F-FMAU, 18F-FIAU and 18F-FAC applicable for clinical routine production.
This may include novel and simplified radiosynthetic approaches with as few steps
after radiofluorination as possible and the improvement of RCY and reproducibil-
ity of established synthetic routes. Late-stage radiofluorinations as reported here
and elsewhere [177,185,222] may be able to meet these requirements if appropriate
precursors and reaction conditions can be developed. Additional studies should
focus on the development of innovative radiosynthesisers (e.g. ELIXYS [180]) that
are capable of providing nucleoside-based PET tracers of clinical standard in
terms of yield, purity and reproducibility. This progression would help to address
the growing demand for novel and more specific PET probes in pre-clinical and
clinical research as well as clinical routine application.
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5.1 General information
5.1.1 Analytics
Proton (1H) NMR spectra were measured on a BrukerAvance Ultra Shield (500
MHz) spectrometer at ambient temperature. Data were recorded as follows:
chemical shift in ppm from internal reference tetramethylsilane on the δ scale,
multiplicity (s = singlet; d = doublet; t = triplet; m = multiplet), coupling
constant (Hz), integration, and assignment. Carbon (13C) NMR spectra were
measured on a BrukerAvance Ultra Shield (125 MHz) spectrometer at ambient
temperature. Chemical shifts were recorded in ppm from the solvent resonance
employed as the internal standard (deuterochloroform at 77.00 ppm). Fluorine
(19F) NMR spectra were recorded on a BrukerAvance Ultra Shield (474 MHz)
spectrometer at ambient temperature.
For thin-layer chromatography (TLC) analysis throughout this work, Merck
precoated TLC plates (silica gel 60 GF254) were used. Mass spectrometry ana-
lysis (LC-ESI-MS) was performed on either an AGILENT 6430 T-Quadrupol
spectrometer (PETIC) or on a Bruker micro-TOF. High-resolution mass spectro-
metry (ESI-HRMS) were carried out by the National Mass Spectrometry Facility
(Swansea, Wales, UK). Melting points were determined using an uncalibrated
Griffin 220V melting point apparatus.
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5.1.2 Solvents and chemicals
In experiments that required dry solvents, ether and THF were freshly distilled
from Na/benzophenone. Acetic anhydride, DMF and acetone were dried over
P2O5. Toluene and dichloromethane were freshly distilled from CaH2. All
anhydrous solvents were stored over 4Å molecular sieves. All other chemicals
had synthetic-grade and were used as commercially available. All reagents and
solvents were used as supplied from Sigma-Aldrich without further purification.
All nucleoside-based starting materials were purchased from Carbosynth Ldt UK.
Column chromatography was performed using Fluka silica gel (35-70 mm) as
stationary phase.
5.2 Experimental data
5.2.1 Nucleoside nomenclature
The positions of the carbon and hydrogen atoms of all nucleoside analogues
throughout this thesis were labelled as follows:
5
6
2
NH34
O
ON
1
3´ 2´
1´
O
4´
5´HO
OH OH
Assignments of the proton and carbon chemical shifts observed in the NMR
spectra are related to the atom numbering shown above. All other substitu-
ents were assigned using appropriate abbreviations. Furthermore, all known com-
pounds (according to the SciFinder data base) are provided with references. All
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novel compounds are fully characterised. Thermally unstable compounds were as
fully analysed as possible.
5.2.2 Procedures and spectral data
N
O
N
O
OH
HO
O
57 ,C9H10N2O5, MW: 226.19
2,2’-anhydro-uridine (57). [225] Uridine (55, 0.52 g, 2,1 mmol) was suspended
in anhydrous MeCN (20 mL). Triphenylphosphine (1.39 g, 5.3 mmol) was added
and the suspension was stirred at -20 ◦C for 20 min. Diisopropyl azadicarboxylate
(1.32 mL, 6.7 mmol) was added dropwise to the solution. The mixture was stirred
at 0 ◦C for 5 h. The solution was poured into cold EtOAc (50 mL) (-20 ◦C) and
stirred for additional 20 min. The white precipitate was filtered and washed
with cold EtOAc (30 mL). Purification of the crude product by column chroma-
tography on SiO2 (eluent: EtOAc/MeOH, 100/0 to 90/10) gave 0.25g (56%) of
the anhydro-compound as a white powder; mp 233-236 ◦C (lit. [225] 234-237 ◦C);
Rf=0.55 (6% MeOH/DCM); 1H NMR (500 MHz, DMSO-d6) δ 8.02 (d, J = 7.8
Hz, 1 H, H-6), 5.93 (d, J = 7.5 Hz, 1 H, H-5), 5.58 (s, 1 H, H-1’), 4.52 (s, 1 H,
H-2’), 4.48 (dd, J = 12.8, 1.6 Hz, 1 H, H-5’) 4.42 (m, 1 H, H-3’), 4.32 (m, 1 H,
H-4’), 4.10 (dd, J = 11.8, 1.1 Hz, 1 H, H-5’); 13C NMR (125 MHz, d6-DMSO) δ
168.1 (C-4), 158.3 (C-2), 136.1 (C-6), 116.2 (C-5), 102.2 (C-1’), 87.5 (C-4’), 77.6
(C-2’), 73.1 (C-3’), 68.2 (C-5’); MS (ESI) m/z 261.2 [M + Cl]−.
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58, C10H12N2O5, MW: 240.21
2,2’-anhydro-5-methyluridine (58). [226] 5-methyluridine (56, 200mg, 0.76
mmol) and PPh3 (510 mg, 1.94 mmol) were suspended in dry MeCN (4.5 mL) at
-20 ◦C. The resulting suspension was stirred at this temperature for 20 min be-
fore diisopropyl azadicarboxylate (0.5 mL, 2.33 mmol) was added dropwise. The
yellowish mixture was stirred at 0 ◦C for 3 h. After completion of the reaction
the mixture was concentrated under reduced pressure. Cold EtOAc (15 mL) was
added to the solid residue and the resulting white precipitate was filtered and
washed with cold EtOAc (10 mL). The crude product was purified by column
chromatography on SiO2 (eluent: EtOAc/MeOH, 100/0 to 90/10 v/v) to furnish
110 mg (51%) of compound as a white solid; mp 224 ◦C (lit. [167] 227-228 ◦C);
Rf=0.55 (6% MeOH/DCM); 1H NMR (500 MHz, DMSO-d6) δ 7.94 (s, 1 H, H-6),
5.52 (m, 2 H, H-1’, H-2’), 5.25 (s, 1 H, OH-3’), 4.49 (dd, J = 12.8, 1.6 Hz, 1 H,
H-5’), 4.47 (s, 1 H, OH-5’), 4.38 (m, 1 H, H-3’), 4.33 (m, 1 H, H-4’), 4.07 (dd, J =
12.7, 0.8 Hz, 1 H, H-5’), 1.81 (s, 3 H, methyl); 13C NMR (125 MHz, d6-DMSO) δ
171.0 (C-4), 156.6 (C-2), 139.2 (C-6), 117.4 (C-5), 100.0 (C-1’), 87.1 (C-4’), 76.9
(C-2’), 74.4 (C-3’), 71.1 (C-5’), 12.7 (CH3); MS (ESI) m/z 275.4 [M + Cl]−.
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59, C19H26N2O7, MW: 394.42
3’,5’-O-bis-tetrahydropyranyl-2,2’-anhydro-uridine (59). [227] Anhydro
compound 57 (200 mg, 0.84 mmol) was suspended in dry THF (6 mL) before
pTsOH (200 mg, 1.1 mmol) and 3,4-dihydro-2H -pyran (0.8 mL, 8.3 mmol) were
added to the suspension at 0 ◦C. The resulting mixture was stirred at r.t. for 3 h.
After completion of the reaction the mixture was neutralised with triethylamine
(0.3 mL) and stirred for additional 10 min. The solution was diluted with brine
(20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layer
was washed with brine (2 × 15 mL), dried over Na2SO4 and concentrated. The
residue was purified by column chromatography on SiO2 (eluent: EtOAc/hexane,
50/50 to 70/30 v/v) to obtain 57 mg (84%) of the title compound as a white
foam (four diastereomers); Rf=0.6 (4% MeOH/DCM); 1H NMR [186] (500 MHz,
CDCl3) δ 7.11-7.05 (4s, 4 H, H-6), 6.05-5.88 (m, 4 H, H-5), 5.21-5.11 (m, 4 H,
H-1’), 4.49-4.43 (m, 4 H), 3.95-3.82 (m, 16 H), 3.79-3.60 (m, 12 H), 3.52-3.37 (m,
12 H), 1.91-1.50 (m, 48 H); MS (ESI) m/z 429.3 [M + Cl]−.
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60, C20H28N2O7, MW: 408.45
3’,5’-O-bis-tetrahydropyranyl-2,2’-anhydro-5-methyluridine (60). [227]
The title compound was obtained from compound 58 as described for com-
pound 64 in 77% yield after purification by column chromatography on SiO2
(eluent: EtOAc/hexane, 40/60 to 60/40 v/v) as a white foam (four diastereo-
mers); Rf=0.55 (4% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 6.55-6.47 (4s,
4 H, H-6), 5.37-5.31 (m, 4 H, H-1,), 4.58-4.55 (m, 4 H), 3.99-3.7 (m, 16 H), 3.66-
3.59 (m, 12 H), 3.52-3.37 (m, 12 H), 2.19-2.11 (m, 12 H, CH3), 1.91-1.50 (m, 48
H); MS (ESI) m/z 443.2 [M + Cl]−.
N
O
N
O
O
O
Si
Si
O
O
61, C21H36N2O6Si2, MW: 468.69
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2,2’-anhydro-
uridine (61). [215] [228] Anhydro compound 57 (42 mg, 0,18 mmol) was coevapor-
ated with dry pyridine (2 × 3 mL) before dry DMF (4 mL) was added under an ar-
gon atmosphere. Pyridine (0.2 mL) and dichloro-1,1,3,3-tetraisopropyldisiloxane
(0.12 mL, 0.37 mmol) were added dropwise to the solution at ambient temper-
ature. The resulting mixture was stirred at r.t. for 16 h. After full conversion
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of the starting material the mixture was poured onto ice in a separation funnel
followed by an extraction with diethyl ether (3 × 10 mL). The combined organic
layer was washed with brine (2 × 10 mL), dried over Na2SO4 and concentrated.
Purification of the crude product by column chromatography on SiO2 (eluent:
EtOAc/hexane, 50/50 v/v) gave 64 mg (71%) of the protected compound as col-
orless needles; mp 183 ◦C (lit. [228] 179-180 ◦C), Rf=0.65 (4% MeOH/DCM); 1H
NMR (500 MHz, CDCl3) δ 7.36 (d, J = 7.9 Hz, 1 H, H-6), 5.82 (d, J = 8.0 Hz,
1 H, H-5), 4.53 (m, 1 H, H-1’), 4.38 (m, 2 H-2’, H-3’), 4.34 (dt, J = 6.5, 3.5 Hz,
1 H, H-4’), 3.90 (dd, J = 11.7, 3.3 Hz, 1 H, H-5’), 3.77 (dd, J = 12.1, 3.5 Hz, 1
H, H-5’), 0.98 - 1.16 (m, 28 H, iPr); 13C NMR (125 MHz, CDCl3) δ 165.5 (C-4),
148.9 (C-2), 137.2 (C-6), 112.8 (C-5), 92.2 (C-1’), 82.4 (C-4’), 76.2 (C-3’), 73.1
(C-5’), 71.5 (H-2’), 18.4 (CH3), 18.1 (CH3), 17.7 (CH3), 17.6 (CH3), 17.2 (CH3),
17.0 (CH3), 16.9 (CH3), 13.7 (CH3), 13.1 (CH), 13.0 (CH), 12.9 (CH), 12.8 (CH);
MS (ESI) m/z 491.2 [M + Na]+
N
O
N
O
O
O
Si
Si
O
O
62, C22H38N2O6Si2, MW: 482.72
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2,2’-anhydro-5-
methyluridine (62). [228] Compound 58 (35 mg, 0.14 mmol) was coevaporated
with dry pyridine (2 × 3 mL) before dry DMF (1.5 mL) was added under an ar-
gon atmosphere. Pyridine (0.3 mL) and dichloro-1,1,3,3-tetraisopropyldisyloxane
(0.05 mL, 0.155 mmol) were added dropwise to the solution at r.t. The resulting
mixture was stirred at for 12 h. After full conversion of the starting mater-
ial the mixture was poured onto ice (15 g) in a separating funnel and extrac-
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ted with EtOAc (3 × 10 mL). The combined organic layer was washed with
brine (2 × 10 mL), dried over Na2SO4 and concentrated to furnish a yellow oil.
Purification of the crude product by column chromatography on SiO2 (eluent:
EtOAc/hexane, 40/60 to 60/40 v/v) gave 57 mg (84%) of the title compound as
a white powder; mp 175-176 ◦C (lit. [228] 179-180 ◦C); Rf=0.6 (3% MeOH/DCM);
1H NMR (500 MHz, CDCl3) δ 7.48 (s, 1 H, H-6), 5.85 (d, J = 3.4 Hz, 1 H, H-1’),
4.49 (m, 1 H, H-2’), 4.38 (m, 1 H, H-3’), 4.30 (dt, J = 6.3, 3.3 Hz, 1 H, H-4’),
3.98 (dd, J = 12.3, 3.2 Hz, 1 H, H-5’), 3.82 (dd, J = 12.3, 3.4 Hz, 1 H, H-5’), 1.95
(s, 3 H, methyl), 1.02 - 1.13 (m, 28 H, iPr); 13C NMR (125 MHz, CDCl3) δ 163.8
(C-4), 149.8 (C-2), 135.9 (C-6), 110.7 (C-5), 91.2 (C-1’), 82.2 (C-4’), 76.0 (C-3’),
72.2 (C-5’), 44.3 (C-2’), 17.5 (CH3), 17.4 (CH3), 17.3 (CH3), 17.2 (CH3), 17.1
(CH3), 17.0 (CH3), 16.9 (CH3), 13.3 (CH3), 13.08 (CH), 13.0 (CH), 12.8 (CH),
12.6 (CH3), 12.5 (CH); MS (ESI) m/z 517.2 [M + Cl]−.
N
O
N
O
O
O
O
63, C12H14N2O5, MW: 266.25
3’,5’-O-propylidene-2,2’-anhydro-uridine (63). Anhydro compound 57
(96 mg, 0,42 mmol) was suspended in absolute acetone (4 mL) before a catalytic
amount of concentrated hydrochloric acid (25 µL) was added dropwise to the
solution at 0 ◦C. The resulting mixture was stirred at r.t. for 16 h. After full
conversion of the starting material the mixture was neutralised with saturated
NaHCO3. The mixture was diluted with water (15 mL) and extracted with EtOAc
(3 × 15 mL). The combined organic layer was washed with brine (2 × 15 mL),
dried over Na2SO4 and concentrated. Purification of the crude product by column
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chromatography on SiO2 (eluent: EtOAc/hexane, 70:30 to 90/10 v/v) gave 94
mg (85%) of the title compound as a white solid; mp 185-188 ◦C; Rf=0.5 (5%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.1 Hz, 1 H, H-6),
5.78 (d, J = 7.2 Hz, 1 H, H-5), 5.70 (d, J = 2.2 Hz, 1 H, H-1’), 5.02 (dd, J =
6.5, 2.3 Hz, 1 H, H-2’), 4.92 (dd, J = 6.5, 3.7 Hz, 1 H, H-3’), 4.38 (td, J = 5.5,
3.8 Hz, 1 H, H-4’), 3.84 (dd, J = 11.5, 5.7 Hz, 1 H, H-5’), 3.74 (dd, J = 11.5, 5.3
Hz, 1 H, H-5’), 1.59 (s, 3 H, methyl), 1.38 (s, 3 H, methyl). 13C NMR (125 MHz,
CDCl3) δ 163.7 (C-4), 150.1 (C-2), 142.5 (C-6), 114.7 (C-5), 102.7 (C-1’), 94.9
(C-4’), 86.7 (C-2’), 84.5 (C-3’), 82.1 (C-5’), 44.1 (Cquat., acetal), 27.2 (CH3), 25.3
(CH3); MS (ESI) m/z 301.2 [M + Cl]−.
N
O
N
O
O
O
O
64, C13H16N2O5, MW: 280.28
3’,5’-O-propylidene-2,2’-anhydro-5-methyluridine (64). Anhydro com-
pound 58 (50 mg, 0.22 mmol) was suspended in absolute acetone (4 mL) at r.t.
before a catalytic amount of 37% HCl solution (25 µL) was added dropwise at
0 ◦C. After 15 h stirring at r.t. and complete conversion of the starting mater-
ial the colorless solution was neutralised with saturated NaHCO3. The mixture
was diluted with water (20 mL) and extracted with EtOAc (3 × 10 mL). The
combined organic layer was washed with brine (2 × 15 mL), dried over Na2SO4
and concentrated. The crude residue was purified by column chromatography on
SiO2 (eluent: EtOAc/hexane, 90/10 to 80/20 v/v) to give 56 mg (88%) of the
title compound as a white solid; mp 202-204 ◦C; Rf=0.55 (5% MeOH/DCM); 1H
NMR (500 MHz, CDCl3) δ 7.16 (s, 1 H, H-6), 5.67 (s, 1 H, H-1’), 5.04 (dd, J =
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6.5, 2.0 Hz, 1 H, H-2’), 4.92 (dd, J = 6.4, 3.7 Hz, 1 H, H-3’), 4.35 (td, J = 5.5,
3.9 Hz, 1 H, H-4’), 3.84 (dd, J = 11.4, 5.8 Hz, 1 H, H-5’), 3.74 (dd, J = 11.4,
5.5 Hz, 1 H, H-5’), 1.98 (s, 3 H, methyl), 1.65 (s, 3 H, methyl), 1.21 (s, 3 H,
methyl). 13C NMR (125 MHz, CDCl3) δ 164.1 (C-4), 150.5 (C-2), 138.4 (C-6),
114.7 (C-5), 111.2 (C-1’), 95.0 (C-4’), 86.8 (C-2’), 84.4 (C-3’), 82.3 (C-5’), 44.1
(Cquat., acetal), 26.9 (CH3), 25.3 (CH3), 12.3 (CH3); MS (ESI) m/z 315.4 [M +
Cl]−; HRMS (ESI) calcd for C13H16N2O5Cl (= [M + Cl]−) m/z 315.1911, found
315.1902.
N
O
N
O
OPG
PGO
O
R
59 (i) R = H, PG = THP
60 (ii) R = Me, PG = THP
61 (iii) R = H, PG = TIPDS
62 (iv) R = Me, PG = TIPDS
63 (v) R = H, PG = acetonide
64 (vi) R = Me, PG = acetonide
HN
O
N
O
PGO
O
R
FOPG
KF/K222 or CsF
MeCN/DMF/DMSO,
85-180°C, 2-12 h
General procedure for the fluorination of precursors 59-64: The fluor-
ination precursor (100 mg) was dissolved in reaction solvent (MeCN/DMF/DMSO,
4 mL) under inert atmosphere before either KF/K222 or CsF (3 eq.) was added
to the solution. The mixture was stirred at the appropriate temperature (85-
180 ◦C) for the given time (2-12 h). Reaction control using TLC was performed
hourly. However, the desired fluorinated compounds could not be observed using
the stated conditions. The reaction mixtures were purified using column chroma-
tography to recover the starting material or the deprotected compounds 57 and
58 using appropriate gradients as stated in the above procedures.
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66, C20H30N2O8, MW: 426.46
3’,5’-O-(bis-tetrahydropyranyl)-2’-arabino-5-methyluridine (66). [155]
Compound 60 (270 mg, 0.66 mmol) was dissolved in MeOH (4.0 mL) at r.t.
before 10 M NaOH (0.1 mL) was added dropwise. The reaction mixture was
stirred at reflux temperature for 4h. After full conversion of the starting mater-
ial the mixture was neutralised with glacial acetic acid. The reaction mixture
was diluted with water (10 mL) and extracted with EtOAc (3 × 20 mL). The
combined organic layer was washed with brine, dried over Na2SO4 and concen-
trated. The resulting crude residue was purified by silica gel chromatography
(eluent: EtOAc/hexane, 80/20 to 100/0 v/v) to give 89.5 mg (47%) of the desired
product as a white powder (four diastereomers); Rf=0.65 (4% MeOH/DCM); 1H
NMR [229] (500 MHz, CDCl3) δ 9.50-9.39 (4s, 4 H, N-H), 7.79-7.61 (4s, 4 H, H-6),
6.13-5.91 (4s, 4 H, H-1’) 5.02-4.87 (m, 4 H), 4.75-4.69 (m, 4 H), 4.34-4.20 (m, 12
H), 3.87-3.69 (m, 12 H), 3.59-3.39 (m, 24 H), 1.95-1.90 (4s, 12 H), 1.82-1.49 (m,
40 H); MS (ESI) m/z 449.2 [M + Na]+.
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67, C13H18N2O6, MW: 298.29
3’,5’-O-propylidene-2’-arabino-5-methyluridine (67). Protected an-
hydro compound 64 (170 mg, 0.61 mmol) was dissolved in MeOH (4.0 mL) at
r. t. before 10 M NaOH (0.1 mL) was added dropwise. The reaction mixture
was stirred at reflux temperature for 5h before it was neutralised with glacial
acid. The reaction mixture was diluted with water (10 mL) and extracted with
EtOAc (3 × 10 mL). The combined organic layer was washed with brine, dried
over Na2SO4 and concentrated. The resulting crude residue was purified by silica
gel chromatography (eluent: EtOAc/hexane, 80/20 to 100/0 v/v) to give 117 mg
(59%) of the desired product as a white powder; mp 187-189 ◦C; Rf=0.5 (5%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 9.17 (s, 1 H, N-H), 7.16 (d, J =
1.1 Hz, 1 H, H-6), 5.53 (d, J = 3.1 Hz, 1 H, H-1’), 5.11 (dd, J = 6.5, 3.1 Hz,
1 H, H-2’), 5.00 (dd, J = 6.5, 3.6 Hz, 1 H, H-3’), 4.29 (dt, J = 6.4, 3.4 Hz, 1
H, H-4’), 3.93 (dd, J = 12.1, 2.7 Hz, 1 H, H-5’), 3.82 (dd, J = 12.1, 3.7 Hz, 1
H, H-5’), 2.56 (s, 1 H, O-H), 1.93 (s, 3 H, CH3), 1.60 (s, 3 H, CH3), 1.38 (s, 3
H, CH3); 13C NMR (125 MHz, CDCl3) δ 163.8 (C-4), 150.7 (C-2), 138.9 (C-6),
114.3 (C-5), 111.3 (C-1’), 95.8 (C-4’), 86.9 (C-2’), 83.2 (C-3’), 80.4 (C-5’), 62.7
(Cquat., acetal), 27.0 (CH3), 25.3 (CH3), 12.2 (CH3); MS (ESI) m/z 299.3 [M +
H]+; HRMS (ESI) calcd for C13H18N2O6Cl (= [M + Cl]−) m/z 335.1911, found
335.1917.
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67b, C14H20N2O6, MW: 313.32
3’,5’-O-propylidene-2’-arabino-2-O-methyl-5-methyluridine (67b).
As a side product from the reaction to compound 67, nucleoside 67b was ob-
tained in 22% yield as a colourless oil; Rf=0.7 (5% MeOH/DCM); 1H NMR (500
MHz, CDCl3) δ 7.72 (d, J = 2.0 Hz, 1 H, H-6), 5.61 (d, J = 2.7 Hz, 1 H, H-1’),
5.21 (dd, J = 6.2, 2.9 Hz, 1 H, H-2’), 5.10 (dd, J = 6.7, 3.5 Hz, 1 H, H-3’), 4.43
(m, 1 H, H-4’), 3.96 (dd, J = 11.8, 2.8 Hz, 1 H, H-5’), 3.88 (s, 3 H, CH3), 3.73
(dd, J = 12.0, 2.9 Hz, 1 H, H-5’), 2.74 (s, 1 H, O-H), 1.95 (s, 3 H, CH3), 1.69
(s, 3 H, CH3), 1.41 (s, 3 H, CH3); 13C NMR (125 MHz, CDCl3) δ 162.5 (C-4),
154.6 (C-2), 139.1 (C-6), 118.9 (C-5), 112.1 (C-1’), 98.2 (C-4’), 88.8 (C-2’), 85.4
(C-3’), 81.1 (C-5’), 67.8 (Cquat., acetal), 58.7 (CH3); 28.1 (CH3), 25.8 (CH3), 13.1
(CH3); MS (ESI) m/z 314.2 [M + H]+.
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68, C26H33N3O12S, MW: 611.62
3’,5’-O-(bis-tetrahydropyranyl)-2’-arabino-(p-nitrobenzenesulfonyl)-
5-methyluridine (68). Pyridine (3 mL) and nosyl chloride (100 mg, 0.45 mmol)
were added to a solution of compound 66 (135 mg, 0.32 mmol) in dry DCM (3
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mL). The yellowish solution was stirred at r.t. for 15 h. After completion of
the reaction the solution was diluted with water (15 mL) and extracted with
DCM (3 × 10 mL). The combined organic layer was washed with brine, dried
over Na2SO4 and concentrated. The crude residue was purified by silica gel
chromatography (eluent: EtOAc/hexane, 20/80 to 50/50 v/v) to give 112 mg
(68%) of the desired product as a yellow solid (four diastereomers); Rf=0.65 (4%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 9.09-8.86 (4s, 4 H, N-H), 8.42-8-35
(m, 8 H), 8.15-7.98 (m, 8 H), 7.27-7.22 (m, 4 H), 7.19-7.02 (m, 8 H), 6.06-5.80
(m, 8 H), 4.88-4.27 (m, 32 H), 3.92-3.72 (m, 12 H), 3.59-3.42 (m, 12 H), 1.95 (4s,
12 H), 1.84-1.63 (m, 24 H); MS (ESI) m/z 612.2 [M + H]+.
NH
O
ON
O
O
O
O S
O
O
NO2
69, C19H21N3O10S, MW: 483.45
3’,5’-O-propylidene-2’-arabino-(p-nitrobenzenesulfonyl)-5-methyl-
uridine (69). Pyridine (1.0 mL) and nosyl chloride (32 mg, 0.14 mmol) were
added to a solution of hydroxy compound 67 (40 mg, 0.14 mmol) in dry DCM
(2.0 mL) under vigorous stirring at r.t. The resulting solution was stirred at
room temperature for 8 h. After full conversion of the starting material the solu-
tion was diluted with water (10 mL) and extrated with DCM (3 × 10 mL). The
combined organic layer was washed with 5% H2SO4 (15 mL), saturated sodium
bicarbonate solution (15 mL) and brine, dried over Na2SO4 and concentrated.
Purification of the resulting crude solid by column chromatography on SiO2 (elu-
ent: EtOAc/hexane, 40/60 to 80/20 v/v) furnished 57 mg (84%) of the title
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compound as a white solid; mp 223-225 ◦C; Rf=0.6 (5% MeOH/DCM); 1H NMR
(500 MHz, CDCl3) δ 9.94 (1 H, s, N-H), 8.37 (d, J = 8.7 Hz, 2 H, Harom.), 8.11
(d, J = 8.7 Hz, 2 H, Harom.), 7.05 (s, 1 H, H-6), 5.50 (d, J = 0.8 Hz, 1 H, H-1’),
5.06 (dd, J = 6.4, 1.2 Hz, 1 H, H-2’), 4.83 (dd, J = 6.3, 3.9 Hz, 1 H, H-3’), 4.46 -
4.40 (m, 2 H, H-4’, H-5’), 4.37 - 4.33 (m, 1 H, H-5’), 1.94 (s, 3 H, CH3), 1.54 (s,
3 H, CH3), 1.33 (s, 3 H, CH3); 13C NMR (125 MHz, CDCl3) δ 163.1 (C-4), 149.8
(C-2), 149.1 (C-6), 140.6 (Carom.), 138.1 (2 C, CHarom.), 128.5 (2 C, CHarom.),
128.0 (Carom.), 113.5 (C-5), 95.4 (C-1’), 84.7 (C-2’), 83.3 (C-4’), 80.0 (C-3’), 69.9
(C-5’), 25.9 (Cquat., acetal), 24.2 (CH3), 20.0 (CH3), 11.1 (CH3); MS (ESI) m/z
484.3 [M + H]+.
NH
O
N
O
PGO
OPG
O
NsO
68 PG = THP
69 PG = acetonide
NH
O
N
O
PGO
OPG
O
F
KF/K222
MeCN/DMF, 
85-145°C, 2-12 h
General procedure for the fluorination of precursors 68 and 69: The
fluorination precursor (100 mg) was dissolved in anhydrous solvent (MeCN/DMF,
4 mL) under inert atmosphere before KF/K222 (3 eq.) was added to the solution.
The mixture was stirred at the appropriate temperature (85-145 ◦C) for the given
time (3-12 h). Reaction control using TLC was performed hourly. However,
the desired fluorinated compounds could not be observed using the described
conditions. The reaction mixtures were purified using column chromatography
to recover the deprotected compounds 60 and 64 using appropriate gradients as
stated in the above procedures.
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70, C23H38N2O8Si,MW : 498.64
3’,5’-O-(bis-tetrahydropyranyl)-2’-arabino-(trimethylsilyl)-5-
methyluridine (70). Triethylamine (0.3 mL, 2.5 mmol) and trimethylsilyl
chloride (0.2 mL, 1.5 mmol) were added dropwise to a solution of compound
66 (200 mg, 0.47 mmol) in dry DCM at 0 ◦C. The solution was stirred at r.t.
for 2.5 h. After full conversion of the starting material the solution was diluted
with water (25 mL) and extracted with DCM (3 × 20 mL). The combined or-
ganic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo.
The crude residue was purified by by column chromatography on SiO2 (eluent:
Et3N/EtOAc/hexane, 1/59/40 to 1/69/30) to obtain 172 mg (73%) of the title
compound as a colourless oil (four diastereomers); Rf=0.7 (4% MeOH/DCM);
HPLC:≥94% (Rt=8.2 min, isocr. 30%MeCN/H2O); 1H NMR (500 MHz, CDCl3)
δ 9.80-9.68 (4s, 4 H, N-H), 7.63-7.53 (4s, 4 H, H-6), 6.17-5.99 (4s, 4 H, H-1’),
4.93-4.69 (m, 8 H), 4.33-4.18 (m, 12 H), 3.92-3.65 (m, 16 H), 3.53-3.42 (m, 8 H),
1.87-1.84 (4s, 12 H), 1.79-1.38 (m, 48 H), 0.17-0.09 (m, 36 H); MS (ESI) m/z
533.2 [M + Cl]−.
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71 C25H38N2O10,MW : 526.58
N3-Boc-3’,5’-O-(bis-tetrahydropyranyl)-2’-arabino-5-methyluridine
(71). DMAP (42 mg, 0.34 mmol) and di-tert-butyl dicarbonate (150 mg, 0.68
mmol) were added to a solution of compound 70 (170 mg, 0.34 mmol) at r.t.
and the resulting mixture was strirred for 14 h. After complete conversion of the
starting material p-toluenesulfonic acid (130 mg, 0.68 mmol) was added slowly
and the solution was stirred for additional 40 min. The remaining solution was
then concentrated under reduced pressure. The crude residue was purified by by
column chromatography on SiO2 (eluent: EtOAc/hexane, 50/50 v/v) to furnish
95 mg (53%) of the title compound as a white foam (four diastereomers); Rf=0.5
(3% MeOH/DCM); HPLC: ≥96% (Rt=10.9 min, isocr. 35% MeCN/H2O); 1H
NMR (500 MHz, CDCl3) δ 7.71-7.29 (4s, 1 H, H-6), 5.92-5.70 (4s, 1 H, H-1’),
4.85-4.80 (m, 1 H), 4.69-4.64 (m, 1 H), 4.52-4.43 (m, 1 H), 4.38-4.18 (m, 2 H),
3.98-3.71 (m, 5 H), 3.52-3.40 (m, 2 H), 1.89 (s, 3 H), 1.85-1.67 (m, 5 H), 1.58-1.54
(m, 9 H), 1.53-1.44 (m, 7 H); MS (ESI) m/z 550.1 [M + Na]+.
N
O
ON
O
O
O
O
O
O
O S
O
O
NO2
O
72, C31H41N3O14S,MW : 711.73
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N3-Boc-3’,5’-O-(bis-tetrahydropyranyl)-2’-arabino-(p-nitrobenzene
-sulfonyl)-5-methyluridine (72). Pyridine (5 mL) and nosyl chloride (190
mg, 0.86 mmol) were added to the solution of compound 71 (300 mg, 0.57 mmol)
in dry DCM (5 mL) at r.t. The resulting mixture was stirred for 3 h. After com-
pletion of the reaction the solution was diluted with water (30 mL) and extracted
with DCM (3 × 15 mL). The combined organic layer was washed with brine,
dried over Na2SO4 and concentrated. The crude residue was purified by silica
gel chromatography (eluent: EtOAc/hexane, 20/80 to 40/60 v/v) to furnish 205
mg (53%) of the title compound as a yellow oil (four diastereomers), Rf=0.6 (2%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.40-8.36 (m, 2 H), 8.13-8.08 (m,
2 H), 7.36-7.13 (m, 3 H), 5.82-5.50 (m, 1 H), 4.93-4.09 (m, 7 H), 3.92-3.70 (m, 2
H), 3.54-3.41 (m, 2 H), 1.95-1.92 (m, 3 H), 1.87-1.58 (m, 5 H), 1.58-1.54 (m, 9
H), 1.51-1.41 (m, 5 H); MS (ESI) m/z 718 [M + Na]+.
NH
O
ON
O
OHO
O
Si
Si
O
73, C21H38N2O7Si2,MW : 500.73
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-uridine (73). [230]
Uridine (55, 770 mg, 3.17 mmol) was coevaporated with dry pyridine (2 × 3 mL)
before it was dissolved in anhydrous DMF (10 mL) under an argon atmosphere.
The solution was cooled to 0 ◦C before dry pyridine (10 mL) and dichloro-1,1,3,3-
tetraisopropyldisiloxane (1.0 g, 3.17 mmol) were added to the solution. The
mixture was stirred at r.t. for 14 h. After completion of the reaction the mix-
ture was diluted with water and extracted with DCM (3 × 30 mL). The com-
bined organic layer was washed with brine (30 mL), dried over Na2SO4 and
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concentrated. The crude residue was purified by column chromatography on
SiO2 (eluent: EtOAc/hexane, 50/50 to 80/20 v/v) to give 1.29 g (82%) of the
title compound as a white foam; mp 166-169 ◦C (lit. [230] 172◦C); Rf=0.45 (4%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 9.92 (s, 1 H, N-H), 7.79 (d, J =
8.1 Hz, 1 H, H-6), 5.76 (s, 1 H, H-1’), 5.72 (d, J = 8.2 Hz, 1 H, H-5), 4.32 (dd,
J = 8.9, 4.7 Hz, 1 H, H-5’), 4.23 (m, 2 H, H-2’, H-3’), 4.18 (dt, J = 9.0, 2.1 Hz,
1 H, H-4’), 4.02 (dd, J = 13.3, 2.6 Hz, 1 H, H-5’), 3.84 (d, 1.9 Hz, 1 H, O-H),
1.15-0.95 (m, 28 H, iPr); 13C NMR (125 MHz, CDCl3) δ 163.5 (C-4), 150.3 (C-2),
139.9 (C-6), 101.9 (C-5), 90.9 (C-1’), 81.7 (C-4’), 75.2 (C-2’), 68.9 (C-3’), 60.2
(C-5’), 17.5 (CH3), 17.4 (CH3), 17.3 (CH3), 17.2 (CH3), 17.0 (CH3), 17.0 (CH3),
16.9 (CH3), 16.8 (CH3), 13.4 (CH), 13.0 (CH), 12.9 (CH), 12.5 (CH); MS (ESI)
m/z 523.3 [M + Na]+.
NH
O
ON
O
OO
O
Si
Si
O
Si
74C24H46N2O7Si3,MW : 558.89
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-(trimethylsilyl)-
uridine (74). [230] To a solution of compound 73 (2.65 g, 5.45 mmol) in dry DCM
(50 mL) were added triethylamine (3.8 mL, 26.3 mmol) and trimethylsilyl chloride
(2.1 mL, 16.1 mmol) dropwise at -10 ◦C. The solution was allowed to warm up to
r.t. and to stir for 2 h. The reaction mixture was then poured onto ice water in a
separation funnel and was extracted with DCM (3 × 50 mL). The combined or-
ganic layer was washed with brine (50 mL), dried over Na2SO4 and concentrated.
Purification by column chromatography on SiO2 (eluent: Et3N/EtOAc/hexane,
1/19/80 to 1/49/50 v/v) gave 2.35 g (78%) of compound as a white foam; mp
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177-178 ◦C (lit. [230] 184◦C); Rf=0.55 (6% MeOH/DCM); 1H NMR (500 MHz,
CDCl3) δ 9.80 (s, 1 H, N-H), 7.98 (d, J = 8.1 Hz, 1 H, H-6), 5.69 (d, J = 8.1
Hz, 1 H, H-5), 5.60 (d, J = 1.6 Hz, 1 H; H-1’), 4.27 (d, J = 13.6 Hz, 1 H, H-5’),
4.17 (m, 2H, H-2’, H-3’), 4.08 (ddd, J = 9.4, 3.6, 1.5 Hz, 1 H, H-4’), 3.99 (d, J =
13.6 Hz, 1 H, H-5’), 1.16-0.92 (m, 28 H, iPr), 0.21 (s, 9 H, TMS); 13C NMR (125
MHz, CDCl3) δ 163.9 (C-4), 149.8 (C-2), 139.5 (C-6), 101.0 (C-5), 91.1 (C-1’),
81.3 (C-4’), 76.2 (C-2’), 67.8 (C-3’), 59.2 (C-5’), 17.3 (CH3), 17.2 (CH3), 17.1
(CH3), 17.0 (CH3), 16.8 (CH3), 16.8 (CH3), 16.7 (CH3), 16.6 (CH3), 13.2 (CH),
13.0 (CH), 12.7 (CH), 12.6 (CH), 0.0 (3 C, CH3, TMS); MS (ESI) m/z 581.2 [M
+ Na]+.
N
O
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75, C26H46N2O9Si2,MW : 586.82
N3-Boc-3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-uridine
(75). Di-tert-butyl dicarbonate (1.85 g, 8.5 mmol) and DMAP (500 mg, 4.15
mmol) were added to a solution of compound 74 (2.32 g, 4.15 mmol) in dry THF
(50 mL) at r.t. The resulting mixture was stirred for 16 h. After full conversion
of the starting material p-toluenesulfonic acid (1.6 g, 8.3 mmol) was added. The
mixture was stirred for additional 50 min, cooled to 0 ◦C, and neutralised with
triethylamine (1.1 mL). The reaction mixture was diluted with water (30 mL)
and extracted with EtOAc (3 × 50 mL). The combined organic layer was washed
with brine (50 mL), dried over Na2SO4 and concentrated. Purification by column
chromatography on SiO2 (eluent: EtOAc/hexane, 30/70 to 60/40 v/v) furnished
1.41 g (58%, overall yield) of the desired compound as a white foam; mp 202-
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204 ◦C; Rf=0.5 (40% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J
= 8.2 Hz, 1 H, H-6), 5.72 (s, 1 H, H-1’), 5.71 (d, J = 8.3 Hz, 1 H, H-5), 4.36 (dd,
J = 8.8, 4.9 Hz, 1 H, H-3’), 4.20 (m, 2 H, H-2’, H-4’), 4.11 (dd, J = 10.8, 2.3 Hz,
1 H, H-5’), 4.00 (dd, J = 13.3, 2.8 Hz, 1 H, H-5’), 2.94 (s, 1H, OH), 1.61 (s, 9
H, TMS), 1.14-0.90 (m, 28 H, iPr); 13C NMR (125 MHz, CDCl3) δ 160.1 (C-4),
148.3 (C-2), 147.6 (C-6), 139.2 (C=O, Boc), 101.5 (C-5), 90.9 (C-1’), 86.8 (C-4’),
81.9 (C-2’), 75.1 (C-3’), 68.9 (C-5’), 60.0 (Ctert, Boc), 27.4 (3 C, CH3, Boc), 17.4
(CH3), 17.4 (CH3), 17.2 (CH3), 17.2 (CH3), 17.0 (CH3), 17.0 (CH3), 16.9 (CH3),
16.8 (CH3), 13.4 (CH), 12.9 (CH), 12.9 (CH), 12.5 (CH); MS (ESI) m/z 609.9
[M + Na]+; HRMS (ESI) calcd for C26H47N2O9Si2 (= [M + H]+) m/z 587.2815,
found 587.2804.
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76, C27H48N2O11SSi2,MW : 664.91
N3-Boc-3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(methanesulfonyl)-uridine (76). Triethyl amine (1.6 mL, 11.5 mmol) and
mesyl chloride (0.55 mL, 5.1 mmol) were added to a solution of compound 75
(1.35 g, 2.3 mmol) in dry DCM (20 mL) at 0 ◦C. The mixture was stirred at this
temperature for additional 10 min before it was allowed to warm up to r.t and
was stirred for 1.5 h. After full conversion of the starting material the mixture
was diluted with sat. NaHCO3-solution and extracted with DCM (2 × 20 mL).
After drying over Na2SO4 and concentration in vacuo the resulting crude oil was
purified by column chromatography on SiO2 (eluent: EtOAc/hexane, 15/85 to
40/60 v/v) to obtain 1.13 g (74%) of the title compound as a white foam; mp
147
5 Experimental Part
187-188 ◦C; Rf=0.55 (20% EtOAc/hexane); 1H NMR (500 MHz, CDCl3) δ 7.80
(d, J = 8.3 Hz, 1 H, H-6), 5.81 (s, 1 H, H-1’), 5.75 (d, J = 8.3 Hz, 1 H, H-5),
5.04 (d, J = 4.4 Hz, 1 H, H-2’), 4.35 (dd, J = 9.6, 4.5 Hz, 1 H, H-5’), 4.28 (d, J
= 13.7 Hz, 1 H, H-3’), 4.12 (dd, J = 9.6, 2.0 Hz, 1 H, H-4’), 4.01 (dd, J = 13.7,
2.5 Hz, 1 H, H-5’), 3.26 (s, 3 H, CH3, mesyl), 1.63 (s, 9 H, CH3, Boc), 1.16-0.92
(m, 28 H, iPr); 13C NMR (125 MHz, CDCl3) δ 161.5 (C-4), 148.8 (C-2), 146.9
(C-6), 139.5 (C=O, Boc), 102.2 (C-5), 92.1 (C-1’), 85.9 (C-4’), 82.1 (C-2’), 75.3
(C-3’), 68.7 (C-5’), 60.8 (Ctert, Boc), 38.5 (CH3, mesyl), 26.3 (3 C, CH3, Boc),
17.6 (CH3), 17.5 (CH3), 17.4 (CH3), 17.1 (CH3), 17.0 (CH3), 16.9 (CH3), 16.9
(CH3), 16.6 (CH3), 14.1 (CH), 12.8 (CH), 12.6 (CH), 12.2 (CH); MS (ESI) m/z
665.9 [M + H]+; HRMS (ESI) calcd for C27H49N2O11SSi2 (= [M + H]+) m/z
665.8529, found 665.8533.
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77, C33H52N2O11SSi2,MW : 741.01
N3-Boc-3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(p-toluenesulfonyl)-uridine (77). Compound 75 (200 mg, 0.38 mmol) was
dissolved in dry DCM (4 mL) before Et3N (0.53 mL, 1.52 mmol), nosyl chloride
(290 mg, 1.52 mmol) and DMAP (94 mg, 0.76 mmol) were added to the solution
at r.t. under an argon atmosphere. The solution was stirred for 24 h. After full
conversion of the starting material the reaction was quenched by pouring it onto
ice. The mixture was extracted with DCM (3 × 15 mL) and the combined organic
layer was washed with brine, dried over Na2SO4 and concentrated under reduced
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pressure in a water bath which was kept below 40 ◦C. The resulting crude product
was purified by column chromatography on SiO2 (eluent: EtOAc/hexane, 60/40
to 50/50 v/v) to give 81 mg of 77 (44%) as a white foam; Rf=0.4 (EtOAc/hexane,
60/40); 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 6.5 Hz, 2 H, Harom), 7.60 (d,
J = 8.3 Hz, 2 H, Harom), 7.34 (d, J = 8.1 Hz, 1 H, H-6), 5.70 (d, J = 8.3 Hz, 1 H,
H-5), 5.09 (d, J = 4.8 Hz, 1 H, H-1’), 4.46 (dd, J = 9.3, 4.8 Hz, 1 H, H-2’), 4.21
(d, J = 13.5 Hz, 1 H, H-5’), 4.09 - 4.05 (m, 2 H, H-3’,5’), 4.00 (dt, J = 13.5, 2.3
Hz, 1 H, H-4’), 2.45 (s, 3 H, CH3), 1.64 (s, 9 H, Boc, CH3), 1.14 - 0.89 (m, 28 H,
iPr); MS (ESI) m/z 742.1 [M + H]+.
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78, C15H22N2O10S,MW : 422.41
N3-Boc-2’-O-(methanesulfonyl)-uridine (78). TBAF (125 mg, 0.4 mmol)
was added to a stirring solution of compound 76 (80 mg, 0.12 mmol) in dry THF
(3 mL) at r.t. The mixture was stirred for 30 min. After completion of the reac-
tion the solvent was removed in vacuo. The resulting crude residue was purified
by column chromatography on SiO2 (eluent: EtOAc/hexane, 90/10 to 100/0 v/v)
to obtain 38 mg (76%) of the title compound as a white foam; mp 223-225 ◦C;
Rf=0.55 (6% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8.3 Hz,
1 H, H-6), 5.87 (s, 1 H, H-1’), 5.72 (d, J = 8.2 Hz, 1 H, H-5), 5.07 (dd, J = 4.5,
3.2 Hz, 1 H, H-3’), 4.40 - 4.36 (m, 1H, H-4’), 4.03 (d, J = 6.6 Hz, 1 H, H-2’),
3.91 (d, J = 11.2 Hz, 1 H, H-5’), 3.77 (d, J = 11.2 Hz, 1 H, H-5’), 3.15 (s, 3
H, CH3, mesyl), 1.51 (s, 9 H, CH3, Boc); 13C NMR (125 MHz, CDCl3) δ 160.1
(C-4), 147.8 (C-2), 146.9 (C-6), 139.4 (C=O, Boc), 101.5 (C-5), 87.7 (C-1’), 86.6
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(C-2’), 83.4 (C-4’), 80.6 (C-3’), 67.2 (C-5’), 59.5 (Ctert, Boc), 37.9 (CH3, mesyl),
26.7 (3 C, CH3, Boc); MS (ESI) m/z 450.5 [M + Na]+.
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79, C25H38N2O12S,MW : 590.64
N3-Boc-3’,5’-O-(bis-tetrahydropyranyl)-2’-O-(methanesulfonyl)-
uridine (79). pTsOH (270 mg, 1.4 mmol) and DHP (0.6 mL, 7.0 mmol) were
added to a solution of compound 78 (300 mg, 0.71 mmol) in dry THF (8 mL)
at 0 ◦C. The solution was allowed to warm up to r.t. and was stirred for 3
h. The solution was then neutralised with triethylamine (0.25 mL). The neutral
mixture was diluted with water (20 mL) and extracted with DCM (3 × 15 mL).
The combined organic layer was washed with brine (50 mL), dried over Na2SO4
and concentrated. Twofold purification by column chromatography on SiO2 (elu-
ent: EtOAc/hexane, 10/90 to 30/70 v/v) furnished 234 mg (56%) of the desired
compound 79 as a white foam (four diastereomers). A small portion (1.5 mg)
was further characterised by analytical HPLC. The precursor was found to be
≥98% pure (Rt=7.5-8.2 min, 80% MeCN/H2O); Rf=0.6 (15% EtOAc/hexane);
1H NMR (500 MHz, CDCl3) δ 8.14-8.07 (4s, 4 H, H-6), 5.96-5.90 (4s, 4 H, H-1’),
5.71-5.67 (4s, 4 H, H-5), 5.15-5.10 (m, 4 H), 4.79-4.66 (m, 8 H), 4.52-4.44 (m,
4 H), 4.34-4.29 (m, 4 H), 4.25-4.07 (m, 4 H), 3.88-3.62 (m, 12 H), 3.56-3.49 (m,
8 H), 3.22-3.21 (4s, 8 H), 1.84-1.63 (m, 24 H), 1.62-1.56 (4s, 36 H, Boc, CH3),
1.56-1.40 (m, 28 H, THP); MS (ESI) m/z 613.7 [M + Na]+; HRMS (ESI) calcd
for C25H39N2O12S (= [M + H]+) m/z 591.3730, found 591.3732.
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80, C24H35FN2O9,MW : 514.54
N3-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-fluoro-arabino-uridine (80).
Fluorination precursor 79 (100 mg, 0.17 mmol) was dissolved in dry acetonitrile
(3 mL) at r.t under an argon atmosphere in an oven dried Schlenk flask. 1 M
TBAF solution in dry THF (0.5 mL, 0.5 mmol) was added dropwise to the solu-
tion. The resulting mixture was stirred at 80 ◦C for 2.5 h. After completion of
the reaction the solvent was removed under reduced pressure. The crude residue
was purified by column chromatography on SiO2 (eluent: EtOAc/hexane, 15/85
to 20/80 v/v) to furnish the fluorinated compound 80 (42 mg, 51%) as a colour-
less oil (four diastereomers); A small portion (≈1 mg) was further characterised
by analytical HPLC. The fluorinated intermediate was found to be ≥95% pure
(Rt=6.3 min, 80% MeCN/H2O); Rf=0.45 (15% EtOAc/hexane); 1H NMR (500
MHz, CDCl3) δ 7.62-7.53 (4s, 4 H, H-6), 6.20-6.11 (4s, 4 H, H-1’), 5.70-5.67 (m,
4 H, H-5)), 5.25-4.97 (m, 4 H, H-2’), 4.75-4.61 (m, 8 H, H-4’, THP), 4.52-4.29
(m, 4 H, H-3’), 4.21-4.14 (m, 4 H, H-5’), 3.98-3.88 (m, 4 H, H-5’), 3.82-3.73 (m,
4 H, THP), 3.66-3.58 (m, 4 H, THP), 3.56-3.49 (m, 8 H, THP), 1.81-1.61 (m,
20 H, THP), 1.57 (s, 36 H, Boc, CH3), 1.53-1.38 (m, 32 H, THP); 19F NMR
(471 MHz, CDCl3) δ -198.46, -198.70, -199.24, -199.44; MS (ESI) m/z 537.3 [M +
Na]+; HRMS (ESI) calcd for C24H36FN2O9 (= [M + H]+) m/z 515.2911, found
515.2916.
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65, C9H11FN2O5,MW : 246.19
2’-deoxy-2’-fluoroarabino-uridine (65). [231] Compound 80 (70 mg, 0.14
mmol) was dissolved in MeOH (4 mL) before 1 M HCl solution (1 mL) was added
dropwise. The mixture was stirred at 60 ◦C for 1 h. After full conversion of the
starting material saturated NaHCO3 (2 mL) was added to the mixture. After
concentration in vacuo the crude product was purified by column chromatography
on SiO2 (eluent: DCM/MeOH, 90/10 v/v) to obtain 21 mg (62%) of 65 as a
white powder; mp 164-165 ◦C (lit. [231] 159-162 ◦C); Rf=0.3 (10% MeOH/DCM);
1H NMR (500 MHz, CDCl3) δ 11.43 (s, 1 H, N-H), 7.72 (d, J = 8.1 Hz, 1 H, H-6),
6.11 (dd, J = 16.0, 4.3 Hz, 1 H, H-3’), 5.89 (d, J = 4.9 Hz, 1 H, OH-3’), 5.65 (d,
J = 8.1 Hz, 1 H, H-5), 5.09 (dd, J = 6.6, 4.3 Hz, 1 H, H-2’), 4.99 (dd, J = 4.1,
3.3 Hz, 1 H, H-1’), 4.22 (ddd, J = 19.8, 7.8, 4.6 Hz, 1 H, H-4’), 3.80 (q, J = 4.7
Hz, 1 H, OH-5’), 3.65 (dd, J = 11.5, 4.8 Hz, 1 H, H-5’), 3.58 (dd, J = 11.8, 5.6
Hz, 1 H, H-5’); 13C NMR (125 MHz, CDCl3) δ 163.0 (C-4), 150.2 (C-2), 141.1
(C-6), 101.0 (C-5), 95.4 (d, 1J(C,F) = 191.8 Hz, C-2’), 83.2 (d, 2J(C,F) = 16.5
Hz, C-1’), 72.7 (d, 2J(C,F) = 23.9 Hz, C-3’), 59.9 (C-5’), 48.4 (C-4’); 19F NMR
(474 MHz, CDCl3) δ -198.6; MS (ESI) m/z 281 [M + Cl]−.
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40, C10H13FN2O5,MW : 260.22
2’-deoxy-2’-fluoro-5-methyl-uridine (40). [232]
via deoxofluorination of compound 71 using XtalFluor M:
A freshly prepared solution of XtalFluor M and Et3N·3HF in dry DCM (2
mL) was added to a solution of compound 71 (200 mg, 0.38 mmol) in dry DCM
(3 mL) dropwise at -78 ◦C. The solution was allowed to heat up slowly to r.t. and
stirred for 3 h. A freshly prepared 1 M solution of HCl in MeOH (5 ML) was
added to the solution. The mixture was stirred for an additional 30 min. The
solution was then neutralised by adding sat. NaHCO3-solution and concentrated
in vacuo. The obtained crude product was purified by column chromatography
on SiO2 (eluent: DCM/MeOH, 90/10 v/v) to obtain 23 mg (25%) of the title
compound as colourless needles; mp 155-157 ◦C (lit. [232] 149-150 ◦C); Rf=0.45
(10% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 11.30 (s, 1 H, N-H), 7.77 (d,
J = 0.8 Hz, 1 H, H-6), 5.93 (dd, J = 17.6, 2.3 Hz, 1 H, H-3’), 5.52 (d, J = 6.3 Hz,
1 H, OH-3’), 5.14 (t, J = 4.7 Hz, 1 H, OH-5’), 5.02 (ddd, J = 53.2, 4.4, 2.4 Hz,
1 H, H-2’), 4.24 - 4.15 (m, 1 H, H-4’), 3.78 (d, J = 12.2 Hz, 1 H, H-5’), 3.61 (dt,
J = 12.3, 3.5 Hz, 1 H, H-5’), 1.77 (s, 3 H, CH3); 13C NMR (125 MHz, CDCl3) δ
163.6 (C-4), 150.3 (C-2), 136.2 (C-6), 109.0 (C-5), 93.3 (d, J = 186.1 Hz, C-2’),
86.8 (d, J = 34.0 Hz, C-1’), 83.3, 67.6 (d, J = 16.1 Hz, C-3’), 59.6 (C-5’), 11.8
(C-4’); 19F NMR (474 MHz, CDCl3) δ -202.7; MS (ESI) m/z 295 [M + Cl]−.
via fluorination of compound 72 using either KF/K222 or TMAF:
Fluorination precursor 72 (100 mg, 141 µmol) was placed in an oven-dried
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Schlenk flask and dissolved in anhydrous solvent (MeCN/DMF, 4 mL) under inert
atmosphere before either KF/K222 or TMAF (3 eq.) was added to the solution.
The mixture was stirred at the appropriate temperature (85-145 ◦C) for the given
time (2-12 h). Reaction control using TLC was performed hourly. However, the
desired fluorinated and protected intermediate could not be observed using the
stated conditions. Hence, the deprotection step to give 40 was not carried out.
The reaction mixtures were purified using column chromatography to recover the
starting material using appropriate gradients as stated in the above procedures.
NH
O
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O
OHO
OSi
Si
O
I
83, C21H37IN2O7Si2,MW : 612.60
3’,5’-O-1,1,3,3-tetraisopropyl-1,3-disiloxane-5-iodouridine (83). [213]
5-iodouridine 82 (500 mg, 1.35 mmol) was coevaporated twice with dry pyrid-
ine (3 mL) and then dissolved in dry pyridine (10 mL) under an argon atmosphere.
The solution was cooled to 0 ◦C before 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane
(0.43 mg, 1.35 mmol) was added dropwise to the cold solution. The reaction mix-
ture was stirred at r.t for 16 h. After full conversion of the starting material pyrid-
ine was removed in vacuo by azeotropic co-evaporation with toluene. The crude
product was purified by column chromatography on SiO2 (eluent: DCM/MeOH,
96/4 to 94/6 v/v) to give 83 (569 mg, 0.92 mmol, 69%) as a white foam; Rf=0.55
(8% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 10.17 (s, 1H, N-H), 8.03 (s,
1H, H-6), 5.68 (s, 1H, H-1’), 4.28 (dd, J = 8.7, 4.9 Hz, 1H, H-5’), 4.21 - 4.20 (m,
2H, H-3’, H-2’), 4.19 - 4.18 (m, 1H, H-4’), 4.04 (s, 1H, OH-2’), 3.98 (dd, J = 13.5,
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2.7 Hz, 1H, 5’-H), 1.10 - 0.98 (m, 28H, H-iPr); 13C NMR (125 MHz, CDCl3) δ
160.4 (C-4), 150.3 (C-2), 144.1 (C-6), 91.5 (C-1’), 82.1 (C-4’), 75.0 (C-2’), 68.7
(C-3’), 68.5 (C-5), 59.9 (C-5’), 17.7 (CH), 17.6 (CH), 17.4 (CH), 17.2 (CH), 17.1
(CH3), 17.0 (CH3), 17.0 (CH3), 16.8 (CH3), 13.5 (CH3), 13.0 (CH3), 12.7 (CH3),
12.5 (CH3); MS (ESI) m/z 635.2 [M + Na]+.
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84, C24H45IN2O7Si3,MW : 684.78
3’,5’-O-1,1,3,3-tetraisopropyl-1,3-disiloxane-2’-O-(trimethylsilyl)-5-
iodouridine (84). Compound 83 (300 mg, 0.94 mmol) was dissolved in dry
DCM (5 mL) under an argon atmosphere and the solution was cooled to -10 ◦C.
Triethylamine (0.36 mL, 2.5 mmol) and trimethylsilyl chloride (0.2 mg, 1.5 mmol)
were added dropwise before the cooling bath was removed and the mixture was
then stirred at r.t. for 5 h. After full conversion of the starting material the
reaction mixture was poured onto a cold saturated aqueous solution of NaHCO3.
The mixture was extracted with DCM (3 × 15 mL). The combined organic layer
was washed with brine (20 mL), dried over Na2SO4 and concentrated. The crude
product was purified via column chromatography on SiO2 (eluent: DCM/MeOH,
98/2 to 96/4 v/v) to give 84 (275 mg, 0.40 mmol, 82%) as a white foam; mp 76-79
◦C; Rf=0.65 (5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 9.94 (s, 1H, H-3),
8.19 (s, 1H, H-6), 5.53 (s, 1H, H-1’), 4.27 (d, J = 13.7 Hz, 1H, H-5’), 4.22 - 4.17
(m, 2H, H-3’, H-2’), 4.10 (dd, J = 9.4, 4.0 Hz, 1H, H-4’), 3.98 (dd, J = 13.7, 2.5
Hz, 1H, H-5’), 1.16 - 0.91 (m, 28H, H-iPr), 0.20 (s, 9H, H-TMS); 13C NMR (125
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MHz, CDCl3) δ 160.4 (C-4), 149.8 (C-2), 143.7 (C-6), 91.6 (C-1’), 81.5 (C-4’),
76.1 (C-2’), 67.8 (C-3’), 67.6 (C-5), 59.0 (C-5’), 17.6 (CH), 17.4 (CH), 17.2 (CH),
17.0 (CH), 16.9 (CH3), 16.8 (CH3), 16.7 (CH3), 13.3 (CH3), 12.7 (CH3), 12.7 (2
C, CH3), 12.6 (CH3), 0.1 (3 C, CH3-TMS); MS (ESI) m/z 708 [M + Na]+; HRMS
(ESI) calcd for C24H45IN2O7Si3 (= [M + H]+) m/z 685.1652, found 685.1650.
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85, C26H45IN2O9Si2,MW : 712.72
N3-Boc-3’,5’-O-1,1,3,3-tetraisopropyl-1,3-disiloxane-5-iodouridine
(85). Compound 84 (250 mg, 0.36 mmol) was dissolved in dry DCM under
an argon atmosphere before 4-(dimethylamino)-pyridine (44 mg, 0.36 mmol) and
di-tert-butyl dicarbonate (94 mg, 0.43 mmol) were added to the solution. The
reaction mixture was stirred at r.t for 15 h. After full conversion of the starting
material p-toluenesulfonic acid monohydrate (143 mg, 0.72 mmol) was added and
the resulting suspension was stirred at r.t. for additional 2 h. After completion
of the reaction the mixture was cooled to 0 ◦C before triethylamine (0.13 mL,
0.72 mmol) was added dropwise. The solution was then poured onto a saturated
NaHCO3-solution and was extracted with DCM (3 × 15 mL). The combined
organic layer was dried over Na2SO4 and concentrated. The crude product was
purified via column chromatography on SiO2 (eluent: cyclohexane/EtOAc, 90/10
to 85/15 v/v) to give 163 mg (58%) of 85 as a white foam; mp 82-84 ◦C; Rf=0.7
(5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.81 (s, 1H, H-6), 5.63 (s, 1H,
H-1’), 4.38 (dd, J = 8.6, 5.2 Hz, 1H, H-3’), 4.19 (dd, J = 13.1, 2.2 Hz, 1H, H-5’),
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4.09 (d, J = 5.2 Hz, 1H, H-2’), 4.05 (dt, J = 8.6, 2.6 Hz, 1H, H-4’), 3.99 (dd,
J = 13.1, 3.0 Hz, 1H, H-5’), 2.91 (s, 1H, OH-2’), 1.67 (s, 9H, Boc), 1.17 - 0.92
(m, 28H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 161.3 (C-4), 157.4 (C=O, Boc)
150.8 (C-2), 141.3 (C-6), 91.7 (C-1’), 81.9 (C-4’), 75.23 (C-2’), 69.55 (C-3’), 69.17
(C-5), 63.69 (C-5’), 60.21 (Cquat., Boc), 29.43 (3 C, CH3, Boc), 17.70 (CH3), 17.55
(CH3), 17.43 (CH3), 17.24 (CH3), 17.05 (CH3), 16.98 (CH3), 16.94 (CH3), 16.85
(CH3), 13.42 (CH), 12.97 (CH), 12.74 (CH), 12.55 (CH); MS (ESI) m/z 726 [M
+ Na]+; HRMS (ESI) calcd for C26H49IN3O9Si2 (= [M + NH4]+) m/z 730.2047,
found 730.2048.
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86, C27H47IN2O11SSi2,MW : 790.81
N3-Boc-3’,5’-O-1,1,3,3-tetraisopropyl-1,3-disiloxane-2’-O-methyl-
sulfonyloxy-5-iodouridine (86). Compound 85 (520 mg, 0.7 mmol) was dis-
solved in dry DCM under an argon atmosphere and cooled to -10 ◦C before tri-
ethylamine (0.5 mL, 3.5 mmol) and methanesulfonyl chloride (0.2 mL, 2.6 mmol)
were added dropwise to the solution. The resulting mixture was stirred at this
temperature for 10 minutes beefore it was allowed to warm up to r.t. and stirred
for additional 2 h. After full conversion of the starting material the solution was
then poured onto cold brine and was extracted with DCM (3 × 20 mL). The com-
bined organic layer was dried over Na2SO4 and concentrated. The crude product
was purified via column chromatography on SiO2 (eluent: cyclohexane/EtOAc,
90/10 v/v) to furnish 512 mg (88%) of the title compound 86 as a white foam;
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mp 92 ◦C; Rf=0.45 (2% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.06 (s,
1H, H-6), 5.75 (s, 1H, H-1’), 5.06 (d, J = 4.6 Hz, 1H, H-2’), 4.36 (dd, J = 9.5,
4.6 Hz, 1H, H-3’), 4.28 (d, J = 13.8 Hz, 1H, H-4’), 4.11 (dd, J = 9.5, 2.0 Hz,
1H, H-5’), 4.00 (dd, J = 13.8, 2.5 Hz, 1H, H-5’), 3.23 (s, 3H, Ms), 1.61 (s, 9H,
Boc), 1.14 - 0.90 (m, 28H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 157.4 (C-4),
147.7 (C-2), 146.5 (C=O, Boc), 142.2 (C-6), 89.5 (C-1’), 87.6 (C-2’), 82.5 (C-4’),
82.2 (C-3’), 67.8 (C-5), 66.6 (C-5’), 58.6 (Cquat., Boc), 39.2 (CH3, Ms), 27.2 (3 C,
CH3), Boc), 17.7 (CH3), 17.6 (CH3), 17.4 (CH3), 17.2 (CH3), 17.0 (CH3), 16.9
(CH3), 16.8 (CH3), 16.8 (CH3), 13.6 (CH), 12.9 (CH), 12.7 (CH), 12.6 (CH); MS
(ESI) m/z 813 [M + Na]+; HRMS (ESI) calcd for C27H51IN3O11SSi2 (= [M +
NH4]+) m/z 808.1822, found 808.1826.
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87, C15H21IN2O10S,MW : 548.30
N3-Boc-2’-O-methylsulfonyloxy-5-iodouridine (87). TBAF (2.3 g, 7.1
mmol) was added to a stirring solution of compound 86 (1.87 g, 2.36 mmol) in
dry THF (35 mL) at r.t. The mixture was stirred for 40 min. After completion
of the reaction the solvent was removed in vacuo. The resulting crude residue
was purified by column chromatography on SiO2 (eluent: EtOAc/hexane, 85/15
to 95/5 v/v) to obtain 856 mg (48%) of the title compound (87) as a white foam;
mp 143 ◦C; Rf=0.45 (7% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.57 (s,
1H), 5.93 (d, J = 2.3 Hz, 1H), 5.11 (dd, J = 4.5, 2.5 Hz, 1H), 4.55 - 4.47 (m,
1H), 4.15 - 3.97 (m, 3H), 3.90 (d, J = 11.4 Hz, 1H), 3.22 (s, 3H), 3.18 - 3.12 (m,
1H), 1.56 (s, 10H); 13C NMR (125 MHz, CDCl3) δ 159.4 (C-4), 144.7 (C-2), 145.6
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(C-6), 139.2 (C=O, Boc), 102.2 (C-5), 87.7 (C-1’), 86.5 (C-2’), 82.2 (C-4’), 79.1
(C-3’), 65.3 (C-5’), 58.4 (Cquat., Boc), 38.5 (CH3, mesyl), 25.9 (3 C, CH3, Boc);
MS (ESI) m/z 571.3 [M + Na]+.
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88, C25H37IN2O12S,MW : 716.54
N3-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-O-methylsulfonyloxy-uri-
dine (88). TBAF (2.3 g, 7.1 mmol) was added to a solution of 87 (1.87 g, 2.36
mmol) in dry THF (35 mL) at r.t. under nitrogen. The resulting yellow solution
was stirred at r.t. for 40 min. After completion of the reaction the solvent was
removed in vacuo and the resulting dried crude mixture was then used for the
next step. pTsOH (1.02 g, 5.4 mmol) and DHP (2.5 mL, 27 mmol) were added
to a solution of the crude compound 87 in THF (38 mL) at 0 ◦C. The solution
was allowed to warm up to r.t. and stirred for 3 h. After completion of the
reaction the solution was neutralised with triethyl amine (1.2 mL). The neutral
mixture was diluted with water (20 mL) and extracted with DCM (3 × 30 mL).
The combined organic layer was washed with brine (50 mL), dried over Na2SO4
and concentrated. Purification of the crude residue by column chromatography on
SiO2 (eluent: EtOAc/hexane, 10/90 to 30/70 v/v) furnished 586 mg (35%, overall
yield) of the desired title compound 88 as a white foam (4 diastereomers); a small
portion (1.5 mg) was further characterised by analytical HPLC. The precursor
was found to be ≥97% pure (Rt=4.1, 6.9-7.2 min, 80% MeCN/H2O); Rf=0.5 (8%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) (1 diastereomer) δ 8.27 (s, 1 H, H-6),
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5.98 (d, J = 3.2 Hz, 1 H, H-1’), 5.16 (dd, J = 4.6, 3.3 Hz, 1 H, THP) 4.59 (t, J
= 4.3 Hz, 1 H, H-3’), 4.49 (dd, J = 6.2, 4.9 Hz, 1 H, H-2’), 4.36 (d, J = 6.3 Hz, 1
H, H-4’), 4.25 (dd, J = 12.0, 1.5 Hz, 1 H, H-5’), 3.99 (dd, J = 11.5, 1.5 Hz, 1 H,
H-5’), 3.96 - 3.91 (m, 1 H, THP), 3.87 - 3.72 (m, 4 H, THP), 3.56 - 3.47 (m, 4 H,
THP), 3.19 (s, 3 H, CH3, mesyl), 1.90 - 1.69 (m, 6 H, THP), 1.56 (s, 11 H, THP,
Boc); MS (ESI) m/z 739 [M + Na]+; HRMS (ESI) calcd for C25H38IN2O12S
(= [M + H]+) m/z 717.4458, found 717.4452.
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89, C24H34FIN2O9,MW : 644.44
N3-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-fluoro-arabino-5-iodo-uridine
(89). Fluorination precursor 88 (30 mg, 0.047 mmol) was dissolved in dry MeCN
or DMF (1-2 mL) at r.t under an argon atmosphere in an oven dried Schlenk
flask. Either KF/K222 (3-6 eq.) or 1 M TBAF/THF solution (3-10 eq.) was ad-
ded to the solution. The resulting mixture was stirred at temperatures between
90-160 ◦C for 1-2 h. The reaction was monitored using TLC and LC-MS. Even
though the starting material was converted after the reaction time evidence for
the desired fluorinated product 89 could not be provided.
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102, C23H41N3O7Si2,MW : 527.76
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-N4-acetylcytidine
(102). [233] N4-acetylcytidine (100, 2.0g, 7.0 mmol) was coevaporated two times
with dry pyridine (4 mL) before it was dissolved in dry pyridine (50 mL) at r.t.
under nitrogen atmosphere. The whitish suspension was cooled to 0 ◦C before
dichloro-1,1,3,3-tetraisopropyldisyloxane (2 mL, 6.3 mmol) was added dropwise
to the suspension. The ice bath was removed and the resulting mixture stirred
at r.t. for 16h. After completion of the reaction the solvent was removed in
vacuo and the resulting crude mixture diluted with DCM (60 mL). The solution
was washed with brine (2 × 30 mL), dried over Na2SO4 and concentrated. The
remaining pyridine was removed by co-evaporation with toluene. The resulting
crude product was subsequently purified via column chromatography on SiO2
(eluent: hexane/EtOAc, 90/10 to 70/30 v/v) to furnish 2.65 g (82%) of the de-
sired compound as a white foam; mp 157-159 ◦C; Rf=0.4 (8% MeOH/DCM); 1H
NMR (500 MHz, CDCl3) δ 10.19 (s, 1 H, NH), 8.22 (d, J = 7.5 Hz, 1 H, H-6),
7.46 (d, J = 7.5 Hz, 1 H, H-5), 5.82 (s, 1 H, H-1’), 4.29 - 4.25 (m, 2 H, H-4’, H-5’)
4.22 (m, 1 H, H-2’) (dd, J = 13.4, 2.3 Hz, 1 H, H-5’), 3.56 (s, 1 H, OH-2’), 2.30
(s, 3 H, acetyl), 1.13 - 0.97 (m, 28H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 170.2
(C-4), 162.2 (C=O, acetyl), 154.1 (C-2), 143.2 (C-6), 95.7 (C-1’), 90.7 (C-5), 80.8
(C-4’), 74.4 (C-2’), 67.8 (C-3’), 58.9 (C-5’), 24.2 (CH3), 16.5 (CH3), 16.4 (CH3),
16.3 (CH3), 16.2 (CH3), 16.0 (CH3), 15.9 (CH3), 15.8 (CH3), 15.8 (CH3), 12.4
(CH), 12.0 (CH), 11.9 (CH), 11.5 (CH); MS (ESI) m/z 550.2 [M + Na]+.
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103, C28H43N3O7Si2,MW : 589.83
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-N4-benzoylcyti-
dine (103). [231] N4-benzoylcytidine (101, 1.2 g, 2.5 mmol) was coevaporated
with dry pyridine (2 × 4 mL) before it was dissolved in dry pyridine (25 mL)
at r.t. under nitrogen atmosphere. The suspension was cooled to 0 ◦C before
dichloro-1,1,3,3-tetraisopropyldisyloxane (1.0 mL, 3.17 mmol) was added drop-
wise to the suspension. The icebath was removed and the resulting mixture
stirred at r.t. for 16 h. After completion of the reaction the solvent was removed
in vacuo and the resulting crude mixture diluted with DCM (30 mL). The solu-
tion was washed with brine (2 × 30 mL), dried over Na2SO4 and concentrated.
The remaining pyridine was removed by coevaporation with toluene. The result-
ing crude product was subsequently purified by column chromatography on SiO2
(EtOAc/hexane, 90/10 to 70/30 v/v) to furnish 1.29 g (63%) of 103 as a white
foam; mp 131-133 ◦C (lit. [231] 142 ◦C); Rf=0.55 (7% MeOH/DCM); 1H NMR
(500 MHz, CDCl3) δ 9.16 (s, 1 H, NH), 8.27 (d, J = 7.5 Hz, 1 H, C-6), 7.93 (d,
J = 7.4 Hz, 1 H, C-5), 7.77 - 7.43 (m, 5 H, benzoyl), 5.86 (s, 1 H, H-1’), 4.32 -
4.23 (m, 5 H), 4.02 (dd, J = 13.4, 2.4 Hz, 1 H, H-5’), 1.16 - 0.94 (m, 28 H, H-iPr);
13C NMR (125 MHz, CDCl3) δ 162.6 (C=O, benzoyl), 154.8 (C-4), 149.5 (C-2),
144.5 (C-6), 136.3 (Carom), 132.9 (CHarom), 129.2 (2 C, CHarom), 127.4 (CHarom),
123.7 (CHarom), 96.4 (C-1’), 91.6 (C-5), 82.1 (C-4’), 77.4 (C-2’), 74.3 (C-3’), 68.5
(C-5’), 17.5 (CH3), 17.4 (CH3), 17.3 (2 C, CH3), 17.0 (2 C, CH3), 16.9 (CH3),
16.8 (CH3), 13.4 (CH), 13.0 (CH), 12.9 (CH), 12.4 (CH); MS (ESI) m/z 612.1 [M
+ Na]+.
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104, C24H43N3O9SSi2,MW : 605.85
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(methane-
sulfonyl)-N4-acetylcytidine (104). Et3N (2.7 mL, 19.0 mmol) and MsCl (0.8
mL, 9.5 mmol) were added dropwise to a solution of 103 (2.0 g, 3.8 mmol) in
dry DCM (40 mL) under nitrogen atmosphere at -10 ◦C. The cooling bath was
removed after 10 minutes and the solution was stirred at rt for additional 2 hours.
After full conversion of the starting material the solution was poured into brine
in a separation funnel and extracted with DCM (2 × 50 mL). The combined
organic layer was dried over Na2SO4 and concentrated. Purification by column
chromatography on SiO2 (DCM/MeOH 98/2 to 97/3 v/v) gave 1.73 g (75%) the
title compound 98a as a white foam; Rf=0.55 (6% MeOH/DCM); 1H NMR (500
MHz, CDCl3) δ 10.18 (s, 1 H, NH), 8.23 (d, J = 7.6 Hz, 1 H, H-6), 7.50 (d, J
= 7.6 Hz, 1 H, H-5), 5.89 (s, 1 H, H-1’), 5.02 (d, J = 4.4 Hz, 1 H, H-2’), 4.33 -
4.26 (m, 2 H, H-3’,H-4’), 4.17 (dd, J = 9.7, 1.5 Hz, 1 H, H-5’), 4.03 (dd, J = 13.6,
2.2 Hz, 1 H, H-5’), 3.34 (s, 3 H, Ms), 2.30 (s, 3 H, acetyl), 1.13 - 1.01 (m, 28 H,
H-iPr); 13C NMR (125 MHz, CDCl3) δ 171.1 (C-4), 163.4 (C=O, acetyl), 154.7
(C-2), 143.7 (C-6), 97.0 (C-1’), 89.3 (C-5), 82.6 (C-4’), 82.0 (C-2’), 66.5 (C-3’),
59.1 (C-5’), 39.2 (CH3, mesyl), 24.9 (CH3, acetyl), 17.4 (CH3), 17.4 (CH3), 17.3
(CH3), 16.9 (CH3), 16.8 (CH3), 16.8 (CH3), 16.7 (CH3), 14.2 (CH3), 13.4 (CH),
13.1 (CH), 13.0 (CH), 12.6 (CH); MS (ESI) m/z 628 [M + Na]+.
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105, C29H45N3O9SSi2,MW : 667.92
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(methane-
sulfonyl)-N4-benzoylcytidine (105). Et3N (0.65 mL, 3.4 mmol) and MsCl
(0.35 mL, 2.5 mmol) were added dropwise to a solution of 103 (1.0 g, 1.7 mmol)
in dry DCM (16 mL) under nitrogen atmosphere at -10 ◦C. The cooling bath was
removed after 10 minutes and the solution was stirred at r.t. for an additional
2 h. After full conversion of the starting material the solution was poured onto
cold brine in a separation funnel and extracted with DCM (2 × 50 mL). The
combined organic layer was dried over Na2SO4 and concentrated. Purification
by column chromatography on SiO2 (DCM/MeOH 98/2 to 97/3 v/v) gave 690
mg (61%) of the title compound as a white foam; Rf=0.7 (4% MeOH/DCM); 1H
NMR (500 MHz, CDCl3) δ 9.45 (s, 1 H, NH), 8.24 (d, J = 7.5 Hz, 1 H, H-6),
7.95 - 7.88 (m, 2 H, benzoyl), 7.57 (m, 2 H, benzoyl, H-5), 7.47 (m, 2 H, benzoyl),
5.85 (s, 1 H, H-1’), 4.98 (d, J = 4.5 Hz, 1 H, H-2’), 4.30 - 4.25 (m, 2 H, H-3’,
H-4’), 4.14 (dd, J = 9.7, 1.7 Hz, 1 H, H-5’), 4.00 (dd, J = 13.7, 2.4 Hz, 1 H, H-5’),
3.29 (s, 3 H, mesyl), 1.15 - 0.90 (m, 28 H, H-iPr); 13C NMR (125 MHz, CDCl3) δ
166.9 (C=O, benzoyl), 162.8 (C-4), 154.2 (C-2), 143.5 (C-6), 133.2 (Carom), 128.9
(2 C, CHarom), 127.4 (2 C, CHarom), 96.5 (CHarom), 88.8 (C-5), 82.7 (C-1’), 81.8
(C-4’), 66.6 (C-2’), 58.9 (C-3’), 53.0 (C-5’), 39.2 (CH3, mesyl), 17.4 (CH3), 17.4
(CH3), 17.3 (CH3), 17.2 (CH3), 16.9 (CH3), 16.8 (CH3), 16.8 (CH3), 16.7 (CH3),
13.4 (CH), 12.9 (CH), 12.8 (CH), 12.6 (CH); MS (ESI) m/z 690.1 [M + Na]+.
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91, C12H17N3O8S,MW : 363.34
2’-O-(methanesulfonyl)-N4-acetylcytidine (91). TBAF (2.65 g, 8.4 mmol)
was added to a solution of 104 (1.71 g, 2.8 mmol) in dry THF (35 mL) at r.t.
under nitrogen. The yellow solution was stirred at r.t. for 40 min. After full
conversion of the starting material the solvent was evaporated in vacuo while the
water bath was kept below 30 ◦C. The resulting crude product was purified by
column chromatography on SiO2 (DCM/MeOH 94/6 to 90/10 v/v) to give the
title compound 100 (552 mg, 41%) as a white foam. Rf=0.35 (9% MeOH/DCM);
1H NMR (500 MHz, CDCl3) δ 10.93 (s, 1 H, NH), 8.46 (d, J = 7.5 Hz, 1 H, H-6),
7.22 (d, J = 7.5 Hz, 1 H, H-5), 5.97 (d, J = 2.1 Hz, 1 H, H-1’), 5.04 (dd, J =
4.8, 2.1 Hz, 1 H, H-2’), 4.25 (dd, J = 7.5, 4.9 Hz, 1 H, H-3’), 3.94 (dt, J = 7.6,
2.4 Hz, 1 H, H-4’), 3.83 (dd, J = 12.4, 2.2 Hz, 1 H, H-5’), 3.64 (dd, J = 12.5, 2.8
Hz, 1 H, H-5’), 3.38 (s, 3 H, mesyl), 2.12 (s, 3 H, acetyl); 13C NMR (125 MHz,
CDCl3) δ 171.0 (C=O, acetyl), 162.7 (C-4), 154.3 (C-2), 145.0 (C-6), 95.5 (C-1’),
88.1 (C-5), 83.8 (C-4’), 82.1 (C-2’), 66.3 (C-3’), 58.9 (C-5’), 38.4 (CH3, mesyl),
24.5 (CH3, acetyl); MS (ESI) m/z 386 [M + Na]+.
165
5 Experimental Part
N
NH
ON
O
OOH
HO
O
S
O
O
106, C17H19N3O8S,MW : 425.41
2’-O-(methanesulfonyl)-N4-benzoylcytidine (106). TBAF (0.75 g, 2.3
mmol) was added to a solution of 105 (0.5 g, 0.75 mmol) in dry THF (15 mL) at
r.t. under a nitrogen atmosphere. The yellow solution was stirred at r.t. for 40
min. After full conversion of the starting material the solvent was evaporated in
vacuo while the water bath was kept below 30 ◦C. The resulting crude product
was purified by column chromatography on SiO2 (DCM/MeOH 94/6 to 90/10
v/v) to give the title compound (193 mg, 45%) as a white foam; Rf=0.45 (9%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 11.30 (s, 1 H, NH), 8.55 (d, J =
7.0 Hz, 1 H, H-6), 8.03 - 7.99 (m, 2 H, Harom.), 7.67 - 7.60 (m, 1 H, Harom.), 7.52
(m, 2 H, Harom.), 7.39 (d, J = 5.8 Hz, 1 H, H-5), 6.03 (d, J = 2.2 Hz, 1 H, H-1’),
5.79 - 5.77 (m, 1 H, H-5’), 5.34 (s, 1 H, H-2’), 5.09 (dd, J = 4.8, 2.3 Hz, 1 H,
H-3’), 4.30 (s, 1 H, OH-3’), 3.97 (dt, J = 7.6, 2.6 Hz, 1 H, H-4’), 3.85 (s, 1 H,
OH-5’), 3.67 (dd, J = 12.4, 2.4 Hz, 1 H, H-5’), 3.40 (s, 3 H, CH3, mesyl); MS
(ESI) m/z 426.4 [M + H]+.
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107, C30H47N3O9SSi2,MW : 681.94
3’,5’O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(p-toluene-
sulfonyl)-N4-acetylcytidine (107). Compound 102 (200 mg, 0.38 mmol) was
dissolved in dry DCM (4 mL) before Et3N (0.53 mL, 1.52 mmol), pTsCl (290 mg,
1.52 mmol) and DMAP (94 mg, 0.76 mmol) were added to the solution at r.t. un-
der an argon atmosphere. The solution was stirred for 24 h. After full conversion
of the starting material the reaction was quenched by pouring it onto ice. The
mixture was extracted with DCM (3 × 15 mL) and the combined organic layer
was washed with brine, dried over Na2SO4 and concentrated under reduced pres-
sure in a water bath which was kept below 40 ◦C. The resulting crude product was
purified by column chromatography on SiO2 (eluent: EtOAc/hexane, 60/40 to
50/50 v/v) to give 71 mg of 98b (44%) as a white foam; Rf=0.4 (EtOAc/hexane,
60/40); 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1 H, NH), 8.17 (d, J = 7.6 Hz,
1 H, H-6), 7.97 (d, J = 8.3 Hz, 2 H, Harom), 7.48 (d, J = 7.6 Hz, 1 H, H-5),
7.33 (d, J = 8.1 Hz, 2 H, Harom), 5.75 (s, 1 H, H-1’), 5.21 (d, J = 4.4 Hz, 1 H,
H-2’), 4.36 (dd, J = 9.5, 4.4 Hz, 1 H, H-4’), 4.27 (d, J = 13.5 Hz, 1 H, H-5’),
4.15 (d, J = 8.6 Hz, 1 H, H-3’), 4.00 (dd, J = 13.6, 2.4 Hz, 1 H, H-5’), 2.43 (s, 3
H, CH3, tosyl), 2.32 (s, 3 H, CH3, acetyl), 1.14-0.83 (m, 28 H, H-iPr); 13C NMR
(125 MHz, CDCl3) δ 171.3 (C-4), 163.4 (C=O, acetyl), 154.5 (C-2), 144.5 (C-6),
144.4 (Carom.), 134.5 (Carom.), 129.6 (2 C, CHarom.), 128.0 (2 C, CHarom.), 96.9
(C-1’), 89.9 (C-4’), 82.3 (C-2’), 82.1 (C-3’), 66.8 (C-5’), 59.3 (CH3, tosyl), 24.9
(CH3, acetyl), 21.6 (CH3), 17.4 (CH3), 17.4 (CH3), 17.3 (CH3), 17.3 (CH3), 16.9
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(CH3), 16.8 (3 C, CH3), 13.3 (CH), 12.9 (CH), 12.8 (CH), 12.6 (CH); MS (ESI)
m/z 682.5 [M + H]+.
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108, C26H49N3O7Si3,MW : 599.94
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(trimethyl-
silyl)-N4-acetylcytidine (108). Compound 102 (2.39 g, 4.5 mmol) was dis-
solved in dry DCM (50 mL) under an argon atmosphere and the solution was
cooled to -10 ◦C. Triethylamine (3.15 mL, 22.6 mmol) and trimethylsilyl chloride
(1.15 mL, 9.0 mmol) were added dropwise before the cooling bath was removed
and the mixture was then stirred at r.t. for 2.5 h. After full conversion of the
starting material the reaction mixture was poured onto a cold saturated aqueous
solution of NaHCO3. The mixture was extracted with DCM (3 × 50 mL). The
combined organic layer was washed with brine (50 mL), dried over Na2SO4 and
concentrated. The crude product was purified via column chromatography on
SiO2 (eluent: DCM/MeOH, 98/2 to 96/4 v/v) to give 2.06 g (76%) of 98a as
a white foam; mp 145-147 ◦C; Rf=0.3 (6% MeOH/DCM); 1H NMR (500 MHz,
CDCl3) δ 11.05 (s, 1 H, NH), 8.21 (d, J = 6.9 Hz, 1 H, H-6), 7.33 (d, J = 7.3
Hz, 1 H, H-5), 5.51 (s, 1 H, H-1’), 4.23 - 3.99 (m, 4 H, H-2’,3’,4’,5’), 3.89 (dd,
J = 12.6, 1.9 Hz, 1 H, H-5’), 2.20 (s, 3 H, CH3, acetyl), 1.09 - 0.71 (m, 28 H,
H-iPr), 0.07 (s, 9 H, TMS); 13C NMR (125 MHz, CDCl3) δ 171.3 (C-4), 162.8
(C=O, acetyl), 154.6 (C-2), 143.7 (C-6), 96.1 (C-5), 91.6 (C-1’), 81.3 (C-4’), 75.9
(C-2’), 67.4 (C-3’), 59.3 (C-5’), 24.26 (CH3, acetyl), 17.3 (CH3), 17.2 (CH3), 17.1
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(CH3), 16.9 (CH3), 16.7 (CH3), 16.7 (CH3), 16.6 (CH3), 16.6 (CH3), 13.2 (CH),
13.1 (CH), 12.6 (CH), 12.5 (CH), 0.02 (3 C, CH3, TMS); MS (ESI) m/z 601.0 [M
+ H]+; HRMS (ESI) (M + H)+ calcd for C26H48N3O7SSi3 m/z 600.2951, found
600.2947.
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109, C31H51N3O7Si3,MW : 662.01
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(trimethyl-
silyl)-N4-acetylcytidine (109). Compound 103 (2.1 g, 3.6 mmol) was dis-
solved in dry DCM (45 mL) under an argon atmosphere and the solution was
cooled to -10 ◦C. Triethylamine (2.56 mL, 18.1 mmol) and trimethylsilyl chloride
(0.92 mL, 7.2 mmol) were added dropwise before the cooling bath was removed
and the mixture was then stirred at r.t. for 3.5 h. After full conversion of the
starting material the reaction mixture was poured onto a cold saturated aqueous
solution of NaHCO3. The mixture was extracted with DCM (3 × 50 mL). The
combined organic layer was washed with brine (50 mL), dried over Na2SO4 and
concentrated. The crude product was purified via column chromatography on
SiO2 (eluent: DCM/MeOH, 99/1 to 97/3 v/v) to give 2.07 g (84%) of 109 as
a white foam; mp 161-164 ◦C; Rf=0.4 (6% MeOH/DCM); 1H NMR (500 MHz,
CDCl3) δ 11.10 (s, 1 H, NH), 8.23 (d, J = 7.0 Hz, 1 H, H-6), 8.11 - 8.04 (m, 2 H,
Harom.), 7.82 - 7.71 (m, 2 H, Harom.), 7.48 - 7.41 (m, 1 H, Harom.), 7.31 (d, J =
7.3 Hz, 1 H, H-5), 5.41 (s, 1 H, H-1’), 4.19 - 3.93 (m, 4 H, H-2’,3’,4’,5’), 3.91 (dd,
J = 12.4, 1.8 Hz, 1 H, H-5’), 1.05 - 0.78 (m, 28 H, H-iPr), 0.12 (s, 9 H, TMS);
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13C NMR (125 MHz, CDCl3) δ 171.3 (C-4), 162.8 (C=O, acetyl), 154.3 (C-2),
143.7 (C-6), 139.0 (Carom), 131.2 (CHarom), 126.1 (2 C, CHarom), 124.1 (CHarom),
122.2 (CHarom), 96.1 (C-5), 91.6 (C-1’), 81.3 (C-4’), 75.9 (C-2’), 67.4 (C-3’), 59.3
(C-5’), 17.3 (CH3), 17.2 (CH3), 18.1 (CH3), 16.9 (CH3), 16.8 (CH3), 16.7 (CH3),
16.6 (CH3), 16.5 (CH3), 13.1 (CH), 13.0 (CH), 12.6 (CH), 12.5 (CH), 0.02 (3 C,
CH3, TMS); MS (ESI) m/z 663.2 [M + H]+.
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111, C21H39N3O6Si2,MW : 485.72
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-cytidine (111). [234]
Cytidine (110, 2.3 g, 9.48 mmol) was coevaporated with dry pyridine (2 × 4 mL)
before it was suspended in dry pyridine (40 mL) at r.t. under a nitrogen atmo-
sphere. The suspension was cooled to 0 ◦C before dichloro-1,1,3,3-tetraisopropyldi-
siloxane (2.0 mL, 6.32 mmol) was added dropwise to the suspension. The icebath
was removed and the resulting mixture stirred at r.t. for 5 h. After comple-
tion of the reaction the solvent was removed in vacuo. The remaining pyridine
was removed by coevaporation with toluene. The resulting crude mixture was
subsequently purified by column chromatography on SiO2 (eluent: DCM/MeOH,
96/4 to 92/8 v/v) to furnish 2.68 g (78%) of the desired compound as a white
powder; mp 177 ◦C; Rf=0.25 (6% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ
8.26 (s, 1 H, NH), 7.83 (s, 1 H, NH), 7.81 (d, J = 7.6 Hz, 1 H, H-6), 5.87 (d, J =
7.6 Hz, 1 H, H-5), 5.69 (s, 1H, H-1’), 5.55 (s, 1 H, OH-2’), 4.17 (d, J = 13.1 Hz,
1 H, H-5’), 4.11 - 4.00 (m, 3 H, H-2’, H-3’, H-4’), 3.92 (dd, J = 13.4, 2.1 Hz, 1 H,
H-5’), 1.15 - 0.92 (m, 28 H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 167.2 (C-2),
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156.8 (C-4), 141.2 (C-6), 94.4 (C-5), 91.9 (C-1’), 80.2 (C-4’), 77.3 (C-2’), 67.2
(C-3’), 58.4 (C-5’), 17.3 (CH3), 17.2 (CH3), 17.0 (CH3), 16.9 (CH3), 16.9 (CH3),
16.4 (CH3), 16.2 (CH3), 15.5 (CH3), 13.2 (CH), 12.7 (CH), 12.6 (CH), 12.5 (CH);
MS (ESI) m/z 508.2 [M + Na]+.
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112, C24H47N3O6Si3,MW : 557.90
3’,5’-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2’-O-(trimethylsil-
yl)-cytidine (112). Compound 111 (2.39 g, 4.5 mmol) was dissolved in dry
DCM (50 mL) under an argon atmosphere and the solution was cooled to -10 ◦C.
Triethylamine (3.15 mL, 22.6 mmol) and trimethylsilyl chloride (1.15 mL, 9.0
mmol) were added dropwise before the cooling bath was removed and the cloudy
mixture was then stirred at r.t. for 2.5 h. After full conversion of the starting ma-
terial the reaction mixture was poured onto a cold saturated aqueous solution of
NaHCO3. The mixture was extracted with DCM (3 × 25 mL). The combined or-
ganic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated.
The crude product was then purified via column chromatography on SiO2 (eluent:
DCM/MeOH, 97/3 to 95/5 v/v) to give 2.06 g (76%) of 112 as a white solid; mp
182-185 ◦C; Rf=0.4 (6% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J
= 7.5 Hz, 1 H, H-6)), 5.67 (d, J = 7.5 Hz, 1 H, H-5), 5.60 (s, 1 H, H-1’), 4.23 (d,
J = 13.5 Hz, 1 H, H-4’), 4.14 (dd, J = 11.7, 2.7 Hz, 1 H, H-5’), 4.03 (m, 2 H, H-2’,
H-3’), 3.95 (dd, J = 13.5, 2.2 Hz, 1 H, H-5’), 0.99 (dd, 28 H, H-iPr), 0.18 (s, 9 H,
TMS); 13C NMR (125 MHz, CDCl3) δ 165.8 (C-2), 155.3 (C-4), 140.1 (C-6), 93.6
(C-5), 91.2 (C-1’), 80.7 (C-4’), 75.8 (C-2’), 67.5 (C-3’), 59.4 (C-5’), 17.2 (CH3),
171
5 Experimental Part
17.1 (CH3), 17.0 (CH3), 16.9 (CH3), 16.7 (CH3), 16.7 (CH3), 16.6 (CH3), 16.5
(CH3), 13.0 (CH), 12.7 (CH), 12.5 (CH), 12.4 (CH), 10.5 (3 C, CH3,TMS); MS
(ESI) m/z 580.9 [M + Na]+; HRMS (ESI) calcd for C24H48N3O6Si3 (= [M +
H]+) m/z 558.8184, found 558.8187.
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113, C32H49N3O8Si3,MW : 688.00
4-(1,2-benzene-dicarboximido)-3’,5’-O-(1,1,3,3-Tetraisopropyldi-
siloxane-1,3-diyl)-2’-O-(trimethylsilyl)-cytidine (113). Compound 112
(400 mg, 0.72 mmol) was coevaporated with dry pyridine (2 × 3 mL) before
it was dissolved in dry pyridine (5 mL) at r.t. under nitrogen. DMAP (cat., ≈15
mg) and phthaloyl chloride (0.25 mL, 1.45 mmol), each dissolved in dry DCM
(0.5 mL), were added to the stirring solution. The ladder dropwise within 5 min
at -5 ◦C. A white precipitate was formed during the addition and the solution
turned slightly yellow. The heterogeneous solution was allowed to warm up to
r.t and was stirred for additional 4 h. After complete conversion of the start-
ing material the reaction was quenched by addition of sat. NaHCO3-solution
(15 mL). The mixture was extracted with DCM (3 × 20 mL). The combined
organic layer was washed with brine (30 mL), dried over Na2SO4 and concen-
trated. The crude product was purified via column chromatography on SiO2
(eluent: EtOAc/hexane, 55/45 to 75/25 v/v) to give 367 mg (81%) of the title
compound 113 as a white solid; mp 187-189 ◦C; Rf=0.75 (4% MeOH/DCM); 1H
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NMR (500 MHz, CDCl3) δ 8.51 (d, J = 7.2 Hz, 1 H, H-6), 7.94 (td, J = 5.3, 2.1
Hz, 2 H, Harom.), 7.82 (td, J = 5.3, 2.1 Hz, 2 H, Harom.), 6.66 (d, J = 7.2 Hz, 1
H, H-5), 5.66 (s, 1 H, H-1’), 4.30 - 4.26 (m, 2 H, H-2’, H-3’), 4.25 (dd, J = 9.5,
2.1 Hz, 1 H, H-5’), 4.05 (dd, J = 9.5, 3.8 Hz, 1 H, H-4’), 3.99 (dd, J = 13.7, 2.3
Hz, 1 H, H-5’), 1.11 - 0.91 (m, 28 H, H-iPr), 0.22 (s, 9 H, H-TMS); 13C NMR
(125 MHz, CDCl3) δ 164.6 (C-4), 159.2 (C-2), 154.2 (2 C, Carom.), 144.6 (2 C,
CHarom.), 134.8 (C-6), 134.1 (2 C, Ccarbonyl), 131.1 (CHarom.), 129.9 (CHarom.),
99.7 (C-5), 92.1 (C-1’), 81.5 (C-4’), 75.5 (C-2’), 67.5 (C-3’), 59.26 (C-5’), 17.2
(CH3), 17.2 (CH3), 17.0 (CH3), 16.9 (CH3), 16.7 (CH3), 16.7 (CH3), 16.7 (CH3),
16.6 (CH3), 13.1 (CH), 12.8 (CH), 12.6 (CH), 12.5 (CH), 11,1 (3 C, CH3, TMS);
MS (ESI) m/z 689.1 [M + H]+; HRMS (ESI) calcd for C32H49N3O8Si3 (= [M +
NH4]+) m/z 705.3166, found: 705.3165.
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115, C29H41N3O8Si2,MW : 615.82
4-(1,2-benzene-dicarboximido)-3’,5’-O-(1,1,3,3-Tetraisopropyldi-
siloxane-1,3-diyl)-cytidine (115). Compound 113 (350 mg, 0.51 mmol) was
dissolved in dry DCM (5 mL) before pTsOH (95 mg, 0.5 mmol) was added in
portions over 10 min at -5 ◦C. The mixture was kept at that temperature and
stirred for additional 30 min. After full conversion of the starting material the
solution was quenched by addition of Et3N (0.4 mL, 2.5 mmol) at -5 ◦C. After
stirring for another 10 min, the mixture was diluted with sat. NaHCO3-solution
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(10 mL). The mixture was extracted with DCM (3 × 10 mL). The combined or-
ganic layer was washed with brine (10 mL), dried over Na2SO4 and concentrated.
The crude product was purified via column chromatography on SiO2 (eluent:
EtOAc/hexane, 70/30 to 80/20 v/v) to give 223 mg (71%) of the title compound
115 as a white foam; Rf=0.55 (4% MeOH/DCM); 1H NMR (500 MHz, CDCl3)
δ 8.59 (d, J = 7.2 Hz, 1 H, H-6), 7.98 (dt, J = 7.0, 3.5 Hz, 1 H, Harom.), 7.94 -
7.89 (m, 2 H, Harom.), 6.90 (d, J = 7.2 Hz, 1 H, H-5), 5.79 (s, 1 H, H-1’), 4.37 -
4.26 (m, 4 H, H-2’,3’,4’,5’), 4.10 (dd, J = 13.5, 1.5 Hz, 1 H, H-5’), 1.33 - 0.77 (m,
28 H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 171.1 (C-4), 166.4 (C-2), 161.2 (2
C, Carom.), 156.8 (2 C, CHarom.), 146.3 (C-6), 136.5 (CHarom.), 134.1 (CHarom.),
132.8 (C-5), 131.9 (2 C, Ccarbonyl), 93.8 (C-1’), 83.4 (C-4’), 75.7 (C-2’), 69.4 (C-
3’), 61.1 (C-5’), 18.1 (CH3), 18.0 (CH3), 17.9 (CH3), 17.7 (CH3), 17.6 (CH3),
17.5 (CH3), 17.5 (CH3), 17.4 (CH3), 14.7 (CH), 14.4 (CH), 14.2 (CH), 13.8 (CH);
MS (ESI) m/z 638.9 [M + Na]+; HRMS (ESI) calcd for C29H42N3O8Si2 (= [M
+ H]+) m/z 616.4424, found 616.4420.
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117, C30H43N3O10SSi2,MW : 693.91
4-(1,2-benzene-dicarboximido)-3’5’-O-(1,1,3,3-Tetraisopropyldi-
siloxane-1,3-diyl)-2’-O-(methanesulfonyl)cytidine (117). Compound 115
(300 mg, 0.43 mmol) was dissolved in dry DCM (5 mL) under an argon atmo-
sphere before Et3N (0.3 mL, 2.1 mmol) and mesyl chloride (0.07 mL, 0.84 mmol)
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were added to the solution at -5 ◦C. The resulting solution was stirred for 2 h
at r.t. After full conversion of the starting material the mixture was diluted
with sat. NaHCO3-solution (10 mL). The mixture was then extracted with DCM
(3 × 10 mL) and the combined organic layer was washed with brine (10 mL),
dried over Na2SO4 and concentrated. The crude product was purified via column
chromatography on SiO2 (eluent: EtOAc/hexane, 20/80 to 30/70 v/v) to give
194 mg (65%) of 117 as a white foam; Rf=0.6 (25% EtOAc/hexane); 1H NMR
(500 MHz, CDCl3) δ 8.59 (d, J = 7.2 Hz, 1 H, H-6), 7.98 (dt, J = 7.0, 3.5 Hz,
1 H, Harom.), 7.94 - 7.89 (m, 3 H, Harom.), 6.90 (d, J = 7.2 Hz, 1 H, H-5), 5.79
(s, 1 H, H-1’), 4.37 - 4.26 (m, 4 H, H-2’,3’,4’,5’), 4.10 (dd, J = 13.5, 1.5 Hz, 1
H, H-5’), 3.38 (s, 3 H, CH3, mesyl), 1.33 - 0.77 (m, 28 H, H-iPr); 13C NMR
(125 MHz, CDCl3) δ 171.1 (C-4), 166.4 (C-2), 161.2 (2 C, Carom.), 156.8 (2 C,
CHarom.), 146.3 (C-6), 136.5 (CHarom.), 134.1 (CHarom.), 132.8 (C-5), 131.9 (2
C, Ccarbonyl), 93.8 (C-1’), 83.4 (C-4’), 75.7 (C-2’), 69.4 (C-3’), 61.1 (C-5’), 18.1
(CH3), 18.0 (CH3), 17.9 (CH3), 17.7 (CH3), 17.6 (CH3), 17.5 (CH3), 17.5 (CH3),
17.4 (CH3), 14.7 (CH), 14.4 (CH), 14.2 (CH), 13.8 (CH); MS (ESI) m/z 716.9 [M
+ Na]+; HRMS (ESI) calcd for C30H44N3O10SSi2 (= [M + H]+) m/z 694.9133,
found 694.9132.
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114, C34H63N3O10Si3,MW : 758.13
N4-bis-Boc-3’,5’-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(trimethylsilyl)-cytidine (114). Compound 112 (3.02 g, 5.4 mmol) was co-
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evaporated with dry pyridine (2 × 5 mL) before it was dissolved in dry DCM (35
mL) under an argon atmosphere at r.t. DMAP (650 mg, 5.4 mmol) and di-tert-
butyl dicarbonate (4.58 g, 21 mmol) were added to the solution. The reaction
mixture was stirred at r.t. for 5 h. After full conversion of the starting material
the solution was poured onto cold brine. The resulting mixture was subsequently
extracted with DCM (3 × 30 mL). The combined organic layer was washed with
brine (30 mL), dried over Na2SO4 and concentrated. The crude product was
purified via column chromatography on SiO2 (eluent: EtOAc/hexane, 45/55 to
55/45 v/v) to furnish 3.18 g of the title compound 114 (77%) as a white solid;
mp 115-118 ◦C; Rf=0.7 (5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.24
(d, J = 7.6 Hz, 1 H, H-6), 6.95 (d, J = 7.6 Hz, 1 H, H-5), 5.56 (s, 1 H, H-1’),
4.22 (d, J = 13.6 Hz, 1 H, H-4’), 4.18 (d, J = 3.7 Hz, 1 H, H-2’), 4.16 (dd, J =
9.5, 1.8 Hz, 1 H, H-5’), 3.98 (dd, J = 9.5, 3.8 Hz, 1 H, H-3’), 3.93 (dd, J = 13.6,
2.3 Hz, 1 H, H-5’), 1.50 (s, 18 H, Boc), 1.19 - 0.90 (m, 28 H, H-iPr), 0.16 (s, 9
H, TMS); 13C NMR (125 MHz, CDCl3) δ 162.5 (C-4), 154.2 (C-2), 149.5 (C-6),
143.52 (2 C, Ccarbonyl, Boc) 95.6 (C-5), 92.1 (C-1’), 84.7 (C-5’), 81.5 (C-2’), 75.8
(C-3’), 68.1 (C-5’), 59.6 (2 C, Cquat., Boc), 27.9 (6 C, CH3, Boc), 17.6 (CH3), 17.5
(CH3), 17.4 (CH3), 17.3 (CH3), 17.0 (CH3), 16.9 (CH3), 16.8 (CH3), 16.8 (CH3),
13.3 (CH), 13.2 (CH), 12.8 (CH), 12.8 (CH), 12.1 (3 C, (CH3), TMS); MS (ESI)
m/z 759.3 [M + H]+; HRMS (ESI) calcd for C34H64N3O10Si3 (= [M + H]+) m/z
759.3894, found 759.3892.
N
NH
ON
O
OO
O
Si
Si
O
Si
O
O
114b, C29H55N3O8Si3,MW : 658.02
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N4-Boc-3’,5’-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(trimethylsilyl)-cytidine (114b). Compound 112 (2.2 g, 3.9 mmol) was co-
evaporated with dry pyridine (2 × 5 mL) before it was dissolved in dry DCM
(25 mL) under an argon atmosphere at r.t. DMAP (408 mg, 3.9 mmol) and di-
tert-butyl dicarbonate (1.1 g, 5 mmol) were added to the solution. The reaction
mixture was stirred at r.t. for 4 h. After full conversion of the starting material
the solution was poured onto cold brine. The resulting mixture was subsequently
extracted with DCM (3 × 30 mL). The combined organic layer was washed with
brine (30 mL), dried over Na2SO4 and concentrated. The crude product was
purified via column chromatography on SiO2 (eluent: EtOAC/hexane, 55/55 to
65/45 v/v) to give 2.08 g of the title compound 114b (81%) as a white foam; mp
127-128 ◦C; Rf=0.6 (5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.32 (d, J
= 7.7 Hz, 1 H, H-6), 6.91 (d, J = 7.3 Hz, 1 H, H-5), 5.66 (s, 1 H, H-1’), 4.12 (d,
J = 12.9 Hz, 1 H, H-4’), 4.15 (d, J = 3.8 Hz, 1 H, H-2’), 4.11 (dd, J = 9.4, 1.6
Hz, 1 H, H-5’), 3.98 (dd, J = 9.2, 4.8 Hz, 1 H, H-3’), 3.93 (dd, J = 13.2, 3.5 Hz,
1 H, H-5’), 1.56 (s, 9 H, Boc), 1.25 - 0.98 (m, 28 H, H-iPr), 0.23 (s, 9 H, TMS);
13C NMR (125 MHz, CDCl3) δ 163.1 (C-4), 152.5 (C-2), 147.9 (C-6), 145.5 (1 C,
Ccarbonyl, Boc) 96.2 (C-5), 93.5 (C-1’), 85.2 (C-5’, 81.5 (C-2’), 77.7 (C-3’), 66.5
(C-5’), 59.2 (1 C, Cquart., Boc), 28.1 (3 C, CH3, Boc), 17.9 (CH3), 17.1 (CH3),
16.9 (CH3), 16.7 (CH3), 16.6 (CH3), 16.5 (CH3), 16.3 (CH3), 16.2 (CH3), 13.1
(CH), 13.0 (CH), 12.7 (CH), 12.6 (CH), 12.4 (3 C, (CH3), TMS); MS (ESI) m/z
659.2 [M + H]+.
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116, C31H55N3O10Si2,MW : 685.95
N4-bis-Boc-3’,5’-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-cyti-
dine (116). Compound 114 (390 mg, 0.5 mmol) was dissolved in dry DCM
(6 mL) before pTsOH (95 mg, 0.5 mmol) was added in portions over 10 min at
-5 ◦C. The mixture was kept at that temperature and stirred for additional 20
min. After full conversion of the starting material the solution was quenched
by addition of Et3N (0.35 mL, 2.5 mmol) at -5 ◦C. After stirring for another 10
min, the mixture was diluted with sat. NaHCO3-solution (10 mL). The mixture
was extracted with DCM (3 × 10 mL). The combined organic layer was washed
with brine (10 mL), dried over Na2SO4 and concentrated. The crude product
was purified via column chromatography on SiO2 (eluent: EtOAC/hexane, 75/25
to 85/15 v/v) to give 311 mg (90%) of 116 as a white foam; mp 139-143 ◦C;
Rf=0.55 (5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 7.6 Hz,
1 H, H-6), 7.02 (d, J = 7.6 Hz, 1 H, H-5), 5.75 (s, 1 H, H-1’), 4.28 - 4.15 (m,
4 H; H-2’,3’,4’,5’), 3.98 (dd, J = 13.2, 1.7 Hz, 1 H, H-5’), 3.44 (s, 1 H, OH-2’),
1.53 (s, 18 H, Boc), 1.14 - 0.85 (m, 28 H, H-iPr); 13C NMR (125 MHz, CDCl3)
δ 162.5 (C-2), 154.2 (C-4), 149.4 (2 C, Ccarbonyl, Boc), 143.5 (C-6), 96.0 (C-5),
91.8 (C-1’), 84.8 (C-4’), 81.8 (C-2’), 74.9 (C-3’), 68.4 (C-5’), 59.9 (2 C, Cquat.,
Boc), 27.6 (6 C, CH3, Boc), 17.4 (CH3), 17.4 (CH3), 17.3 (2 C, CH3), 17.0 (CH3),
16.9 (CH3), 16.8 (CH3), 16.8 (CH3), 13.3 (CH), 12.9 (CH), 12.8 (CH), 12.4 (CH);
MS (ESI) m/z 687.0 [M + H]+; HRMS (ESI) calcd for C31H56N3O10Si2 (= [M +
H]+) m/z 686.8283, found: 686.8279.
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118, C32H57N3O12SSi2,MW : 764.04
N4-bis-Boc-3’,5’-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(methanesulfonyl)-cytidine (118). Compound 116 (290 mg, 0.42 mmol) was
dissolved in dry DCM (4 mL) under an argon atmosphere before Et3N (0.290
mL, 2.1 mmol) and mesyl chloride (0.065 mL, 0.84 mmol) were added to the
solution at -5 ◦C. The resulting solution was stirred for 1 h at r.t. After full
conversion of the starting material the mixture was diluted with sat. NaHCO3-
solution (10 mL). The mixture was then extracted with DCM (3 × 10 mL) and
the combined organic layer was washed with brine (10 mL), dried over Na2SO4
and concentrated. The crude product was purified via column chromatography
on SiO2 (EtOAC/hexane, 45/55 to 55/45 v/v) to give 230 mg (71%) of 118 as a
white powder; Rf=0.75 (5% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.14
(d, J = 7.6 Hz, 1 H, H-6), 7.10 (d, J = 7.6 Hz, 1 H, H-5), 5.81 (s, 1 H, H-1’),
4.96 (d, J = 4.4 Hz, 1 H, H-2’), 4.26 (t, J = 4.7 Hz, 1 H, H-3’), 4.21 (dt, J =
9.6, 4.4 Hz, 1 H, H-4’), 4.12 (dd, J = 9.6, 1.8 Hz, 1 H, H-5’), 3.97 (dd, J = 13.7,
2.4 Hz, 1 H, H-5’), 3.32 (s, 3 H, mesyl), 1.53 (s, 18 H, Boc), 1.17 - 0.81 (m, 28
H, H-iPr); 13C NMR (125 MHz, CDCl3) δ 162.8 (C-4), 153.9 (C-2), 149.3 (2 C,
Ccarbonyl, Boc), 142.6 (C-6), 96.3 (C-5), 89.2 (C-1’), 85.1 (C-2’), 82.5 (C-4’), 81.9
(C-3’), 66.4 (C-5’), 59.0 (2 C,Cquart., Boc), 39.2 (CH3, mesyl), 27.64 (6 C, CH3,
Boc), 17.4 (CH3), 17.3 (CH3), 17.2 (CH3), 17.1 (CH3), 16.8 (CH3), 16.7 (CH3),
16.7 (CH3), 16.6 (CH3), 13.3 (CH), 12.9 (CH), 12.7 (CH), 12.5 (CH); MS (ESI)
m/z 765.1 [M + H]+; HRMS (ESI) calcd for C32H58N3O12SSi2 (= [M + H]+)
m/z 765.2043, found: 765.2045.
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93, C20H31N3O11S,MW : 521.54
N4-bis-Boc-2’-O-(methanesulfonyl)-cytidine (93). Compound 118 (4.7
g, 6.15 mmol) was dissolved in dry THF (110 mL) before TBAF (3.88g, 12.3
mmol) was added slowly at -10 ◦C to the stirring solution. The resulting reaction
mixture was stirred for additional 20 min at that temperature. After completion
of the reaction the solvent was removed under reduced pressure and the resulting
crude oil purified via column chromatography on SiO2 (eluent: EtOAC/hexane,
75/25 to 95/5 v/v) to give 1.44 g the title compound 93 (46%) as a white solid;
Rf=0.45 (10% MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.64 (d, J = 7.6 Hz,
1 H, H-6), 7.14 (d, J = 7.6 Hz, 1 H, H-5), 6.06 (d, J = 1.6 Hz, 1 H, H-1’), 5.17
(dd, J = 4.9, 1.6 Hz, 1 H, H-2’), 4.38 (dd, J = 8.1, 4.9 Hz, 1 H, H-3’), 4.10 (dd,
J = 5.3, 2.8 Hz, 1 H, H-4’), 4.03 (dd, J = 12.6, 2.2 Hz, 1 H, H-5’), 3.83 (dd, J =
12.6, 2.6 Hz, 1 H, H-5’), 3.34 (s, 3 H, mesyl), 1.58 (s, 18 H, Boc); 13C NMR (125
MHz, CDCl3) δ 164.6 (C-4), 156.6 (C-2), 150.9 (2 C, Ccarbonyl, Boc), 146.3 (C-6),
97.9 (C-5), 90.9 (C-1’), 85.3 (C-2’), 84.1 (C-4’), 68.3 (C-3’), 61.6 (C-5’), 60.4 (2
C,Cquart., Boc), 39.02 (CH3, mesyl), 28.0 (2 C, CH3), 21.1 (2 C, CH3), 14.7 (2 C,
CH3); MS (ESI) m/z 522.3 [M + H]+.
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119, C30H47N3O13S,MW : 689.77
N4-bis-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-O-(methanesulfonyl)-
cytidine (119). Compound 93 (1.4 g, 2.68 mmol) was dissolved in dry DCM (30
mL) under an argon atmosphere, 3,4-dihydro-puran (2.45 mL, 26.8 mmol) and
pTsOH (130 mg, 0.27 mmol) were added to the reaction mixture at 0 ◦C. The
resulting solution was stirred at r.t. for 5 h. After completion of the reaction the
mixture was neutralised with Et3N. Saturated NaHCO3-solution (30 mL) was
added and the resulting suspension was then extracted with DCM (3 × 50 mL).
The combined organic layer was washed with brine (50 mL), dried over Na2SO4
and concentrated. The crude product was purified twice via column chromato-
graphy on SiO2 (eluent: EtOAC/hexane, 40/60 to 65/35 v/v) to furnish 856 mg
of precursor 119 (47%) as a white foam (4 diastereomers); HPLC: ≥98% pure
(Rt=14.2-15.6 min, 96% MeCN/H2O); 1H NMR (500 MHz, CDCl3) δ 8.57-8.48
(4 s, 1 H, H-6), 7.14-7.06 (4 s, 1 H, H-5), 5.92-5.87 (4 s, 1 H, H-1’), 5.12-5.07 (m,
1 H), 4.77-4.62 (4 m, 2 H), 4.55-4.45 (m, 1 H), 4.38-4.27 (m, 2 H), 4.02-4.10 (m,
1 H), 3.90-3.75 (m, 3 H), 3.73-3.65 (m, 1 H), 3.63-3.54 (m, 1 H), 3.54-3.41 (m, 3
H), 3.38-3.34 (4 s, 3 H, CH3, mesyl), 1.82-1.62 (m, 5 H), 1.53-1.52 (m, 18 H, CH3,
Boc), 1.52-1.41 (m, 3 H); MS (ESI) m/z 690.7 [M + H]+; HRMS (ESI) calcd for
C30H48N3O13S (= [M + H]+) m/z 690.6891, found: 690.6893..
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120, C29H44FN3O13,MW : 613.67
N4-bis-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-deoxy-2’-fluoro-arabino-
cytidine (120). Fluorination precursor 119 (138 mg, 0.2 mmol) was dissolved
in dry DMF (3 mL) in an oven dried Schlenk flask at r.t under an argon atmo-
sphere. Freshly opened 1 M TBAF solution in dry THF (0.6 mL, 0.6 mmol) was
added dropwise to the solution. The resulting mixture was stirred at 100 ◦C
for 100 min. After the full conversion of the starting material the solvent was
removed under reduced pressure. The crude residue was subsequently purified by
column chromatography on SiO2 (eluent: EtOAc/hexane, 10/90 to 25/80 v/v) to
furnish 23 mg (19%) of the fluorinated compound 120 as a colourless oil (four di-
astereomers); HPLC: ≥95% pure (Rt=17.3 min, 92% MeCN/H2O); Rf=0.6 (4%
MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 8.44-8.39 (4 s, 1 H, H-6), 7.24-7.17
(4 s, 1 H, H-5), 5.90-5.86 (4 s, 1 H, H-1’), 5.22-5.17 (m, 1 H), 4.82-4.67 (4 m, 2
H), 4.54-4.49 (m, 1 H), 4.36-4.28 (m, 2 H), 4.14-4.10 (m, 1 H), 3.91-3.77 (m, 3
H), 3.70-3.61 (m, 1 H), 3.55-3.48 (m, 1 H), 3.21-3.11 (m, 3 H), 1.88-1.60 (m, 5 H),
1.50-1.46 (m, 18 H, CH3, Boc), 1.39-1.22 (m, 3 H); 19F NMR (474 MHz, CDCl3)
δ -198.6, -198.8, -199.4, -199.2; MS (ESI) m/z 636.7 [M + Na]+; HRMS (ESI)
calcd for C29H45FN3O13 (= [M + H]+) m/z 614.6512, found: 614.6510.
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125, C31H53N3O10Si2,MW : 683.94
N4-bis-Boc-3’,5’O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2’-keto-
cytidine (125). A solution of 116 (250 mg, 0.37 mmol) in DCM (5 mL) was
cooled to 0 ◦C before DMP (0.46 g, 1.1 mmol) was added through a funnel to the
solution. The resulting cloudy mixture was allowed to warm up to r.t. and was
stirred for additional 24 h. After complete conversion of the starting material
(monitored by LC-MS) the reaction was quenched with sat. Na2S2O3/Na2CO3-
solution (10 mL). The mixture was then extracted with DCM (2 × 15 mL). The
combined organic layer was washed with brine, dried over Na2SO4 and concen-
trated in vacuo. The crude product was subsequently purified by column chroma-
tography on SiO2 (eluent: EtOAC/hexane, 75/25 to 85/15 v/v) to give 141 mg
(57%) of 125 as a white foam; mp 152-154 ◦C; Rf=0.4 (80% EtOAc/hexane); 1H
NMR (500 MHz, CDCl3) δ 8.45 (d, J = 7.5 Hz, 1 H, H-6)), 7.1 (d, J = 7.7 Hz, 1
H, H-5)), 5.75 (s, 1 H, H-1’), 4.26 - 4.2 (m, 4 H; H-2’,3’,4’,5’), 3.92 (dd, J = 13.2,
1.7 Hz, 1 H, H-5’), 1.55 (s, 18 H, Boc), 1.18 - 0.89 (m, 28 H, H-iPr); 13C NMR
(125 MHz, CDCl3) δ 208 (C-2’), 163.5 (C-2), 152.1 (C-4), 149.2 (2 C, Ccarbonyl,
Boc), 142.5 (C-6), 96.1 (C-5), 91.5 (C-1’), 84.7 (C-4’), 74.9 (C-3’), 67.2 (C-5’),
57.2 (2 C,Cquart., Boc), 26.6 (6 C, CH3, Boc), 17.2 (CH3), 17.2 (CH3), 17.1 (2
C, CH3), 17.0 (CH3), 16.9 (CH3), 16.8 (CH3), 16.7 (CH3), 13.3 (CH), 12.8 (CH),
12.8 (CH), 12.4 (CH); MS (ESI) m/z 687.0 [M + H]+; HRMS (ESI) calcd for
C31H54N3O10Si2 (= [M + H]+) m/z 684.8707, found: 684.8710.
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126, C23H39N3O7Si2,MW : 525.74
3’,5’O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-2’keto-N4-
acetylcytidine (126). [233]
DMP oxidation:
A solution of 102 (950 mg, 1.8 mmol) in DCM (15 mL) was cooled to 0 ◦C
before DMP (3.0 g, 7.1 mmol) was added through a funnel to the solution. The
resulting cloudy solution was allowed to warm up to r.t. and was stirred for 20 h.
After complete conversion of the starting material the reaction was quenched with
sat. Na2S2O3/Na2CO3-solution (20 mL). The mixture was then extracted with
DCM (2 × 30 mL). The combined organic layer was washed with brine, dried
over Na2SO4 and concentrated in vacuo. The crude product was subsequently
purified by column chromatography on SiO2 (DCM/MeOH 98/2 v/v) to furnish
520 mg of the title compound (55%) as a white foam.
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Swern oxidation:
Oxalyl chloride (0.2 mL, 1.3 mmol) was dissolved in dry DCM (6 mL) under
an argon atmosphere. The solution was cooled to -78 ◦C before dry DMSO (0.25
mL, 2.8 mmol) was added dropwise to the solution. The mixture was stirred at
that temperature for additional 15 min before a solution of compound 102 (300
mg, 0.57 mmol) dissolved in dry DCM (1 mL). Afrer 15 min Et3N (0.4 mL, 2.8
mmol) was added dropwise and the resulting yellow solution. The mixture was
kept additional 15 min at that temperature and was then allowed to warm up
r.t. within 30 min. TLC indicated the full conversion of the starting material.
The mixture was subsequently poured onto cold brine in a separation funnel
followed by an extraction with DCM (2× 20 mL). The combined organic layer was
dried over Na2SO4 and concentrated under reduced pressure. The resulting crude
mixture was then purified by column chromatography on SiO2 (DCM/MeOH 97/3
to 95/5 v/v) to furnish 142 mg of the title compound (49%) as a white foam.
mp 145 ◦C (lit. [233] mp 153 ◦C); Rf=0.55 (6% MeOH/DCM); 1H NMR (500
MHz, CDCl3) δ 10.51 (s, 1 H, NH), 8.20 (d, J = 7.5 Hz, 1 H, H-6), 7.45 (d, J
= 6.3 Hz, 1 H, H-5), 5.81 (s, 1 H, H-1’), 4.28-4.20 (m, 4H), 4.01 (dd, J = 13.3,
2.2 Hz, 1 H, H-5’), 2.30 (s, 3 H, acetyl), 1.13-1.01 (m, 28 H, H-iPr); 13C NMR
(125 MHz, CDCl3) δ ppm 204.1 (C-2’), 170.5 (C-4), 163.1 (C-2), 153.5 (C=O,
acetyl), 148.0 (C-6), 96.4 (C-5), 85.4 (C-1’), 80.1 (C-4’), 71.4 (C-3’), 62.6 (C-5’),
23.7 (CH3), 16.5 (CH3), 16.4 (CH3), 16.3 (CH3), 16.3 (CH3), 15.9 (CH3), 15.8
(CH3), 15.8 (CH3), 15.6 (CH3), 12.3 (CH), 12.1 (CH), 11.6 (CH), 11.4 (CH); MS
(ESI) m/z 548 [M + Na]+.
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128, C15H19N3O8,MW : 369.31
3’,5’-diacetyl-N4-acetyl-arabinocytidine (128). [159] N4-Acetyl cytidine
(4.5 g, 15.8 mmol) was azeotropically dried with pyridine (2 × 5 mL). before
it was suspended in dry acetonitrile (80 mL) under inert atmosphere. Boron
trifluoride etherate (5.45 mL, 45.0 mmol) was added dropwise and the solution
was refluxed for 1 h. Acetyl chloride ( 5.35 mL, 75.0 mmol) was then added via
an addition funnel over a period of 15 min. The resulting mixture was refluxed
for another 2 h followed by removal of the solvent under reduced pressure. A
mixture of diethyl ether/Isopropanol (1.5/1 v/v) was added (3 × 50 mL) to
obtain a dark yellow oily residue and a clear filtrate. The crude intermediate was
then hydrolised using sat. NaHCO3-solution (70 mL) at r.t for 24 h. The product
was filtered and washed with water (3 × 10 mL) before azeotropic drying was
performed using pyridine (2 × 5 mL) to give 2.7g of title compound 128 (48%) as
a white solid; mp 102-103 ◦C; Rf=0.45 (10% MeOH/DCM); 1H NMR (500 MHz,
CDCl3) δ 10.85 (s, 1 H, NH), 7.97 (d, J = 7.5 Hz, 1 H, H-6), 7.22 (d, J = 7.5 Hz,
1 H, H-5), 6.06 (m, 2 H, H-1’, H-2’), 4.96 (s, 1 H, 2’-OH), 4.40 (dd, J = 11.6, 7.5
Hz, 1 H, H-5’), 4.28 (m, 2 H, H-3’, H-4’), 4.21 (m, 1 H, H-5’), 2.12 (s, 3 H, CH3,
acetyl), 2.11 (s, 3 H, CH3, acetyl), 2.06 (s, 3 H, CH3, acetyl); 13H NMR (125
MHz, CDCl3) δ 172.2 (C-4), 169.3 (C-2), 168.5 (C=O, acetyl), 165.2 (C-6), 157.2
(C=O, acetyl), 143.2 (C=O, acetamide), 101.0 (C-5), 95.3 (C-1’), 81.2 (C-4’),
74.1 (C-2’), 63.3 (C-3’), 58.5 (C-5’), 21.7 (CH3, acetamide), 21.2 CH3, acetyl),
21.1 CH3, acetyl); MS (ESI) m/z 370 [M + H]+.
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35, C15H17N3O8,MW : 367.31
3’,5’-O-diacetyl-N4-acetyl-2’-ketocytidine (35). [159]
Starting from Compound 126
Compound 126 (530 mg, 1.0 mmol) was dissolved in dry DCM (8 mL) under
nitrogen before a solution of Et3N (0.8 mL, 5.0 mmol) and Et3N × 3HF (0.5 mL,
3.0 mmol) in dry DCM (2 mL) was added dropwise to the reaction mixture at
room temperature. The resulting solution was stirred for 1 h. After complete
deprotection the mixture was cooled to 0 ◦C before another aliquot of Et3N (0.5
mL) and acetyl chloride (0.4 mL, 5.0 mmol) were added dropwise to the reaction
mixture. The cloudy solution was allowed to warm up to room temperature and
was then stirred over night. The reaction was quenched with sat. NaHCO3-
solution and subsequently extracted with DCM (2 × 30 mL). The combined
organic layer was dried over Na2SO4 and concentrated under reduced pressure.
The resulting crude mixture was then purified by column chromatography on
SiO2 (DCM/MeOH 95/5 to 92/8 v/v) to obtain 135 mg of the title compound
(32%) as an off-white powder.
Starting from Compound 128
Compound 128 (950 mg, 2.57 mmol) was dissolved in dry MeCN (12 mL)
under nitrogen before DMP (3.18 g, 7.5 mmol) to the mixture at 0 ◦C. The solu-
tion was stirred at r.t. for 24 h. After full conversion of the starting material
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(monitored LC-MS) the reaction was quenched by adding sat. Na2S2O3/Na2CO3-
solution (10 mL). The mixture was then extracted with DCM (2 × 15 mL). The
combined organic layer was washed with brine, dried over Na2SO4 and concen-
trated in vacuo. The crude product was subsequently purified by column chro-
matography on SiO2 (DCM/MeOH 95/5 to 92/8 v/v) to obtain 639 mg of the
title compound (68%) as an off-white powder.
mp 129-132 ◦C; Rf=0.6 (8% MeOH/DCM); HPLC: ≥96% pure (Rt=9.6 min,
45% MeCN/H2O; 1H NMR (500 MHz, CDCl3) δ 10.77 (s, 1 H, NH), 7.81 (d, J =
6.5 Hz, 1 H, H-6), 7.47 (d, J = 6.1 Hz, 1 H, H-5), 6.49 (s, 1 H, H-1’), 4.99-4.85 (m,
1 H, H-4’), 4.43-4.32 (m, 1 H, H-2’), 4.33-4.08 (m, 3 H, H-3’, H-5’), 2.28 (s, 3 H,
CH3, acetamide), 2.07 (s, 3 H, CH3, acetyl), 2.05 (s, 3 H, CH3, acetyl); 13H NMR
(125 MHz, CDCl3) δ 209.4 (C-2’), 171.6 (C-4), 170.3 (C-2), 168.2 (C=O, acetyl),
163.7 (C-6), 154.42 (C=O, acetyl), 145.6 (C=O, acetamide), 103.04 (C-5), 96.4
(C-1’), 80.1 (C-4’), 62.6 (C-3’), 59.51 (C-5’), 24.9 (CH3, acetamide), 21.3 CH3,
acetyl), 20.5 CH3, acetyl); MS (ESI) m/z 368.1 [M + H]+; HRMS (ESI) calcd
for C15H18N3O8 (= [M + H]+) m/z 368.1088, found: 368.1085.
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129, C15H17F2N3O7,MW : 389.31
3’,5’-O-diacetyl-N4-acetyl-2’-difluoro-deoxycytidine (129).
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Acetylation of Gemcitabine:
Gemcitabine (1.0 g, 3.8 mmol) was suspended in dry DCM (15 mL) under
nitrogen atmosphere before Et3N (4.8 mL, 38 mmol) and acetyl chloride (1.36
mL, 19 mmol) were added dropwise to the solution at -10 ◦C. The mixture was
stirred at r.t. for 24 h. After full conversion of the starting material (monitored
by LC-MS) the reaction was quenched by pouring the reaction mixture onto ice-
cold NaHCO3-solution (50 mL) in a separation funnel. After extraction with
DCM (3 × 40 mL) the combined organic layer was washed with brine, dried over
Na2SO4 and concentrated in vacuo. The crude product was subsequently purified
by column chromatography on SiO2 (DCM/MeOH 98/2 to 96/4 v/v) to obtain
1.37 g of the title compound (93%) as a white powder; mp 129-132 ◦C; Rf=0.6
(8% MeOH/DCM); HPLC: ≥96% pure (Rt=9.6 min, 45% MeCN/H2O; 1H NMR
(500 MHz, CDCl3) δ 10.59 (s, 1 H, NH), 7.77 (d, J = 7.7 Hz, 1 H, H-6), 7.45 (d, J
= 7.7 Hz, 1 H, H-5), 6.36 (t, J = 8.1 Hz, 1 H, H-4’), 5.26 â€“ 5.19 (m, 1 H, H-3’),
4.36 - 4.25 (m, 3 H, H-1’,5’), 2.18 (s, 3 H, CH3), 2.07 (s, 3 H, CH3), 2.02 (s, 3
H, CH3); 13H NMR (125 MHz, CDCl3) δ 171.6 (C-4), 170.3 (C-2), 168.2 (C=O,
acetyl), 163.7 (C-6), 154.42 (C=O, acetyl), 145.6 (C=O, acetamide), 109.4 (t,
1J(C,F) = 254.7 Hz, C-2’), 103.04 (C-5), 96.4 (t, 2J(C,F) = 27.7 Hz, C-1’), 80.1
(C-4’), 62.6 (t, 2J(C,F) = 22.1 Hz, C-3’), 59.51 (C-5’), 24.9 (CH3, acetamide),
21.3 CH3, acetyl), 20.5 CH3, acetyl); 19F NMR (474 MHz, CDCl3) δ -115.27,
-115.76; MS (ESI) m/z 390.2 [M + H]+; HRMS (ESI) calcd for C15H18F2N3O7
(= [M + H]+) m/z 390.1107, found: 390.1108.
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Non-radioactive 2’-difluorination of precursor 35 (general procedure):
Precursor 35 (20 mg, 51.4 µmol) was dissolved in the reaction solvent (MeCN,
DMF (1.0 mL)) under inert atmosphere. The first fluorination agent (KF/K222
or py/HF (1.0 eq.)) was added to the reaction mixture before the organic flu-
orination agent dissolved in reaction solvent (0.2 mL) (DAST or XtalFluor or
Fluolead (10 eq.)) was added dropwise. The resulting mixture was heated to the
appropriate reaction temperature and stirred for the appropriate time (2-3 h).
The reaction mixture was analysed hourly using LC-MS and TLC. Even though
the starting material could not be detected evidence for the formation of the
desired 2’-difluorinated compound 129 could not be provided.
5.2.3 Radiochemistry
Production of [18F]fluoride and hot cell equipment
Non-carrier-added [18F]fluoride was produced in an IBA Cyclon 18/9 cyclotron
using the 18O(p,n)18F nuclear reaction. 18O-enriched water (enrichment grade
98%, 2.2 mL, Nukem GmbH Germany) was irradiated with 18 MeV protons.
Starting activities were between 2.5-55 GBq at the end of bombardment. Ra-
diofluorinations were performed using an Eckert & Ziegler module system and
a RNF LAB Laboport vacuum pump N820 (Neuberger, Freiburg, Germany).
High-performance liquid chromatography (HPLC) analysis was conducted using
an AGILENT Technology 1200 Series System with either an analytical reversed
phase column (Phenomenex Synergi 4µ Hydro-RP 80 C-18 4.6 · 250 mm) or
a semi-preparative reversed phase column (Phenomenex Synergi 4µ Hydro-RP
80 C-18 10 · 250 mm) coupled with a β-RAM/γ-RAM Model 4 detector (Lab-
logic Systems, Ltd.) for radioactivity detection. Semi-preparative HPLC was
performed with a Smartline pump 100 (Knauer, Germany) and Smartline UV
detector 2500 (Knauer, Germany). Radio-TLC was performed using a Canberra
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UNISPEC iScan (Meriden, CT, USA) instrument. Radioactivity was determ-
ined using a calibrated ion chamber (Capintec CRC-15R). Radioactive material
was purified using Sep-Pak Al/C18/QMA cartridges (Waters Corp., Milford, MA,
USA). Al cartridges were equilibrated using distilled water (5 mL) and N2-gas
(to dryness). C18 cartridges were equilibrated using distilled water (5 mL) and
absolute ethanol (10 mL) followed by N2-gas (to dryness). QMA cartridges used
a Chromafix 30-PS-HCO3-resin for ion-exchange and were equilibrated using dis-
tilled water (5 mL), NaHCO3-solution (0.5 M, 5 mL) and N2-gas (to dryness).
Aqueous tracer solutions were sterilized using Millx-GS 0.22 µm filter units, Mil-
lipore, Co. Cork, Ireland.
The automated Eckert & Ziegler synthesis module in the hot cell was con-
figured as shown below (Figure 34).
Figure 34: Module system for tracer development at PETIC in the hot cell: (1) prep.
HPLC pump; (2) UV detector; (3) reactor; (4) 18F-delivery line; (5) dose calibrator; (6)
reagent vials; (7) vacuum pump; (8) argon/nitrogen supply; (9) prep. HPLC column
(behind lead brigs); (10) 10 mL HPLC injection loop; (11) HPLC radioactivity detector.
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Prior to each experiment all tubing material and vials of the module sys-
tem were cleaned and dried. All vials were filled with the appropriate react-
ants/solvents and put in place before radioactivity was delivered. The hot cell
remained shut after delivery of radioactivity and thus all reaction parameters such
as drying/reaction temperatures, reaction times and reagents were configured us-
ing the module system software (Figure 35).
Figure 35: Program configuration of the Eckert & Ziegler module system for general
18F-labelling reactions.
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Labelling reactions
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81, C24H3518FN2O9, MW:513.54
N3-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-18F-arabino-uridine (81).
Aqueous [18F]fluoride (nca) was trapped on a QMA cartridge and released with an
aqueous acetonitrile solution (0.6 mL) containing K2CO3 (4.2 mg, 0.03 mmol) and
K222 (22.6 mg, 0.06 mmol) into a V-vial. The basic [18F]fluoride/K222-mixture
was dried by azeotropic evaporation with MeCN (3 × 0.8 mL) at 120 ◦C. A solu-
tion of precursor 79 (10 mg, 0.017 mmol) in dry DMF (0.45 mL) was added to
the dried [18F]fluoride/K222-complex. The reaction mixture was heated to 120 ◦C
and stirred for 20 min. The crude reaction mixture was then passed through an
Al and a C18 cartridge. The 18F-labelled intermediate was subsequently released
using EtOAc (2.0 mL) into a V-vial filled with water (2.0 mL). The heterogen-
eous mixture was stirred for 5 minutes at r.t. An aliquot of the organic layer was
analysed by analytical HPLC and LC-MS. The 18F-labelled intermediate 81 was
eluted at Rt=6.3 min (80% MeCN/H2O (v/v), 1 ml/min flow rate). A spiked
sample containing the non-radioactive reference compound confirmed the identity
of the intermediate 81 by co-elution. LC-MS gave a strong signal at m/z=512
([M−H]−) further confirming the identity of 81. The RCY was calculated to
8.7% (decay-corrected, n = 3) using radio-TLC.
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9, C9H1118FN2O5, MW:245.19
2’-deoxy-2’-18F-arabino-uridine (9). Aqueous [18F]fluoride (nca) was
trapped on a QMA cartridge and eluted with an H2O/acetonitrile solution (0.6
mL, 50/50 v/v) containing K2CO3 (4.2 mg, 0.03 mmol) and K222 (22.6 mg,
0.06 mmol) into a V-vial. The basic [18F]fluoride/K222-mixture was dried by
azeotropic evaporation with MeCN (3 × 0.8 mL) at 120 ◦C. A solution of pre-
cursor 79 (10 mg, 0.017 mmol) in dry DMF (0.45 mL) was added to the dried
[18F]fluoride/K222-complex. The reaction mixture was heated up to 120 ◦C and
for 20 min. The solvent was then removed under reduced pressure and a stream
of nitrogen at 130 ◦C. Subsequently, a HCl/MeOH-solution (1 M, 0.3 mL) was
added to the crude residue and the mixture was stirred at 70 ◦C for 10 min. The
solvent was evaporated and the residue diluted with a solution of 10%MeCN/H2O
(1 mL). The cooled reaction mixture was then purified using a semi-preparative
HPLC column via a 10 mL injection-loop. The product was eluted with 10%
MeCN/H2O (v/v) at a flow of 3mL/min. The appropriate fraction containing
18F-FAU was collected at 15.3 min. An aliquot of the product solution (0.2 mL)
was analysed by analytical HPLC (10% MeCN/H2O, 1mL/min) to verify the
purity (≥95%). The specific activity of ≥42 GBq/µmol and RCYs (2.8-3.9%,
decay-corrected, n = 3) were calculated with a synthesis time of 178 min.
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14, C9H1018FIN2O5, MW:371.09
2’-deoxy-2’-18F-arabino-5-iodouridine (14). Aqueous [18F]fluoride (nca)
was trapped on a QMA cartridge and eluted with an aqueous acetonitrile solu-
tion (0.6 mL) containing K2CO3 (4.2 mg, 0.03 mmol) and K222 (22.6 mg, 0.06
mmol) into a V-vial. The basic [18F]fluoride/K222-mixture was dried by azeo-
tropic evaporation with MeCN (3 × 0.8 mL) at 120 ◦C. A solution of precursor
88 (10 mg, 0.017 mmol) in dry DMF/DMSO (0.3-0.4 mL) was added to the dried
[18F]fluoride/K222-complex. The reaction mixture was heated up to 120-140 ◦C
and stirred at that temperature for 20 min. The solvent was then removed un-
der reduced pressure and a stream of nitrogen at 130-140 ◦C. Subsequently, a
HCl/MeOH-solution (1 M, 0.3 mL) was added to the crude residue and the mix-
ture was stirred at 80 ◦C for 10 min. The cooled crude reaction mixture was ana-
lysed using radio-HPLC and radio-TLC by co-elution with the non-radioactive
reference standard FIAU. However, the radioactive product 14 could not be de-
tected.
N
N
ON
O
O
OO
O
O
O O
O
18F
121, C29H4418FN3O10,MW : 612.67
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18F-FAC-intermediate (121). Aqueous [18F]fluoride (nca) (15 GBq) was
trapped on a QMA cartridge before it was eluted with an aqueous solution (0.7
mL) of KHCO3 (22.6 mg/mL) and kryptofix K222 (22.6 mg/mL) in acetonitrile
(50% H2O/MeCN v/v). The resulting [18F]fluoride/K222/KHCO3-mixture was
dried by co-evaporation under reduced pressure and a stream of nitrogen. The
drying process was repeated 3 times (3 × 1 mL MeCN). A solution of precursor
119 (10 mg, 14.5 µmol) in DMF (0.3 mL) was added and the resulting mixture
was stirred at 110 ◦C for 20 min. The crude mixture was passed through an Al and
a C18 cartridge. The 18F-labelled intermediate 121 was released using EtOAc
(2 mL) and an aliquot (0.2 mL) of the mixture was subsequently analysed by
analytical HPLC using co-elution with the non-radioactive reference compound
120, Rt = 16.7 min (4% H2O/MeCN (v/v), 1.0 mL/min flow rate). Radio-HPLC
confirmed the identity of the 18F-labelled intermediate 121 and the RCY was
calculated to 9.4±0.8 (decay-corrected, n = 3).
N
NH2
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15, C9H1218FN3O4,MW : 244.21
18F-FAC (15). The procedure for the synthesis of the 18F-labelled interme-
diate 121 was identical as described above. After the 18F-labelled intermediate
was released from the cartridges with EtOAc (2 mL) into a new reaction vial, the
solvent was removed under reduced pressure and a stream of nitrogen at 80 ◦C.
Aqueous HCl-solution (2 M, 0.3 mL) was added to the dried residue followed by
stirring at 90 ◦C for 15 min. The solution was then neutralised using a NaOH
solution (2 M, 0.3 mL). The resulting mixture was purified by semi-preparative
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HPLC. The fraction containing 18F-FAC was collected after 22.5 min with 3%
MeCN/H2O (v/v) and a flow rate of 3.5 mL/min. The collected solution was
concentrated and the product taken up in saline before it was flushed through a
sterile filter. An aliquot of the final solution was analysed by analytical HPLC to
determine identity and purity. 18F-FAC was confirmed and its purity calculated
to ≥98% with specific activities ≥1700 mCi/µmol and RCYs between 4.3-5.5%
(n = 6, decay-corrected from end of bombardment (EoB)) with a synthesis time
of 168 min. Additionally, a carrier-added synthesis was performed according to
the above procedure and the product 19F/18F-FAC was saved for decay for 20
half-lives (≈2 days) and subsequently analysed by mass spectrometry; MS (ESI):
m/z (%): 245.4 (5) [M + H]+, 267.7 (95) [M + Na]+.
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123, C15H1718FFN3O7, MW:388.31
18F-Gemcitabine intermediate (123). Aqueous [18F]fluoride (nca) (8
GBq) was trapped on a QMA cartridge before it was eluted with an aqueous
solution (0.7 mL) of KHCO3 (22.6 mg/mL) and kryptofix K222 (22.6 mg/mL)
in acetonitrile (50% H2O/MeCN v/v). The resulting 18F/K222/KHCO3-mixture
was dried by coevaporation under reduced pressure and a stream of nitrogen. The
drying process was repeated 3 times (3 × 1 mL MeCN). A solution of precursor
35 (10 mg, 2.7 µmol) in anhydrous MeCN (0.2 mL) was added followed by the
addition of DAST (35 µL, 27 µmol) in anhydrous MeCN (0.2 mL). The result-
ing mixture was stirred at 60 ◦C for 30 min and at 90 ◦C for an additional 60
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min. The reaction mixture was cooled to r.t. and the radiolabelled intermediate
123 was then confirmed using radio-HPLC (Rt=7.4 min, 50% MeCN/H2O (v/v),
1 ml/min flow rate) by co-injection of the non-radioactive reference compound
129. The crude reaction mixture could be purified using Al and C18 cartridges.
The intermediate was released using MeCN (3 mL). The RCY was calculated to
0.3±0.05% (decay-corrected, n = 3) after a synthesis time of 212 min.
5.2.4 Computational procedures
MOE 2010.10 software was used to design each compound and to explore possible
conformations. The searching method applied was LowModMD which generates
conformations using a short run of Molecular Dynamics (MD) at constant tem-
perature followed by an all-atom energy minimization. Among the conformations,
sixteen of them were selected for each compound for quantum mechanics (QM)
evaluation. QM calculations were executed for the selected conformations with
the GAMESS [214] software. A geometry optimisation was performed in vacuo,
using analytical energy gradients with the Restricted Hartree Fock (RHF) wave
function.
The 3-21G split valence basis set was used and diffuse sp shell was added to
heavy atoms. The initial hessian was guessed and the convergence gradient toler-
ance was set to 0.0005 Hartree/Bohr. The electrostatic potential was calculated
at points determined by Michael Connolly algorithm on the surface of van der
Waals fused spheres. Atomic charges were consequently fitted to this potential.
The partial net charges of atoms of interest were gathered from each molecule
conformation and values were averaged.
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6.1 Selected NMR spectra
Figure 36: 1H NMR spectrum of mesylate precursor 79 showing the characteristic
mesyl-group signals at around 3.2 ppm
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Figure 37: 1H NMR spectrum of the fluorinated FAU intermediate 80.
Figure 38: 19F NMR spectrum of the fluorinated FAU intermediate 80. The four
signals correspond to the four diastereomers of the mixture.
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Figure 39: 1H NMR spectrum of FAU (65).
Figure 40: 19F NMR spectrum of FAU (65).
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Figure 41: 1H NMR spectrum of FAC-Intermediate 120.
Figure 42: 19F NMR spectrum of FAC-Intermediate 120.
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